defm14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
|
|
|
Filed by the Registrant
x |
|
Filed by a Party other than the Registrant
o |
|
|
Check the appropriate box: |
|
|
|
o Preliminary Proxy Statement |
|
o
Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2)) |
|
x Definitive Proxy Statement |
|
o Definitive Additional Materials |
|
o
Soliciting Material Pursuant to §240.14a-12 |
CIPHERGEN BIOSYSTEMS,
INC.
(Name
of Registrant as Specified In Its Charter)
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
o No fee required. |
|
x
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11. |
|
|
|
1) Title of each
class of securities to which transaction applies: |
|
|
|
Not Applicable
|
|
|
|
2) Aggregate number of securities to which transaction applies: |
|
|
|
Not Applicable
|
|
|
|
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined): |
|
|
|
Not Applicable
|
|
|
|
4) Proposed maximum aggregate value of transaction: |
|
|
|
$23,000,000
|
|
|
|
x Fee paid previously with preliminary materials. |
|
|
|
o Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing. |
|
|
|
1) Amount Previously Paid: |
|
|
|
2) Form, Schedule or Registration Statement No.: |
SPECIAL
MEETING OF STOCKHOLDERS
YOUR VOTE IS VERY IMPORTANT
Dear stockholder of Ciphergen Biosystems, Inc.:
The proxy statement attached to this letter provides you with
information about the special meeting of Ciphergens
stockholders and the proposals to be considered at the special
meeting. We encourage you to read the entire proxy statement
carefully. The proposal for which we are asking your approval is
critical to focusing our efforts on building a dynamic specialty
diagnostics business with a streamlined financial and
organizational structure as well as the technical and managerial
resources to address what we believe is a substantial
opportunity. The board of directors and management of Ciphergen
ask that you consider the following proposals.
Most importantly, you are asked to approve the sale of
Ciphergens proteomics instrument business, which includes
Ciphergens surface enhanced laser desorption/ionization,
or SELDI, technology,
ProteinChip®
Arrays and accompanying software to BioRad Laboratories, Inc.
pursuant to an asset sale. Ciphergen will retain rights to the
clinical diagnostics market and will continue to develop the
science to build this business. Upon stockholder approval of
this transaction and completion of the sale, Ciphergen will be
paid up to $20 million in cash by Bio-Rad, on the terms and
subject to adjustment as described in the attached proxy
statement. In addition, Bio-Rad will be making a $3 million
equity investment in Ciphergen.
Stockholders of Ciphergen will be asked, at the special meeting
of Ciphergens stockholders, to approve the asset sale and
a proposal to grant discretionary authority to adjourn or
postpone the Ciphergen special meeting to another time or place
for the purpose of soliciting additional proxies. The board
of directors of Ciphergen recommends that Ciphergens
stockholders vote FOR approval of the sale of assets used
in our proteomics instrument business and the adjournment
proposal.
The date, time and place of the special meeting to consider and
vote upon the proposals are as follows:
Thursday, October 26, 2006
2:00 p.m., local time
Ciphergen Biosystems, Inc.
6611 Dumbarton Circle
Fremont, California 94555
Your vote is very important. Whether or not you plan to
attend the special meeting, if you are a holder of Ciphergen
common stock, please take the time to vote by completing,
signing, dating and mailing the enclosed proxy card to us so
your shares are represented at the special meeting. If you do
not vote, it will have the same effect as a vote against the
asset sale to Bio-Rad and the adjournment proposal.
Gail S. Page
President and Chief Executive Officer
Ciphergen Biosystems, Inc.
The proxy statement is dated September 28, 2006, and is
first being mailed to stockholders of Ciphergen on or about
September 28, 2006.
CIPHERGEN
BIOSYSTEMS, INC.
6611 Dumbarton Circle
Fremont, California 94555
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Be Held on Thursday, October 26, 2006
To our stockholders:
NOTICE IS HEREBY GIVEN that a special meeting of stockholders of
Ciphergen Biosystems, Inc., a Delaware corporation, will be held
on Thursday, October 26, 2006, at 2:00 p.m., local
time, at Ciphergens headquarters located at
6611 Dumbarton Circle, Fremont, California: Your vote is
very important. Please take a moment to read this letter in an
effort to help Ciphergen to avoid the added expense of further
solicitation. The proposals to be considered at the special
meeting of stockholders are as follows
1. To consider and vote upon a proposal to approve the
proposed sale of the assets used in our proteomics business,
referred to as our research tools business, to Bio-Rad
Laboratories, Inc. pursuant to the asset purchase agreement
attached as Annex A to the accompanying proxy statement.
2. To consider and vote upon a proposal to grant
discretionary authority to adjourn or postpone the Ciphergen
special meeting to another time or place for the purpose of
soliciting additional proxies.
3. To transact such other business as may properly come
before the Ciphergen special meeting and any adjournments
thereof.
The foregoing items of business are more fully described in the
proxy statement accompanying this notice, which you are
encouraged to read in its entirety. The board of directors of
Ciphergen has fixed the close of business on September 15,
2006, as the record date for the determination of stockholders
entitled to notice of, and to vote at, the special meeting and
any adjournment or postponement thereof. Only holders of record
of shares of Ciphergen common stock at the close of business on
the record date are entitled to notice of, and to vote at, the
special meeting or any adjournment or postponement of it. At the
close of business on the record date, Ciphergen had outstanding
and entitled to vote 36,075,017 shares of common stock.
Your vote is important. The affirmative vote of the holders of a
majority of the outstanding shares of Ciphergen common stock is
required to approve the proposed asset sale. The affirmative
vote of a majority of the votes cast is required to approve the
adjournment proposal. Even if you plan to attend the special
meeting in person, we request that you complete, sign, date and
return the enclosed proxy to ensure that your shares will be
represented at the special meeting if you are unable to attend.
If you fail to return your proxy card, the effect will be that
your shares will not be counted for purposes of determining
whether a quorum is present at the Ciphergen special meeting,
but will effectively be counted as a vote against the proposed
asset sale and other matters. If you do attend the special
meeting and wish to vote in person, you may withdraw your proxy
and vote in person.
The Ciphergen board of directors recommends that you vote
FOR the asset sale to Bio-Rad and other matters as
described in the proxy.
By Order of the Board of Directors,
Gail S. Page
President and Chief Executive Officer
Fremont, California
September 28, 2006
PROXY
STATEMENT
Special Meeting of Stockholders
Of Ciphergen Biosystems, Inc.
To Be Held On Thursday, October 26, 2006
GENERAL
INFORMATION
We are first mailing this proxy statement and accompanying
notice and the enclosed proxy card to stockholders beginning on
September 28, 2006. Our board of directors is soliciting
your proxy to vote your shares of common stock at the special
meeting of stockholders to be held on Thursday, October 26,
2006, or at any adjournment or postponement of the special
meeting. We will bear all expenses incurred in connection with
this solicitation, which is expected to be primarily by mail. In
addition to solicitation by mail, our directors, officers and
regular employees may solicit your proxy by telephone, by
facsimile transmission or in person, for which they will not be
compensated. If your shares of common stock are held through a
broker, bank or other nominee (i.e., in street
name), we have requested that they forward this proxy
statement to you and obtain your voting instructions, for which
we will reimburse them for their reasonable
out-of-pocket
expenses.
If your shares of common stock were held in street name on the
record date, the broker or other nominee that was the record
holder of your shares of common stock may have the authority to
vote them at the special meeting. If your shares of common stock
are held in street name and you want to vote your shares of
common stock in person at the special meeting or change your
vote, you must obtain a legal proxy from your broker or nominee.
If you vote by signing and returning the enclosed proxy card,
the individual named as proxy on the card may vote your shares
of common stock, in their discretion, on any other matter
requiring a stockholder vote that comes before the meeting.
You will receive more than one proxy statement and proxy card or
voting instruction form if your shares of common stock are held
through more than one account (i.e., through different names or
different brokers or nominees). Each proxy card or voting
instruction form only covers those shares of common stock held
in the applicable account. If you hold shares of common stock in
more than one account, you have to provide voting instructions
for all your accounts in order to vote all of your shares of
common stock.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
9
|
|
|
|
|
9
|
|
|
|
|
9
|
|
|
|
|
11
|
|
|
|
|
11
|
|
|
|
|
12
|
|
|
|
|
15
|
|
|
|
|
15
|
|
|
|
|
15
|
|
|
|
|
15
|
|
|
|
|
15
|
|
|
|
|
15
|
|
|
|
|
16
|
|
|
|
|
16
|
|
|
|
|
16
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
18
|
|
|
|
|
18
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
24
|
|
i
|
|
|
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
26
|
|
|
|
|
26
|
|
|
|
|
31
|
|
|
|
|
31
|
|
|
|
|
31
|
|
|
|
|
31
|
|
|
|
|
34
|
|
|
|
|
|
|
|
|
|
A-1
|
|
|
|
|
B-1
|
|
|
|
|
C-1
|
|
ii
SUMMARY
This summary of the terms of the agreement highlights selected
information contained in Proposal One of this proxy
statement and may not contain all of the information that is
important to you regarding Proposal One. To understand
fully the proposed sale of our research tools business and for a
more complete description of the legal terms of the sale, you
should carefully read this entire proxy statement, including the
asset purchase agreement attached as Annex A.
The
Parties to the Asset Sale
|
|
|
Ciphergen Biosystems, Inc.
|
6611 Dumbarton Circle
Fremont, California 94555
Telephone:
(510) 505-2100
Ciphergen is a Delaware corporation and is a provider of
consumables, instruments and research and development services
for biomarker discovery. Ciphergen is dedicated to the
discovery, development and commercialization of specialty
diagnostic tests that change the way a physician treats a
patient and that improve patient outcomes.
|
|
|
Bio-Rad Laboratories, Inc.
|
1000 Alfred Nobel Drive
Hercules, California 94547
Telephone:
(510) 724-7000
Bio-Rad is a Delaware corporation and is a provider of products
for the life science research and clinical diagnostics markets.
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad Parties to the
Asset Sale.
Description
of the Proposed Asset Sale
On August 14, 2006, we entered into an asset purchase
agreement with Bio-Rad. Under the terms of the asset purchase
agreement, we have agreed to sell our assets used in connection
with our research tools business to Bio-Rad in exchange for a
total purchase price of up to $20 million in cash for the
assets and the assumption by Bio-Rad of certain liabilities of
our research tools business. At the closing of the asset sale,
we will receive $16 million in cash and an additional
$2 million will be put into an escrow account for at least
three years following the close of the asset sale, to secure our
indemnification obligations under the asset purchase agreement.
Bio-Rad will retain an additional $2 million pending the
issuance of a reexamination certificate of U.S. Patent
No. 6,734,022, referred to as our SELDI patent, confirming
the patentability of all of the claims as originally issued in
such patent or claims of equivalent scope.
In connection with the proposed asset sale, we also agreed to
enter into a manufacture and supply agreement and a cross
license agreement with Bio-Rad upon the closing of the proposed
asset sale. Under the terms of the manufacture and supply
agreement, Bio-Rad has agreed to supply us with the
instrumentation, chips and supplies previously manufactured by
us in the research tools business, which are necessary to
continue the development of our specialty diagnostics business.
Under the terms of the cross license agreement, for a five-year
period we will have an exclusive license to commercialize the
intellectual property being transferred to Bio-Rad in the
clinical diagnostics market.
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad The Asset Purchase
Agreement, Proposal No. 1
Proposal to Approve the Asset Sale to Bio-Rad
Ancillary Agreements.
Our
Reasons for the Proposed Asset Sale
The proposed asset sale will enable us to realize immediately
the value of our research tools business in cash, thereby
increasing our ability to finance our specialty diagnostics
business, as described in Annex B New Business
Strategy.
1
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad Ciphergens
Reasons for the Asset Sale.
Recommendation
of Our Board of Directors Regarding the Proposed Asset
Sale
At a meeting on August 14, 2006, our board of directors
unanimously determined that the proposed asset sale is in the
best interest of Ciphergen and our shareholders and unanimously
approved the proposed asset sale. Our board of directors
recommends that you vote FOR the approval of the
proposed asset sale.
Opinion
of our Financial Advisor
Oppenheimer & Co. Inc. delivered its oral opinion to
our board of directors on August 14, 2006, subsequently
confirmed in writing as of August 14, 2006, to the effect
that and based upon and subject to the various assumptions set
forth in the written opinion, the consideration to be paid by
Bio-Rad in the asset sale was fair, from a financial point of
view, to us.
The full text of the written opinion of Oppenheimer, dated
August 14, 2006, which sets forth the assumptions made,
procedures followed, other matters considered and limitations on
the review undertaken by Oppenheimer in connection with the
opinion, is attached as Annex C to this proxy statement and
is incorporated in this proxy statement by reference. We
encourage you to read the opinion in its entirety. Oppenheimer
provided its opinion for the information and assistance of our
board of directors in connection with its consideration of the
asset sale. The Oppenheimer opinion is not a recommendation as
to how any holder of our common stock should vote with respect
to the asset sale.
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad Opinion of our
Financial Advisor.
Interests
of Our Directors and Executive Officers in the Proposed Asset
Sale
In considering the recommendation of our board of directors with
respect to the proposed asset sale, our stockholders should be
aware that certain of our executive officers may have an
interest in the sale of our assets that could differ from the
interests of our stockholders.
We entered into an employment agreement, dated December 31,
2005, with Gail S. Page, our president and chief executive
officer and a member of our board of directors. In relevant
part, the agreement provides that if Ciphergen undergoes a
change of control and within 12 months afterwards
Ms. Pages employment is terminated or constructively
terminated without cause, she will receive severance pay and
medical benefits for a period of 12 months and all of the
options granted to her will immediately vest.
We entered into an employment agreement, dated January 15,
2005, with James P. Merryweather, PhD, our executive vice
president, sales and marketing. In relevant part, the agreement
provides that if Ciphergen undergoes a change of control and
within 12 months afterwards Dr. Merryweathers
employment is terminated or constructively terminated without
cause, he will receive severance pay and medical benefits for a
period of 12 months and all of the options granted to him
will immediately vest.
As used in each of these agreements, (i) a change of
control includes the sale or other disposition of all or
substantially all of our companys assets; (ii) a
constructive termination includes any purported
termination of the employee which is not effected for
cause or for which the grounds relied upon are not
valid; and (iii) cause includes, among other
things, termination of employment due to the employees
willful, repeated failure substantially to perform his or her
duties, a willful act by the employee that constitutes gross
misconduct and that is injurious to our company and conviction
of a felony crime. It is our position that the asset sale to
Bio-Rad does not constitute a change in control as defined in
these agreements. Should the asset sale be deemed to be a change
of control, and the aforementioned employees are terminated
within twelve months of the proposed asset sale for reasons
other than for cause, we would be required to provide the
severance pay and benefits described above.
2
Closing
of the Proposed Asset Sale
We expect to close the proposed asset sale following the
satisfaction or waiver of all of the conditions to each
partys obligations under the asset purchase agreement. We
expect to complete the proposed asset sale soon after this
special shareholders meeting
Conditions
to the Completion of the Asset Sale
Our and Bio-Rads obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following conditions:
|
|
|
|
|
approval by our shareholders;
|
|
|
|
each partys representations and warranties in the asset
purchase agreement are true and correct as of the closing date;
|
|
|
|
all consents, approvals, permits and waivers from governmental
authorities and other parties necessary to allow Ciphergen to
transfer the assets to Bio-Rad and to operate the research tools
business have been obtained;
|
|
|
|
the absence of any orders or injunctions prohibiting the
completion of the asset sale;
|
|
|
|
the receipt of required legal opinions and officers
certificates from each party;
|
|
|
|
the receipt of board resolutions from each party approving the
asset purchase agreement and all ancillary agreements and the
transactions contemplated thereby; and
|
|
|
|
execution of the ancillary agreements described in the asset
purchase agreement.
|
Ciphergens obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following additional condition:
|
|
|
|
|
Bio-Rad executes the assumption document evidencing
Bio-Rads assumption of assumed liabilities pursuant to the
asset purchase agreement.
|
Bio-Rads obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following additional conditions:
|
|
|
|
|
we have executed and delivered to Bio-Rad all documents
necessary to transfer the assets and liabilities contemplated by
the asset purchase agreement; and
|
|
|
|
Bio-Rad has obtained or been granted the right to use all
licenses, permits, franchises, approvals, authorizations,
consents and the like, necessary and desirable for the present
conduct of or relating to the current operation of the research
tools business.
|
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad The Asset Purchase
Agreement.
Termination
of the Asset Purchase Agreement
We and Bio-Rad may terminate the asset purchase agreement by
mutual written consent, or either party can terminate if the
asset sale has not closed on or before November 1, 2006,
and if our stockholders vote not to approve the asset sale and
other transactions contemplated by the asset purchase agreement.
We may terminate the asset purchase agreement if, before the
vote of our stockholders at the special meeting and after
compliance with our no-solicitation covenant, we elect to enter
into a binding agreement with respect to a superior proposal. In
such event, we are obligated to pay Bio-Rad a termination fee of
$2 million.
See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad The Asset Purchase
Agreement.
3
QUESTIONS
AND ANSWERS ABOUT THE SPECIAL MEETING
|
|
|
Q: |
|
What proposals will be voted on at the special meeting? |
|
A: |
|
The following proposals will be voted on at the special meeting: |
|
|
|
|
|
The first proposal to be voted on is a proposal to approve the
proposed sale of the assets of our research tools business to
Bio-Rad Laboratories, Inc. pursuant to the terms of the asset
purchase agreement attached as Annex A to this proxy
statement. See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad.
|
|
|
|
The second proposal to be voted on is a proposal to grant
discretionary authority to adjourn or postpone the Ciphergen
special meeting to another time or place for the purpose of
soliciting additional proxies, which we refer to in this proxy
statement as the Ciphergen adjournment proposal. See
Proposal No. 2 Proposal to Grant
Authority to Adjourn or Postpone the Special Meeting.
|
|
|
|
Q: |
|
Why are you selling the assets of the research tools
business? |
|
A: |
|
We are selling the assets of the research tools business so that
we can focus on developing our emerging specialty diagnostics
business. This diagnostics focus stems from our core competency,
which involves biomarker discovery derived from a suite of tools
for protein separation combined with rigorous study design. |
|
Q: |
|
What will you do with the proceeds from the sale of the
assets of the research tools business? |
|
A: |
|
We will use the proceeds of the asset sale to support the
development of our emerging specialty diagnostics business. |
|
Q: |
|
Who is the purchaser in the proposed asset sale? |
|
A: |
|
The purchaser is Bio-Rad Laboratories, Inc. Bio-Rad is a public
company headquartered in Hercules, California, which serves more
than 70,000 research and industry customers worldwide through
its global network of operations. Bio-Rad employs over 5,000
people globally and had revenues of $1.1 billion in 2005. |
|
Q: |
|
What is the purchase price for our assets? |
|
A: |
|
Bio-Rad has agreed to pay us a total purchase price of up to
$20 million in cash for the assets and to assume certain
liabilities of our research tools business. At the closing of
the asset sale, we will receive $16 million in cash and an
additional $2 million will be put into an escrow account
for at least three years after the close of the asset sale, to
secure our indemnification obligations under the asset purchase
agreement. Bio-Rad will retain an additional $2 million
pending the issuance of a reexamination certificate of a
specific patent, as more fully discussed below in this proxy
statement. |
|
Q: |
|
What will happen if the asset sale to Bio-Rad is approved? |
|
A: |
|
If the asset sale to Bio-Rad is approved, we will complete the
sale of the assets to Bio-Rad in accordance with the terms of
and subject to satisfaction of the closing conditions set forth
in the asset purchase agreement. We anticipate that the
transaction will close shortly after the special meeting.
Following this sale, we will focus on developing our emerging
specialty diagnostics business. |
|
Q: |
|
What will happen if the asset sale to Bio-Rad is not
approved? |
|
A: |
|
If our stockholders do not approve the sale of the research
tools business, we will continue to operate the research tools
business and continue to explore strategic alternatives. The
failure of the sale of the research tools business to be
consummated could adversely effect our research tools business
through loss of customers, loss of employees and other factors. |
|
Q: |
|
Do I have any appraisal rights in connection with the asset
sale? |
|
A: |
|
No. Our stockholders do not have appraisal rights in
connection with the asset sale. |
4
|
|
|
Q |
|
What is our board of directors recommendation with
respect to the proposals to be considered at the special
meeting? |
|
A: |
|
Our board of directors recommends a vote FOR
approval of the asset sale and the grant of discretionary
authority to adjourn or postpone the special meeting. |
|
Q: |
|
What vote is required? |
|
A: |
|
The affirmative vote of the holders of a majority of the
outstanding shares of Ciphergen common stock is required to
approve the proposed asset sale. The affirmative vote of a
majority of the votes cast is required to approve the
adjournment proposal. |
|
Q: |
|
What do I need to do now? |
|
A: |
|
After carefully reading and considering the information
contained in this proxy statement, you should complete and sign
your proxy and return it in the enclosed return envelope as soon
as possible so that your shares may be represented at the
meeting. A majority of shares entitled to vote must be
represented at the meeting to enable us to conduct business at
the meeting. See Information About the Special
Meeting. |
|
Q: |
|
Can I change my vote after I have mailed my signed proxy? |
|
A: |
|
Yes. You can change your vote in one of three ways at any time
before proxies are voted at the meeting. First, you can send a
written notice via registered mail to our president and chief
executive officer, Gail S. Page, at our executive offices,
stating that you would like to revoke your proxy. Second, you
can complete and submit a new proxy. If you choose either of
these two methods, you must submit the notice of revocation or
the new proxy to us before the special meeting. Third, you can
attend the meeting and vote in person. See Information
About the Special Meeting Revocability of
Proxies. |
|
Q: |
|
If my Ciphergen shares are held in street name by
my broker, will the broker vote the shares on my behalf? |
|
A: |
|
A broker will vote Ciphergen shares only if the holder of
these shares provides the broker with instructions on how to
vote. Shares held in street name by brokers or
nominees who indicate on their proxies that they do not have
discretionary authority to vote such shares as to a particular
matter, referred to as broker non-votes, will not be
voted in favor of such matter. The proposal to approve the
proposed asset sale requires the affirmative vote of a majority
of our outstanding shares in order for the sale to be approved
by our stockholders. Accordingly, broker non-votes will have the
effect of a vote against the proposed asset sale. The proposal
to grant discretionary authority to adjourn or postpone the
special meeting requires the affirmative vote of a majority of
the votes cast at the special meeting, so a broker non-vote will
have no effect on the outcome of that proposal. We encourage all
stockholders whose shares are held in street name to provide
their brokers with instructions on how to vote. See
Information About the Special Meeting Quorum;
Abstentions; Broker Non-Votes. |
|
Q: |
|
Can I still sell my shares of Ciphergen common stock? |
|
A: |
|
Yes. Our common stock is currently traded on The Nasdaq Capital
Market. |
|
Q: |
|
Who can help answer my questions? |
|
A: |
|
If you have any questions about the special meeting or the
proposals to be voted on at the special meeting, or if you need
additional copies of this proxy statement or copies of any of
our public filings referred to in this proxy statement, you
should contact our Investor Relations department at
510-505-2233. Our public filings can also be accessed at the
Securities and Exchange Commissions web site at
www.sec.gov. |
5
CAUTION
AGAINST FORWARD-LOOKING STATEMENTS
This proxy statement contains certain forward-looking
statements, including statements concerning the value of our
assets, projections of our future revenue and financial
condition, anticipated deployment, capabilities and uses of our
products and our product development activities and product
innovations, existing and future collaborations and
partnerships, our belief that biomarker discoveries may have
diagnostic and/or therapeutic utility; our belief that we and
our collaborators can discover relevant biomarkers and
successfully develop diagnostic tests based on such biomarkers,
our plans to commercialize diagnostic tests by ourselves and
through our strategic alliance with Quest Diagnostics and to
enter into strategic alliances with other parties to do so, the
size of potential markets for our diagnostic tests, our ability
to comply with applicable government regulations, our ability to
expand and protect our intellectual property portfolio, our
ability to decrease costs, the estimates of ongoing expenses,
and the likelihood of stockholder value resulting from the sale
of our assets. We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995, and are including this statement for purposes of
invoking these safe harbor provisions. Such forward-looking
statements involve known and unknown risks, uncertainties and
other important factors that could cause our actual results,
performance or achievements, or industry results, to differ
materially from our expectations of future results, performance
or achievements expressed or implied by such forward-looking
statements. These risks include the risk that the asset sale may
not be consummated, that the
ProteinChip®
technology may fail to discover successful protein biomarkers
that have diagnostic utility, that any biomarkers which are
discovered may not successfully be developed into diagnostic
tests, and that we may fail in our ability to protect and
promote our proprietary technologies, decrease costs and obtain
future funding. Although we believe that the expectations
reflected in any forward-looking statements are reasonable, we
cannot guarantee future events or results. Except as may be
required under federal law, we undertake no obligation to update
publicly any forward-looking statements for any reason, even if
new information becomes available or other events occur.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
We are a public company subject to the reporting requirements of
the Securities Exchange Act of 1934, as amended, and, in
accordance with the Securities and Exchange Act, we are
obligated to file with the Securities and Exchange Commission
(SEC) periodic reports, proxy statements and other information
relating to our business, financial condition and other matters.
We are incorporating by reference into this proxy statement each
document that we file with the SEC under the Securities and
Exchange Act after the date of this proxy statement and prior to
the special meeting. All such documents will be deemed to be
part of this proxy statement from the date that such documents
are filed with the SEC.
We are also incorporating by reference into this proxy statement
the following documents that we have previously filed with the
SEC:
|
|
|
|
|
Annual Report on
Form 10-K
for the fiscal year ended December 31, 2005, filed with the
SEC on March 17, 2006;
|
|
|
|
Quarterly Report on
Form 10-Q
for the quarter ended March 31, 2006, filed with the SEC on
May 15, 2006;
|
|
|
|
Quarterly Report on
Form 10-Q
for the quarter ended June 30, 2006, filed with the SEC on
August 16, 2006; and
|
|
|
|
Current Reports on
Form 8-K
filed with the SEC on March 23, 2006, April 18, 2006,
May 4, 2006, May 26, 2006, May 31, 2006,
June 13, 2006, June 30, 2006, and August 14, 2006.
|
Each of the documents referred to above may also be examined and
copies may be obtained from the SECs Public Reference Room
at 100 F Street, NE, Washington, D.C. 20549, or from the
SECs Internet website at http://www.sec.gov. You
can obtain information on the operation of the SECs Public
Reference Room by calling the SEC at
1-800-SEC-0330.
Our SEC filings are also available, free of charge, through our
Internet website at http://
6
www.ciphergen.com under the Investor
Relations portion of our website. You may also obtain
copies of our SEC filings, free of charge, by contacting us in
writing or by telephone as follows:
Ciphergen Biosystems, Inc.
6611 Dumbarton Circle
Fremont CA 94555
(510) 505-2100
If you would like to request documents from us, please do so
promptly in order to ensure timely receipt before the special
meeting.
INFORMATION
ABOUT THE SPECIAL MEETING
This proxy statement is being furnished to you in connection
with the solicitation of proxies by our board of directors in
connection with our special meeting of stockholders.
Date,
Time and Place of Special Meeting
We will hold the special meeting of Ciphergen stockholders at
6611 Dumbarton Circle, Fremont, California on Thursday,
October 26, 2006, at 2:00 p.m., local time.
Purpose
of Special Meeting
At the special meeting, the following proposals will be
presented:
|
|
|
|
|
The first proposal to be voted on is a proposal to approve the
proposed sale of the assets of our research tools business to
Bio-Rad pursuant to the terms of the asset purchase agreement
attached as Annex A to this proxy statement. See
Proposal No. 1 Proposal to Approve
the Asset Sale to Bio-Rad.
|
|
|
|
The second proposal to be voted on is a proposal to grant
discretionary authority to adjourn or postpone the Ciphergen
special meeting to another time or place for the purpose of
soliciting additional proxies, which we refer to in this proxy
statement as the Ciphergen adjournment proposal. See
Proposal No. 2 Proposal to Grant
Authority to Adjourn or Postpone the special meeting.
|
Ciphergen stockholders will also be asked to consider any other
business that may properly come before the special meeting or
any adjournment or postponement of the special meeting. We
currently do not contemplate that any other matters will be
considered at the special meeting.
Record
Date and Voting Securities
Stockholders of record as of the record date, September 15,
2006, are entitled to notice of and to vote at the special
meeting. As of the record date, 36,075,017 shares of our
common stock were issued and outstanding. Each share of common
stock outstanding as of the record date will be entitled to one
vote and stockholders may vote in person or by proxy.
Vote
Required
The proposal to approve the asset sale to Bio-Rad requires the
affirmative vote of a majority of our outstanding shares in
order for the sale to be approved by our stockholders. The
proposal to grant discretionary authority to adjourn or postpone
the special meeting requires the affirmative vote of a majority
of our outstanding shares in order for the adjournment proposal
to be approved.
7
Revocability
of Proxies
Execution of a proxy will not in any way affect a
stockholders right to attend the special meeting and vote
in person. Any stockholder giving a proxy has the right to
revoke it in one of three ways:
|
|
|
|
|
you can send a written notice via registered mail to our
president and chief executive officer, Gail S. Page, at our
executive offices, stating that you would like to revoke your
proxy;
|
|
|
|
you can complete and submit a new proxy; or
|
|
|
|
you can attend the meeting and vote in person.
|
If you choose either of the first two methods, you must submit
the notice of revocation or the new proxy to us before the
special meeting.
Quorum;
Abstentions; Broker Non-Votes
The presence in person or by proxy of the holders of at least a
majority of the outstanding shares of common stock entitled to
vote at the special meeting is necessary to establish a quorum
for the transaction of business. Votes cast by proxy or in
person at the special meeting will be tabulated by the inspector
of elections. The inspector of elections will also determine
whether or not a quorum is present. Abstentions are included in
the number of shares present or represented at the special
meeting.
Shares held in street name by brokers or nominees
who indicate on their proxies that they do not have
discretionary authority to vote such shares as to a particular
matter, referred to as broker non-votes, and shares
which abstain from voting as to a particular matter, will not be
voted in favor of such matters. The proposal to approve the
asset sale to Bio-Rad requires the affirmative vote of a
majority of our outstanding shares in order for the sale to be
approved by our stockholders. Accordingly, abstentions and
broker non-votes will have the effect of a vote against the
proposal to approve the asset sale to Bio-Rad.
Adjournment
and Postponement
Whether or not a quorum is represented at a stockholder meeting,
our bylaws permit the stockholders present in person or
represented by proxy to adjourn the meeting from time to time by
the vote of the majority of the shares represented at that
meeting without notice other than announcement at the meeting,
until a quorum is present or represented. The Delaware General
Corporation Law requires that if a meeting is adjourned for more
than 30 days after the date for which the meeting was
originally noticed, or if a new record date is fixed for the
adjourned meeting, written notice of the place, date and time of
the adjourned meeting must be given to the stockholders.
Solicitation
of Proxies
We will bear the cost of soliciting proxies. In
addition, we may reimburse brokerage firms and other persons
representing beneficial owners of shares for their expenses in
forwarding solicitation material to such beneficial owners.
Solicitation of proxies by mail may be supplemented by
telephone, facsimile,
e-mail or
personal solicitation by our directors, officers or regular
employees. We will not pay any additional compensation to such
persons for such services.
8
Assistance
If you have any questions about the proposals or how to vote or
revoke a proxy, or if a Ciphergen stockholder wishes to obtain
additional copies of this document or election forms, the
stockholder should contact:
Ciphergen Biosystems, Inc.
6611 Dumbarton Circle
Fremont, California 94555
Attention: Investor Relations
Telephone Number:
(510) 505-2100
PROPOSAL NO. 1
PROPOSAL TO APPROVE THE ASSET SALE TO BIO-RAD
This section of the proxy statement describes material aspects
of the proposed asset sale to Bio-Rad, including the asset
purchase agreement attached as Annex A to this proxy
statement. This summary may not contain all of the information
that is important to you. You should carefully read this proxy
statement, including the full text of the asset purchase
agreement, for a more complete understanding of the asset sale.
Background
of the Asset Sale
We have incurred operating losses and negative cash flows since
our inception, and revenues from the research tools business
have declined from $43.6 million in 2003 to
$40.2 million in 2004 to $27.2 million in 2005.
However, during that time, we have discovered and filed patents
on biomarkers and patterns of biomarkers that can potentially be
developed into specialty diagnostic tests to improve patient
care. In July 2005, we entered into a strategic alliance
agreement with Quest Diagnostics Incorporated pursuant to which
the parties have agreed to develop and commercialize up to three
diagnostics tests based on Ciphergens proprietary SELDI
technology during a three year period.
In the fourth quarter of 2005, we held a series of discussions
with Bio-Rad about their possible interest in our designing a
customized version of our PCS 4000 ProteinChip instrument for a
particular application which would complement Bio-Rads
existing product lines sold to life science researchers. As a
result of a series of meetings in the fourth quarter, criteria
were drawn up for the specifications for such an instrument and
we began to develop preliminary data for this application. This
was followed up by a meeting of members of the parties
respective scientific and business staffs at our Fremont
facility in December 2005.
In December 2005, there were a series of significant changes in
our management team. Following the retirement of
Dr. William E. Rich, Gail S. Page became president and
chief executive officer. Ms. Page had joined Ciphergen in
early 2005 as executive vice president and president of our
diagnostics division and, in mid-2005, Ms. Page was
promoted to president and chief operating officer.
In January 2006, there was a strategic planning meeting of the
new management team where the business prospects of the research
tools business and our diagnostics business, as well as the
financial picture of Ciphergen, were discussed at length. At
this meeting, it was the consensus view of management that our
greatest opportunity for future value creation lay in focusing
our resources on the emerging specialty diagnostics business.
While we believe our ProteinChip platform is a powerful research
tool, it is only one of a variety of tools needed by proteomics
researchers today. We currently offer a single instrument, while
our competitors offer a suite of instruments and related
products. Therefore, we determined that it would be in our
stockholders best long-term interest to focus on the
commercialization of our biomarker capability in the specialty
diagnostics market, and that strategic options regarding our
research tools business, including the sale of the research
tools business to provide capital for our diagnostics efforts,
should be explored.
In January 2006, Mr. Norman Schwartz, chief executive
officer, and Mr. Todd Morrill, director, acquisitions and
business development for Bio-Rad, met at our headquarters with
Gail Page and Dr. Simon Shorter, vice president of
corporate business development. At this meeting we presented a
business plan which included a potential strategic transition of
our business from manufacturing and selling instruments,
consumables and software, into a business developing and selling
diagnostic products. Discussions moved from the possibility
9
of our building a customized instrument to be resold by Bio-Rad
to the potential acquisition by Bio-Rad of our entire research
tools business.
On January 26, 2006, members of Bio-Rads acquisitions
and business development group visited our headquarters and the
first of a series of documents including Ciphergens
financial information and intellectual property were provided
pursuant to a confidentiality agreement.
On February 8, 2006, there was a meeting of our board of
directors. At this meeting, plans for the potential divestiture
of the research tools business were discussed and an update on
all the discussions to date was presented. This update included
a summary of discussions with two other entities, referred to
here as Party A and Party B, described below, as well as the
status of discussions with Bio-Rad. It was stated at this
meeting that Bio-Rad had made a non-binding, verbal offer to
purchase the research tools business for up to $20 million.
Initial discussions about a possible business arrangement with
Party A began in October 2005. This was followed by a conference
call with our management in January 2006 and a site visit to our
headquarters in February 2006. Detailed financial information,
technical data, intellectual property and other due diligence
materials were provided to Party A. Following these discussions,
a non-binding indication of interest was made by Party A to buy
only the consumables portion of our research tools business.
This offer was deemed to be insufficient and all further
conversations with this party ceased at that time.
In March 2006, a meeting took place between our chief executive
officer and our executive chairman of the board and the chief
executive officer of Party B, in which we provided a business
update and the nature of our strategic transition plans were
described. Following this meeting, Party B verbally described
interest in an arrangement whereby Party B would manufacture a
mass spectrometer for sale by us. Since this type of transaction
failed to accomplish our broader strategic goals, no further
discussion with this party took place.
During this period, two additional companies were approached
about potentially acquiring our research tools business but
neither party expressed interest.
In summary, there were discussions with five companies. Three of
these had significant but varied interests, and the management
team determined that further discussions with Bio-Rad offered
the greatest opportunity for future value creation.
Throughout March and April 2006, further discussions took place
with Bio-Rad and, on April 12, 2006, our board of directors
had a meeting at which it was agreed that we should proceed with
the offer from Bio-Rad and also established that there was no
continuing or acceptable interest from other parties at this
time.
On May 12, 2006, Ciphergen and Bio-Rad signed a nonbinding
letter of intent, which included binding confidentiality and
standstill provisions. These letters were approved by a
telephonic meeting of our board on May 12, 2006. Following
execution of these agreements, we and our outside counsel began
negotiating the terms of a definitive agreement with Bio-Rad.
Following discussions among our management and further
discussions with Bio-Rad regarding our requirement to retain the
right to continue to conduct business in the clinical
diagnostics area, Bio-Rad indicated a willingness to consider
purchasing the assets of our research tools business for up to
$20 million, as well as to make an equity investment of up
to $3 million in Ciphergen.
Subsequently, multiple due diligence meetings between the
parties took place. On May 23, 2006, Mr. Todd Morrill
and other members of Bio-Rad management conducted an
on-site
visit to our headquarters. This meeting was followed by a
subsequent
on-site due
diligence session on June 2, 2006. On June 13, 2006, a
third
on-site due
diligence visit took place in which Mr. Todd Morrill and
members of the Bio-Rad legal, financial and technical team spent
another day at our headquarters.
During the week of June 12, 2006, Mr. Todd Morrill and
Mr. Tom Slyker, new technologies marketing manager,
of Bio-Rad accompanied Dr. Jim Merryweather, executive
vice president of sales and marketing, and Dr. Simon
Shorter on visits to our customers on the east coast of the
United States and to our Biomarker Discovery
Center®
laboratory in Malvern, Pennsylvania. During the week of
June 26, 2006, a similar due diligence visit was conducted
by Mr. Morrill and Drs. Merryweather and Shorter, with
visits to our Guildford, UK and Copenhagen, Denmark, Biomarker
Discovery Center laboratories.
10
Between July 1 and August 13, 2006, we and Bio-Rad and
our respective legal counsel negotiated the terms and conditions
of the asset purchase agreement, including the specific assets
and liabilities to be transferred, the closing conditions and
the terms under which we could consider alternative proposals to
the asset sale to Bio-Rad, termination, termination fees and the
indemnification provisions and the terms of the stock sale,
manufacture and supply agreement, cross license agreement and
other ancillary agreements.
On August 14, 2006, our board of directors held a
telephonic meeting. Ms. Gail Page gave an overview of the
terms of the proposed transaction with Bio-Rad. Our outside
legal counsel then reviewed with our board their fiduciary
duties in connection with the proposed transaction with Bio-Rad
and reviewed with our board the terms and conditions of the
proposed asset purchase agreement, stock purchase agreement and
ancillary agreements negotiated with Bio-Rad, including the
termination, termination fee and indemnification provisions.
Also at this time, our board of directors reviewed the oral
opinion and proposed form of opinion letter from
Oppenheimer & Co., to the effect that and based upon
and subject to the various assumptions set forth in the written
opinion, the consideration to be paid by Bio-Rad in the asset
sale was fair, from a financial point of view, to us. See
Proposal No. 1 Proposal to Approve
the Asset Sale to Bio-Rad Opinion of our Financial
Advisor. The analyses supplied by Oppenheimer and its
opinion were among several factors taken into consideration by
our board of directors in making its decision to enter into the
asset sale to Bio-Rad, and should not be considered as
determinative of such decision. After extensive discussion and
deliberation, our board of directors approved the asset purchase
agreement and the transactions contemplated by the asset
purchase agreement, resolved to recommend that our stockholders
approve the asset purchase agreement, and authorized execution
of the asset purchase agreement.
The parties executed the asset purchase agreement and issued a
press release announcing the execution on August 14, 2006.
Use of
Proceeds from the Proposed Asset Sale
If the proposed asset sale is completed, we currently intend to
utilize the net proceeds to fund the development of our emerging
specialty diagnostics business. We believe that there is a
market opportunity in the discovery, development and
commercialization of specialty diagnostic tests that help
physicians manage their patients and that improve patient
outcomes.
Ciphergens
Reasons for the Asset Sale; Recommendation of the Board of
Directors
Our board of directors considered a number of factors before
recommending that our stockholders approve the proposed asset
sale, including the following:
|
|
|
|
|
that we had explored strategic alternatives, including
discussions with alternative parties concerning the sale of
Ciphergens research tools business, as described above;
|
|
|
|
that we would require additional time and resources to locate
and negotiate with any other potential purchasers for the
assets, with no assurance that any such negotiations would be
completed successfully, in a timely fashion, or at all;
|
|
|
|
that the consideration offered by Bio-Rad for our research tools
business represented what our management and board of directors
believed was the offer that would result in higher value to our
stockholders with greater certainty of timely consummation than
any offer from any third party and would be paid substantially
in cash;
|
|
|
|
that certain of the ancillary agreements to the asset purchase
agreement would still allow us to commercialize our biomarker
technology in the specialty diagnostics market;
|
|
|
|
the financial presentation of Oppenheimer on August 14,
2006 and the oral opinion of Oppenheimer delivered on
August 14, 2006 to our board of directors, subsequently
confirmed in writing as of August 14, 2006, to the effect
that and based upon and subject to the various assumptions set
forth in the written opinion, as of August 14, 2006, the
consideration to be paid by Bio-Rad in the asset sale was fair,
from a financial point of view, to us (the full text of the
written opinion of Oppenheimer, which sets forth the assumptions
|
11
|
|
|
|
|
made, procedures followed, other matters considered and
limitations on the review undertaken by Oppenheimer in
connection with the opinion, is attached as Annex C to this
proxy statement and is incorporated into this proxy statement by
reference);
|
|
|
|
|
|
that we would be entitled to engage with third parties who make
acquisition proposals under certain circumstances and that we
would be entitled to terminate the asset purchase agreement,
with the payment of a termination fee, to enter into an
agreement for a superior proposal;
|
|
|
|
that the value of our assets, particularly our intellectual
property and certain contracts and customer relationships, would
decline with the passage of time;
|
|
|
|
our business and financial prospects if we were to continue the
operation of our business as currently conducted;
|
|
|
|
our financial condition, historical results of operations and
business and strategic objectives, including the risks involved
in achieving those objectives and the fact that we have incurred
operating losses and negative cash flows from operations since
our inception and we expect to continue to incur operating and
net losses for the foreseeable future;
|
|
|
|
that Bio-Rad would assume certain of our obligations; and
|
|
|
|
the terms and conditions of the asset purchase agreement and the
likely timing of closing of the asset sale to Bio-Rad.
|
In the course of its deliberations, our board of directors also
considered, among other things, the following negative factors:
|
|
|
|
|
risks and contingencies related to the announcement and pendency
of the asset sale, including the likely impact of the asset sale
on our employees, customers and partners and the expected effect
of the asset sale on our existing relationships with third
parties;
|
|
|
|
the possibility that the asset sale will not be completed and
the potential negative effect of public announcement of the
asset sale in that event on our sales, operating results and our
ability to retain key management and personnel;
|
|
|
|
we will not benefit from any potential increase in the value of
the research tools business;
|
|
|
|
the conditions to Bio-Rads obligation to complete the
asset sale and the right of Bio-Rad to terminate the asset
purchase agreement under certain circumstances; and
|
|
|
|
the interests that certain of our directors and executive
officers may have with respect to the asset sale in addition to
their interests as stockholders of Ciphergen generally as
described in Proposal No. 1 Proposal
to Approve the Asset Sale to Bio-Rad Interests of
our Directors and Executive Officers in the Asset Sale.
|
The foregoing includes the material factors considered by our
board of directors. In view of its many considerations, our
board of directors did not quantify or otherwise assign relative
weight to the specific factors considered. In addition,
individual members of our board of directors may have given
different weights to different factors. After weighing all of
these considerations, our board of directors was unanimous in
determining to approve the asset sale and to recommend that our
stockholders approve the proposed asset sale to Bio-Rad.
Factors
to be Considered by Stockholders in Deciding Whether to Approve
the Asset Sale
You should carefully consider the following risk factors
relating to the asset sale before you decide whether to vote to
approve the asset sale proposal. You should also consider the
other information in the proxy statement and the additional
information in our other reports on file with the Securities and
Exchange Commission.
There
is no plan to distribute any of the proceeds of the asset sale
to our stockholders.
We do not intend to distribute any portion of the proceeds from
the asset sale to our stockholders. We currently intend to use
the proceeds from the asset sale to fund and grow our
diagnostics business. However, in light of the
12
evolving nature of our diagnostics business, we cannot specify
exactly how we will spend or invest the proceeds from the asset
sale.
There
is no guarantee of success in the specialty diagnostics
market.
We believe that it is in our best interest to exit the research
tools business and focus our resources on the specialty
diagnostics market. However, to date, we have not developed any
diagnostic products and can offer no assurance that we will be
able to develop any diagnostic products or that we will succeed
in commercializing any diagnostic products we do develop, or
that we will be able to secure sufficient equity or debt
financing necessary to sustain operations until our diagnostic
products generate meaningful revenues. Even if we are able to
complete the development and commercialization of diagnostic
products, we cannot guarantee that we will achieve profitability
or that the diagnostics business will prove successful.
Immediately following the sale of our research tools business,
our remaining business operations will be significantly smaller
and we will not expect revenues until the successful development
and commercialization of products in our diagnostics business.
Our research tools business is currently the only revenue
generating portion of our operations. After the closing of the
asset sale, the specialty diagnostics business will comprise our
remaining business.
We
will be dependent on Bio-Rad for the manufacture and supply of
the ProteinChip platform tools necessary for the successful
development and commercialization of diagnostic
tests
We currently manufacture the ProteinChip instruments, arrays,
and supplies utilized for biomarker discovery and the
development of diagnostic tests. Following the completion of the
asset purchase, Bio-Rad will be the sole supplier to us of these
ProteinChip instruments, arrays, and supplies. Although Bio-Rad
has agreed to manufacture and supply the ProteinChip
instruments, arrays, and supplies for us pursuant to the
manufacture and supply agreement, there can be no assurance
Bio-Rad will manufacture such items meeting applicable
specifications in the quantities and according to the schedule
which we may require. In the event that Bio-Rad is unable to
provide the instruments and ProteinChip arrays as required,
under certain conditions we are allowed to manufacture these
items ourselves or seek a third party supplier, but there is no
guarantee that we will be able to find such a supplier, or that
the cost of purchasing these items will be commercially
reasonable. If we are not able to obtain the necessary
ProteinChip instruments, arrays, and supplies, our ability to
develop diagnostic products will be adversely affected.
Our
strategic alliance with Quest Diagnostics may be negatively
affected by the sale of the research tools
business.
In July 2005, we entered into a strategic alliance with Quest
Diagnostics with the goal of commercializing up to three
diagnostic assays over a three year period. Pursuant to the
strategic alliance agreement, we are responsible for selling
ProteinChip instruments, arrays, and other supplies to Quest
Diagnostics and to develop new versions of such products as may
be required for Quest Diagnostics. Because Bio-Rad will be
responsible for research and development and manufacture related
to the ProteinChip platform following the asset sale, we will
not be able directly to control whether Bio-Rad will devote
sufficient attention and resources to the production and
development of the ProteinChip platform. If we cannot provide
sufficient ProteinChip instruments, arrays, and other supplies
to Quest Diagnostics pursuant to the strategic alliance
agreement, we may be in breach of our obligation to Quest
Diagnostics and, even if we fulfill all our contractual
obligations to Quest Diagnostics, it is possible that our
relationship with Quest Diagnostics will be adversely affected
by the sale of the research tools business to Bio-Rad, which
could have an impact on our successful ability to commercialize
our potential diagnostic tests.
The
asset sale will expose us to contingent liabilities and we may
not receive any of the contingent portion of the consideration
to be paid by Bio-Rad.
Under the asset purchase agreement, we have agreed to indemnify
Bio-Rad for any breaches of our representations, warranties and
covenants contained in the asset purchase agreement, as well as
for certain patent and other matters, up to a maximum amount of
$20 million. $2 million of the purchase price will be
held in escrow for at least three years following the completion
of the asset sale and available to satisfy indemnification
claims made by Bio-Rad against us. An additional $2 million
of the purchase price will be held back by Bio-Rad pending the
issuance of a reexamination certificate relating to one of our
patents, referred to as the SELDI patent, and we have agreed to
a maximum potential liability of $10 million with respect
to the SELDI patent. Unless a
13
reexamination certificate for the SELDI patent is issued which
confirms the patentability of all of the claims as originally
issued in that patent (or claims of equivalent scope), we will
not receive the $2 million being held back by Bio-Rad. It
is possible that, following the completion of the asset sale, we
may receive significant indemnification claims by Bio-Rad, which
may exceed the $2 million escrow amount, potentially
resulting in liabilities to Ciphergen up to the $20 million
cap. We also may receive indemnification claims relating to the
SELDI patent, potentially up to the $10 million cap. The
occurrence of any of these events could have a material adverse
effect on our business following the completion of the asset
sale. See Proposal No. 1 Proposal to
Approve the Asset Sale to Bio-Rad The Asset Purchase
Agreement.
We
will continue to incur liabilities and expenses that will reduce
the cash available to Ciphergen prior to the
closing.
Liabilities and expenses from operations (such as operating
costs, salaries, directors and officers insurance, payroll and
local taxes and legal and accounting fees), including operation
of our research tools business, will continue to be incurred as
we seek to close the asset sale to Bio-Rad, reducing the amount
of cash available for the diagnostics business.
The
asset sale to Bio-Rad could cause the holders of our convertible
promissory notes to demand immediate repayment of the
notes.
Pursuant to the indenture agreement governing the terms of our
outstanding convertible promissory notes, upon a change in
control (as defined in the indenture), the debtholders may elect
to require us to repurchase all or a portion of their notes at a
premium over the face value of the notes. While it is our
position that the asset sale to Bio-Rad does not constitute a
change in control as defined in the indenture, the debtholders
may disagree and seek to force us to repurchase some or all of
their notes, which may result in costly litigation and a
distraction for management. An entity which we believe holds
$18.5 million in principal amount of our convertible
promissory notes has advised us that they disagree with our
position that the asset sale does not constitute a change of
control as defined in the indenture. Such entity has indicated
that it reserves its rights to the remedies set forth in the
indenture, which include the right to have their notes
repurchased at 105% of their principal amount in the event the
asset sale is determined to be a change in control. In the event
that we are required to repurchase notes, we may not have
sufficient funds to do so nor be able to arrange for refinancing
of the notes.
We may
not be able to obtain necessary third party consents to the
transfer of certain assets for closing of the asset
sale.
In addition to other conditions that must be satisfied prior to
closing the asset sale, we are obligated to obtain certain third
party consents, including some of our clients, customers, and
lessors. If we are unable to obtain these consents, the asset
sale may not be consummated. The receipt of these consents
depends upon parties other than us over which we have no control.
If we
do not sell our research tools business, we will have difficulty
sustaining operations over the long-term without significant
amounts of new capital.
Ciphergen has incurred operating losses and negative cash flows
since our inception, and revenues from the research tools
business have declined from $43.6 million in 2003 to
$40.2 million in 2004 to $27.2 million in 2005. There
is no guarantee that, if the asset sale is not approved, we will
be able to obtain additional capital to continue operation of
the business through debt or equity financings.
If we
do not sell our research tools business at this time its value
may decrease.
The value of our assets, particularly our intellectual property
and certain contracts and customer relationships, may decline in
value with the passage of time. If we do not complete the sale
of assets to Bio-Rad, there is no guarantee that, if and when we
find another buyer for the research tools business, the assets
will be valued by such buyer at the same amount as that offered
by Bio-Rad.
14
If we
do not sell our research tools business to Bio-Rad as announced,
it may negatively affect the price of our stock, relationships
with our customers, and our ability to retain key management and
personnel.
If we fail to complete the sale of the research tools business
to Bio-Rad, it may be perceived in the market as a negative sign
of the ability of Ciphergen to sustain its operations over the
long term. This perception could negatively affect the price of
Ciphergens stock, the willingness of customers to renew
contracts, and the ability to retain employees.
Federal
Income Tax Consequences to Us of the Proposed Asset
Sale
As a result of the proposed asset sale, we will sell our
research tools business to Bio-Rad in exchange for up to
$20 million. This amount, plus the amount of liabilities
assumed by Bio-Rad that are required to be capitalized for tax
purposes, will be allocated among all of our assets that are
sold to Bio-Rad. We will recognize gain or loss on each of the
assets sold in an amount equal to the difference between the
sales price allocated to that asset and our tax basis in such
asset.
We do not believe the proposed asset sale will result in federal
or state corporate income tax liability (including any
alternative minimum tax liability), because we anticipate that
any taxable gain with respect to a particular asset will be
offset for income tax purposes by losses that we will recognize
with respect to the sale of other assets as well as our
operating losses, including losses from prior years. However,
tax authorities may disagree with our determination of our
available operating losses or our allocation of the purchase
price among the assets sold, or our operating losses could be
less than anticipated, which may increase our income tax
liability as a result of the proposed asset sale.
Accounting
Treatment of the Proposed Asset Sale
We will account for the proposed asset sale as a sale of assets
and assumption of liabilities, in accordance with accounting
principles generally accepted in the United States (GAAP). Upon
the completion of the asset sale, we will recognize a financial
reporting gain, if any, equal to the net proceeds (the sum of
the purchase price received less the expenses relating to the
asset sale) less the net book value of the assets purchased and
the fair value of the indemnification liability retained.
Regulatory
Approvals
No federal or state regulatory requirements must be complied
with or approvals obtained as a condition of the proposed asset
sale.
Appraisal
Rights
Our stockholders have no appraisal rights in connection with the
sale of assets to Bio-Rad.
Vote
Required and Board of Directors Recommendation
The approval of the proposed asset sale to Bio-Rad requires the
approval of a majority of the outstanding shares of our common
stock.
Our board of directors believes that the proposed asset sale is
in our best interests and the best interests of our stockholders
and recommends a vote FOR the Ciphergen proposal to
approve the asset sale.
Interests
of Our Directors and Executive Officers in the Proposed Asset
Sale
In considering the recommendation of our board of directors with
respect to the proposed asset sale, our stockholders should be
aware that certain of our executive officers may have an
interest in the sale of our assets that could differ from the
interests of our stockholders.
We entered into an employment agreement, dated December 31,
2005, with Gail S. Page, our president and chief executive
officer and a member of our board of directors. In relevant
part, the agreement provides that if Ciphergen undergoes a
change of control and within 12 months afterwards
Ms. Pages employment is terminated or
15
constructively terminated without cause, she will receive
severance pay and medical benefits for a period of
12 months and all of the options granted to her will
immediately vest.
We entered into an employment agreement, dated January 15,
2005, with James P. Merryweather, PhD, our executive vice
president, sales and marketing. In relevant part, the agreement
provides that if Ciphergen undergoes a change of control and
within 12 months afterwards Dr. Merryweathers
employment is terminated or constructively terminated without
cause, he will receive severance pay and medical benefits for a
period of 12 months and all of the options granted to him
will immediately vest.
As used in each of these agreements, (i) a change of
control includes the sale or other disposition of all or
substantially all of our companys assets; (ii) a
constructive termination includes any purported
termination of the employee which is not effected for
cause or for which the grounds relied upon are not
valid; and (iii) cause includes, among other
things, termination of employment due to the employees
willful, repeated failure substantially to perform his or her
duties, a willful act by the employee that constitutes gross
misconduct and that is injurious to our company and conviction
of a felony crime. It is our position that the asset sale to
Bio-Rad does not constitute a change in control, as defined in
these agreements. Should the asset sale be deemed to be a change
of control, and the aforementioned employees are terminated
within twelve months of the proposed asset sale for reasons
other than for cause, we would be required to provide the
severance pay and benefits described above.
The Asset
Purchase Agreement
Parties
to the Asset Sale
Ciphergen
We are a provider of consumables, instruments and research and
development services for biomarker discovery. We are dedicated
to the discovery, development and commercialization of specialty
diagnostic tests that change the way a physician treats a
patient and that improve patient outcomes.
We were incorporated in the state of Delaware on May 23,
2000. We maintain our principal offices at 6611 Dumbarton
Circle, Fremont, California 94555, telephone
(510) 505-2100.
Bio-Rad
Bio-Rad Laboratories provides a broad range of innovative tools
and services to the clinical diagnostics and life science
research markets. The company is world renowned among hospitals,
universities, major research institutions, biotechnology and
pharmaceutical firms for its commitment to quality and customer
service. It has built strong customer relationships that advance
research and development efforts and support the
commercialization of new technology, especially in the
high-growth fields of genomics, proteomics, biopharmaceutical
discovery, food safety and biotechnology education.
Bio-Rad is a corporation organized under the laws of Delaware
and maintains its principal offices at 1000 Alfred Nobel
Drive, Hercules, California 94547, telephone
(510) 724-7000.
General
On August 14, 2006, our board of directors unanimously
approved the asset purchase agreement between us and Bio-Rad,
under which we agreed to sell the assets relating to our
research tools business to Bio-Rad for a total purchase price of
up to $20 million, subject to adjustment as described
below, to be paid by Bio-Rad in cash. The material terms of the
asset purchase agreement are summarized below. A copy of the
asset purchase agreement is attached as Annex A to this
proxy statement and is incorporated into this proxy statement by
reference. We encourage you to read the asset purchase agreement
in its entirety.
16
Assets
to be Sold or Assigned
The assets proposed to be sold to Bio-Rad consist of all right,
title and interest in and to the properties, assets and rights
owned by us and used or held for use principally in connection
with the operation of our research tools business including,
without limitation:
|
|
|
|
|
all contracts or other obligations relating to the research
tools business or the assets;
|
|
|
|
certain leases for real or personal property relating to the
research tools business;
|
|
|
|
all improvements to real property situated in or on real
property subject to the leases to be assigned to Bio-Rad;
|
|
|
|
all fixtures and equipment owned and used in connection with the
research tools business;
|
|
|
|
all inventory used or held for use in connection with the
research tools business;
|
|
|
|
all books and records relating to the research tools business;
|
|
|
|
all right, title and interest in and to any proprietary rights
including, without limitation, intellectual property rights,
relating to the research tools business;
|
|
|
|
all permits and licenses necessary or desirable for the present
conduct of or relating to the current operation of the research
tools business, to the extent transferable;
|
|
|
|
all computers and software principally used in connection with
the research tools business;
|
|
|
|
all insurance policies, to the extent assignable;
|
|
|
|
all accounts and notes receivable, refunds, deposits,
prepayments or prepaid expenses relating to the research tools
business;
|
|
|
|
all available supplies, sales literature, promotional
literature, customer, supplier and distributor lists, art work,
display units, telephone and fax numbers and purchasing records
related to the research tools business;
|
|
|
|
all rights under or pursuant to all warranties, representations
and guarantees made by suppliers in connection with the assets
or services relating to the research tools business or affecting
the assets, to the extent assignable; and
|
|
|
|
all claims, causes of action, choses in action, rights of
recovery and rights of set-off pertaining to the research tools
business including, without limitation, any liens, security
interests, pledges or other rights to payment or to enforce
payment in connection with products delivered prior to the
closing of the asset sale.
|
The assets proposed to be sold to Bio-Rad specifically exclude:
|
|
|
|
|
certain inventory identified in the asset purchase agreement as
excluded assets;
|
|
|
|
all cash and cash equivalents held by us as of the closing of
the asset sale; and
|
|
|
|
all permits and licenses, to the extent not transferable.
|
Liabilities
to be Assumed
The liabilities proposed to be assumed by Bio-Rad in the
transaction consist of the following:
|
|
|
|
|
the liabilities specifically set forth on the closing balance
sheet solely to the extent relating to the research tools
business and incurred in the ordinary course of the research
tools business as of the close of the asset sale: accounts
payable, accrued liabilities, deferred revenue (current) and
deferred revenue (long term); and
|
|
|
|
all liabilities accruing, arising out of or relating to events
or occurrences happening after the close of the asset sale
(1) under certain contracts and leases (a) as listed
on a schedule to the asset purchase agreement or (b) which
are not listed on such schedule, but which we and Bio-Rad agree
in writing that Bio-Rad will accept and assume, but excluding
any liability for any default under any such contract or lease
prior to the close of the asset sale and (2) under the
assigned contracts or leases including, without limitation, all
service
|
17
|
|
|
|
|
and warranty obligations relating to such contracts or leases
arising in the ordinary course of the research tools business.
|
The liabilities proposed to be assumed by Bio-Rad specifically
exclude:
|
|
|
|
|
any liability to or in respect of any of our employees or former
employees;
|
|
|
|
any liability in respect of any tax, except as provided in the
asset purchase agreement;
|
|
|
|
certain liabilities identified in the asset purchase agreement
as excluded liabilities;
|
|
|
|
any liability arising from any injury to or death of any person
or damage to or destruction of any property, whether based on
negligence, breach of warranty, strict liability, enterprise
liability or any other legal or equitable theory arising from
defects in products manufactured or services performed by or on
behalf of Ciphergen or any other person or entity on or prior to
the close of the asset sale;
|
|
|
|
any liability arising out of or related to any claim or legal
proceeding which adversely affects the assets and (1) which
is asserted on or prior to the close of the asset sale or
(2) to the extent the basis of which has arisen on or prior
to the close of the asset sale including, without limitation,
the litigation between Health Discovery Corporation and
Ciphergen;
|
|
|
|
any liability of Ciphergen resulting from entering into,
performing its obligations pursuant to or consummating the
transactions contemplated by the asset purchase
agreement; and
|
|
|
|
any liability related to any former facility.
|
Purchase
Price
Bio-Rad has agreed to pay us a total purchase price of up to
$20 million in cash for the assets and to assume certain
liabilities of our research tools business. At the closing of
the asset sale, we will receive $16 million in cash and an
additional $2 million will be put into an escrow account
for at least three years to secure our indemnification
obligations under the asset purchase agreement. Bio-Rad will
retain an additional $2 million until the issuance of a
reexamination certificate of a specific patent, as more fully
discussed below in this proxy statement.
Bio-Rad represents in the asset purchase agreement that it will
have available to it adequate funds to pay the purchase price in
cash.
Holdback
Bio-Rad will retain a holdback equal to $2 million of the
cash purchase price pending the issuance of a reexamination
certificate of U.S. Patent No. 6,734,022, referred to
as the SELDI patent, confirming the patentability of all of the
claims as originally issued in such patent or claims of
equivalent scope. In the event that such a reexamination
certificate is not issued, we will not receive the
$2 million.
Indemnification
Under the terms of the asset purchase agreement, we have agreed
to indemnify Bio-Rad against any costs, losses, taxes,
liabilities, obligations, damages, lawsuits, deficiencies,
claims, demands and expenses, including interest, penalties,
costs of mitigation, losses in connection with any environmental
law, lost profits and other losses resulting from any shutdown
or curtailment of operations, damages to the environment,
attorneys fees and all amounts paid in investigation,
defense or settlement of any of the foregoing (which we refer to
in this proxy statement as damages) incurred in connection with,
arising out of, resulting from or incident to:
|
|
|
|
|
any breach of any representation or inaccuracy of any
representation made by us in or pursuant to the asset purchase
agreement;
|
|
|
|
any breach of any covenant or agreement made by us in or
pursuant to the asset purchase agreement;
|
|
|
|
any excluded liability;
|
18
|
|
|
|
|
any liability imposed upon Bio-Rad by reason of Bio-Rads
status as a transferee of the research tools business or the
assets directly resulting from any breach of any representation,
warranty, covenant or agreement made by us in or pursuant to the
asset purchase agreement;
|
|
|
|
any liability imposed upon Bio-Rad related to certain
U.S. patents to be transferred to Bio-Rad or any other
patent asserted by certain named business entities; or
|
|
|
|
any liability imposed upon Bio-Rad, related to any patent to be
transferred to Bio-Rad, in which a claim of infringement is made
against the making, using, selling or importation of the laser
incorporated in the
ProteinChip®
Series 4000 instrument as of the close of the asset sale.
|
Under the terms of the asset purchase agreement, Bio-Rad has
agreed to indemnify us against any damages that we may incur in
connection with, arising out of, resulting from or incident to:
|
|
|
|
|
any breach of any representation or warranty or the inaccuracy
of any representation made by Bio-Rad in or pursuant to the
asset purchase agreement;
|
|
|
|
any breach of any covenant or agreement made by Bio-Rad in or
pursuant to the asset purchase agreement; or
|
|
|
|
any assumed liability of the operations of the research tools
business by Bio-Rad from and after the close of the asset sale.
|
Our indemnification obligations are capped at $20 million
in the aggregate, with a lower cap of $10 million for
liability with respect to the SELDI patent. Subject to certain
exceptions, our indemnification obligations with respect to
representations and warranties, covenants, and other agreements
made with Bio-Rad survive for a period of three years after
closing.
Other
Terms of the Asset Purchase Agreement
Representations
and Warranties.
In the asset purchase agreement, we make representations and
warranties to Bio-Rad including, among other things, regarding:
|
|
|
|
|
our corporate status and qualification to do business;
|
|
|
|
our subsidiaries corporate status;
|
|
|
|
our authority to complete the asset sale;
|
|
|
|
absence of certain changes or events;
|
|
|
|
assets being transferred;
|
|
|
|
facilities being transferred;
|
|
|
|
contracts and commitments being assumed by Bio-Rad;
|
|
|
|
our permits and licenses being transferred;
|
|
|
|
no conflicts or violations will result from the transfer;
|
|
|
|
accuracy of our financial statements;
|
|
|
|
correctness of our books and records;
|
|
|
|
absence of relevant litigation;
|
|
|
|
conflict with any labor agreements or any relevant labor
disputes;
|
|
|
|
absence of undisclosed liabilities;
|
|
|
|
compliance with law;
|
|
|
|
no obligations to brokers;
|
19
|
|
|
|
|
no other agreements to sell the assets;
|
|
|
|
accuracy of descriptions of proprietary rights;
|
|
|
|
absence of transactions with certain persons;
|
|
|
|
completeness and accuracy of tax filings and payments;
|
|
|
|
accuracy of list of insurance policies;
|
|
|
|
accuracy of stated inventory;
|
|
|
|
purchase commitments and outstanding bids;
|
|
|
|
no illegal payments;
|
|
|
|
accuracy of stated customers, distributors and suppliers;
|
|
|
|
compliance with environmental laws;
|
|
|
|
accuracy of stated banking relationships; and
|
|
|
|
accuracy of stated accounts receivable.
|
Bio-Rad makes representations and warranties to us, including
among other things, regarding:
|
|
|
|
|
Bio-Rads corporate status;
|
|
|
|
Bio-Rads authority to complete the asset sale;
|
|
|
|
no conflicts or violations;
|
|
|
|
consents and approvals required in connection with the asset
sale; and
|
|
|
|
no obligations to brokers.
|
Covenants
In the asset purchase agreement, we have agreed to provide
Bio-Rad and its officers, employees, auditors and other
representatives with access to data and information about the
transferred assets and the research tools business. We also
agreed that between the signing of the asset purchase agreement
and closing of the asset sale, subject to certain exceptions,
unless Bio-Rad otherwise consents in writing, we will, among
other things, carry on the research tools business only in the
ordinary course of business and consistent with past practice.
We also agreed that, subject to certain exceptions, except in
the ordinary course of business, we will not take certain
actions related to the research tools business without the prior
written consent of Bio-Rad (which consent may not be
unreasonably withheld), including changing or amending our
certificate of incorporation or bylaws, entering into,
extending, materially modifying, terminating or renewing any
contract or lease, selling, assigning, selling, otherwise
disposing of or encumbering any of the transferred assets, for
any employees hired by Bio-Rad, taking any action with respect
to granting any bonus, severance or termination pay or with
respect to any increase of benefits payable under its severance
or termination pay policies or agreements in effect on the date
of the asset purchase agreement or increase in any manner the
compensation or benefits of any employee or pay any benefit not
required by any existing employee plan or policy, entering into
or amending any employee plan, agreement, trust, fund or other
arrangement for the benefit or welfare of any employee, failing
to maintain all employee plans in accordance with applicable
regulations, declaring, setting aside, making or paying any
dividend or other distribution with respect to our capital
stock, failing to expend funds for budgeted capital expenditures
or commitments of the research tools business, willingly
allowing or permitting to be done any act by which any of the
insurance policies may be suspended, impaired or canceled,
failing to pay our accounts payable and any debts owed or
obligations due to us or to pay or discharge any liabilities
related to the research tools business in the ordinary course of
business, failing to maintain the assets in substantially their
current state of repair, except for normal wear and tear, or
failing to replace inoperable, worn out or obsolete or destroyed
assets consistent with our past practices, failing to comply in
any material respect with all regulations applicable to the
assets or the research tools business, intentionally doing any
other act which could cause any of our representations or
warranties in the asset purchase agreement to be or
20
become untrue in any material respect, failing to use reasonable
commercial efforts to retain our employees involved in the
research tools business, to maintain the research tools business
so that such employees will remain available to us on and after
the close of the asset sale, to maintain existing relationships
with suppliers, customers and others having business dealings
with us related to the research tools business and otherwise
preserve the goodwill of the research tools business, entering
into any agreement, or otherwise becoming obligated, to do any
action prohibited thereunder, entering into, renewing, modifying
or revising any agreement or transaction with any relevant or
making any payment of any kind whatsoever to or on behalf of any
of the subsidiaries listed as part of the asset purchase
agreement, or any officer or director of any of such
subsidiaries, pursuant to any agreement between us and any of
such subsidiaries or otherwise.
Limitations
on Considering other Acquisition Proposals
We have agreed that we and our officers, directors and other
representatives and our subsidiaries will not:
|
|
|
|
|
directly or indirectly enter into, solicit or continue any
discussions or negotiations with, or encourage or respond to any
inquiries or proposals by, or participate in any negotiations
with, or provide any information to, or otherwise cooperate in
any other way with, any entity or person other than Bio-Rad
concerning any proposed acquisition transaction;
|
|
|
|
engage in any discussions, negotiations or other communications
relating to an acquisition proposal; or
|
|
|
|
furnish to any other person any information with respect to us
or our subsidiaries for the purposes of, or otherwise cooperate
in any way with, or assist or participate in any effort or
attempt by any other person to seek or effect a proposed
acquisition transaction.
|
However, prior to the close of the asset sale, we may provide
access to our properties and books and records in response to a
request by a person who has made an unsolicited bona fide
written acquisition proposal if and only to the extent that,
prior to taking any of those actions:
|
|
|
|
|
our board of directors has determined in good faith, after
consultation with our outside legal counsel and financial
advisors, that the failure to take that action would violate its
fiduciary duties under applicable law and that the proposed
acquisition transaction constitutes or is reasonably likely to
result in a superior proposal from the party that made the
proposal for a proposed acquisition transaction; and
|
|
|
|
we inform Bio-Rad promptly after we take the action.
|
A proposed acquisition transaction is any
discussion, negotiation, inquiry or proposal concerning any sale
of all or a portion of the assets or the research tools business
or all or substantially all of our capital stock, or any merger,
consolidation, liquidation, dissolution or similar transaction
involving us.
A superior proposal is a proposed acquisition
transaction:
|
|
|
|
|
that is reasonably capable of being consummated, taking into
account all legal, financial, regulatory, timing, and similar
aspects of, and conditions to, the proposal, the likelihood of
obtaining necessary financing and the corporation, partnership,
person or other entity or group making the proposal; and
|
|
|
|
which, if consummated, would result in a transaction more
favorable to our stockholders from a financial point of view
than the asset sale as contemplated by the asset purchase
agreement.
|
We have agreed that promptly after we receive any written
proposal for a proposed acquisition transaction, or any inquiry
or contact with any person with respect thereto, we will provide
Bio-Rad with oral and written notice of the proposed acquisition
transaction and a copy of such offer, and will keep Bio-Rad
informed of the status of any negotiations regarding such offer.
We have also agreed to notify Bio-Rad immediately if any
discussions or negotiations are sought to be initiated, any
inquiry or proposal is made, or any information is requested
with respect to any proposed acquisition transaction and notify
Bio-Rad of the terms of any proposal we may receive in respect
of any such proposed acquisition transaction.
However, we may terminate the asset purchase agreement if, prior
to the close of the asset sale and after compliance in all
material respects with the obligations set forth above, we elect
to enter into a binding agreement
21
with respect to a superior proposal. In the event of such
termination, we have agreed to pay Bio-Rad a termination fee of
$2 million.
Non-Competition
We have agreed, for a period of 5 years after the closing
date, that neither we nor any of our subsidiaries, unless acting
in accordance with Bio-Rads prior written consent, will,
directly or indirectly, own, manage, join, operate or control,
or participate in the ownership, management, operation or
control of, or be connected as a partner, consultant or
otherwise with, or permit their names to be used by or in
connection with, any profit or non-profit business or
organization which produces, designs, conducts research on,
provides, sells, distributes or markets products, goods,
equipment or services which directly compete with the research
tools business as conducted by us immediately prior to the close
of the asset sale anywhere in the world other than in the
clinical diagnostics market (as that term is defined in the
cross license agreement attached as an exhibit to the asset
purchase agreement). This limitation does not restrict us from
acquiring control of any company or business which derives less
than 2% of its revenue from a business that competes directly
with the research tools business as conducted by us immediately
prior to the closing or making passive investments of less than
2% of the outstanding equity securities in any entity listed on
a national stock exchange or quoted on any recognized automatic
quotation system.
We and Bio-Rad have also agreed that, for a period of
1 year after the closing date, neither we nor Bio-Rad will,
directly or indirectly, hire or offer employment to or seek to
hire or offer employment to any employee of the other party
whose employment is continued by such party after the closing
date, unless such other party first terminates the employment of
such employee or gives its written consent to such employment or
offer of employment.
Transfer
Taxes and Conveyance Fees
Bio-Rad will pay all sales, use, value added, goods and
services, filing, recording, registration, stamp, documentary
and other similar taxes and fees applicable to and payable in
connection with the transactions contemplated by the asset
purchase agreement.
Ciphergen will pay the fees and costs of recording or filing all
applicable conveyancing instruments and the costs of applying
for new permits or obtaining the transfer of existing permits.
Closing
Conditions
Our and Bio-Rads obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following conditions:
|
|
|
|
|
the other partys representations and warranties in the
asset purchase agreement (read without regard to any
qualifications regarding materiality or material adverse effect
or any similar standard or qualification) were true and correct
as of the date of the asset purchase agreement and are true and
correct at and as of the closing date, except as and to the
extent that the facts and conditions upon which such
representations and warranties are based are expressly required
or permitted to be changed by the terms of the asset purchase
agreement and, with respect to Ciphergen, other than such
failures to be true and correct that individually or in the
aggregate would not have a material adverse effect;
|
|
|
|
all consents, approvals and waivers from governmental
authorities and other parties and, in Bio-Rads case,
permits, necessary to permit Ciphergen to transfer the assets to
Bio-Rad as contemplated by the asset purchase agreement and for
the operation of the research tools business will have been
obtained and the parties are satisfied that all approvals
required under any regulations to carry out the transactions
contemplated by the asset purchase agreement have been obtained
and the parties will have complied with all regulations
applicable to the asset sale;
|
|
|
|
no action of any nature of any governmental authority is
threatened or instituted that questions the validity or legality
of the transactions contemplated by the asset purchase agreement
that could reasonably be expected to damage either party, the
assets or the research tools business materially if such
transactions are consummated and there is no regulation or court
order that makes the purchase and sale of the research tools
business or the assets illegal or otherwise prohibited;
|
22
|
|
|
|
|
Each party has delivered to the other party an opinion of such
partys legal counsel substantially to the effect that:
|
|
|
|
|
|
such party is incorporated and in good standing under the laws
of the State of Delaware and, in Ciphergens case,
Ciphergen is qualified to do business as a foreign corporation
and is in good standing in each jurisdiction requiring such
qualification, except where the failure to be so qualified would
not have a material adverse effect on the research tools
business or the assets;
|
|
|
|
such party has the necessary corporate power and authority to
enter into the asset purchase agreement and the sublease
agreement, cross license agreement, transition services
agreement, stock purchase agreement and manufacture and supply
agreement, referred to as the ancillary agreements,
and to consummate the transactions contemplated by such
agreements and, in Ciphergens case, Ciphergen has the
necessary corporate power and authority to own, lease and
operate the assets and its other properties and to conduct the
research tools business as presently conducted;
|
|
|
|
the execution, delivery and performance of the asset purchase
agreement and the ancillary agreements by such party have been
duly authorized by all necessary corporate action of such party,
no approval of such partys stockholders is required or, if
required, such approval has been duly obtained in accordance
with the provisions of such partys certificate of
incorporation, bylaws and applicable law, and the asset purchase
agreement and ancillary agreements have been duly executed and
delivered by such party and constitute legally valid and binding
obligations of such party, enforceable against such party in
accordance with their terms, except as limited by
(1) bankruptcy, insolvency, reorganization, moratorium or
other similar laws relating to creditors rights or by
equitable principles, (2) limitations imposed by law or
equitable principles upon the availability of specific
performance, injunctive relief or other equitable remedies or
(3) other customary limitations;
|
|
|
|
neither the execution and delivery of the asset purchase
agreement or ancillary agreements by such party, nor the
consummation of the transactions contemplated thereby, will
violate or result in a failure to comply with any regulation or
court order applicable to such party and, in Ciphergens
case, such regulations or court orders as are known to
Ciphergens legal counsel;
|
|
|
|
|
|
the receipt of officers certificates from the other party;
|
|
|
|
the receipt of board resolutions from the other party approving
the asset purchase agreement and the ancillary agreements and
the transactions contemplated thereby; and
|
|
|
|
the other party has executed the ancillary agreements.
|
Ciphergens obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following additional condition:
|
|
|
|
|
Bio-Rad has executed the assumption document evidencing
Bio-Rads assumption of assumed liabilities pursuant to the
asset purchase agreement.
|
Bio-Rads obligations to complete the transactions
contemplated by the asset purchase agreement are subject to
satisfaction of the following additional conditions:
|
|
|
|
|
we have executed and delivered to Bio-Rad:
|
|
|
|
|
|
one or more bills of sale conveying owned personal property
included in the assets;
|
|
|
|
assignments of lease for those facilities with respect to which
Bio-Rad has agreed to take assignment pursuant to the asset
purchase agreement;
|
|
|
|
assignments of contracts to be assumed by Bio-Rad pursuant to
the asset purchase agreement;
|
|
|
|
assignments of patents, trademarks and other proprietary rights
to be transferred to Bio-Rad pursuant to the asset purchase
agreement;
|
23
|
|
|
|
|
the assumption document; and
|
|
|
|
such other instruments as may reasonably be requested by Bio-Rad
to vest in Bio-Rad all right, title and interest in and to the
assets.
|
|
|
|
|
|
Bio-Rad has obtained or been granted the right to use all
licenses, permits, franchises, approvals, authorizations,
consents and the like, necessary and desirable for the present
conduct of or relating to the current operation of the research
tools business.
|
Termination
of the Asset Purchase Agreement
We and Bio-Rad may terminate the asset purchase agreement:
|
|
|
|
|
by mutual written consent;
|
|
|
|
by either party if the asset sale has not closed on or before
November 1, 2006; or
|
|
|
|
by either party if our stockholders vote not to approve the
asset sale and the other transactions contemplated by the asset
purchase agreement at the special meeting, or any adjournment or
postponement of the special meeting.
|
We may terminate the asset purchase agreement if, before the
vote of our stockholders at the special meeting and after
compliance in all material respects with our no-solicitation
covenant, we elect to enter into a binding agreement with
respect to a superior proposal. In such event, we are obligated
to pay Bio-Rad a termination fee of $2 million.
Termination
Fee
The asset purchase agreement requires that we pay Bio-Rad a
termination fee of $2 million if, among other things:
|
|
|
|
|
Bio-Rad terminates the asset purchase agreement as a result of
the conditions to Bio-Rads obligations to close specified
in the asset purchase agreement not having been satisfied by
November 1, 2006 (provided that at such time all of the
conditions to our obligation to close have been satisfied by
Bio-Rad or validly waived);
|
|
|
|
we terminate the asset purchase agreement for any reason prior
to November 1, 2006 or for any reason after
November 1, 2006 (provided that, except in the case of our
termination of the asset purchase agreement by reason of our
election to enter into binding agreement with respect to a
superior proposal, at such time as all of the conditions to our
obligation to close have been satisfied by Bio-Rad or validly
waived);
|
|
|
|
we terminate the asset purchase agreement to enter into a
binding agreement with respect to a superior proposal,
regardless of whether Bio-Rad has satisfied all of the
conditions to our obligation to close; or
|
|
|
|
we or Bio-Rad terminate this Agreement because our stockholders
vote not to approve the transactions contemplated by the asset
purchase agreement at the special meeting and, within nine
months thereafter, we close a transaction in which we sell or
otherwise transfer all or substantially all of the assets
comprising the research tools business to a third party.
|
The asset purchase agreement requires that Bio-Rad pay us a
termination fee of $2 million if, among other things:
|
|
|
|
|
we terminate the asset purchase agreement if the closing has not
occurred by November 1, 2006 and we have not been the
primary cause of the failure to consummate the asset purchase
sale, yet the conditions to our obligations to close specified
in the asset purchase agreement not having been satisfied
(provided that at such time all of the conditions to
Bio-Rads obligation to close have been satisfied by us or
validly waived); or
|
|
|
|
Bio-Rad terminates the asset purchase agreement for any reason
prior to November 1, 2006 or for any reason after
November 1, 2006 (provided that at such time all of the
conditions to Bio-Rads obligations to close have been
satisfied by us or validly waived).
|
24
Ancillary
Agreements
Under the asset purchase agreement, we and Bio-Rad have agreed
to execute the several ancillary agreements, incorporated as
exhibits to the asset purchase agreement, upon the closing of
the asset purchase.
Indemnification
Escrow Agreement
Bio-Rad will pay out of the purchase price $2 million to be
held in an escrow account in accordance with the terms of an
indemnification escrow agreement. The asset purchase agreement
provides that we will indemnify Bio-Rad against damages, costs,
and losses resulting from any breach of or liabilities resulting
from a breach of our representations and warranties, or any
covenants or agreements assigned under the asset purchase
agreement, from any excluded liabilities and for certain other
matters. All of the escrow funds will be available for Bio-Rad
to satisfy indemnification claims against us. The escrow funds
will held in the escrow account and available for
indemnification claims by Bio-Rad for a period of three years,
or longer if there are unresolved indemnifiable claims against
Ciphergen by Bio-Rad, and will be disbursed to us in accordance
with the terms and conditions of the agreement. The escrow fees
are to be paid one half by Bio-Rad and one-half by Ciphergen.
Cross
License Agreement
Pursuant to the asset purchase agreement, Bio-Rad acquired
certain proprietary rights used in the research tools business.
At the closing of the asset purchase, we will enter into a cross
license agreement with Bio-Rad where we will retain the right to
commercially exploit those proprietary rights, including SELDI
technology, in the clinical diagnostics market. The clinical
diagnostics market includes laboratories engaged in the research
and development or manufacture of assays, or tests, using
biomarkers to identify, characterize, define or diagnose a
disease state, commercial clinical laboratories, and the
development and sale of diagnostic tests. Ciphergen has been
granted exclusive rights to commercialize the proprietary rights
in the clinical diagnostics market during a five-year
exclusivity period. After the end of the five-year period, we
and Bio-Rad will share exclusive rights. Ciphergen and Bio-Rad
each have the right to engage in negotiations with the other
party for a license to any improvements in the proprietary
rights created by the other party.
Manufacture
and Supply Agreement
At the closing, we will enter into a manufacture and supply
agreement, whereby Bio-Rad will be the sole supplier to
Ciphergen of certain instruments and ProteinChip arrays,
pursuant to Ciphergens specifications. For the first three
years of the agreement, Ciphergen agrees to a minimum purchase
of specified quantities. If Bio-Rad develops new products using
SELDI technology, Bio-Rad has agreed to make such products
available to Ciphergen. Ciphergen can also request that Bio-Rad
develop and manufacture new products to written specifications
and the parties will negotiate in good faith the terms for
purchasing such products. If Bio-Rad fails to manufacture or
sell the products to Ciphergen, then under certain conditions
Ciphergen has the right to manufacture the products or have the
products manufactured by a third party. The parties agree to
establish a technology escrow to deposit the manufacturing
information for the production of the products contemplated by
the agreement.
Transition
Services Agreement
Pursuant to a transition services agreement, Ciphergen will
provide consulting and IT services at cost, to assist Bio-Rad to
become self sufficient with respect to the operation of the
research tools business. Bio-Rad will also provide certain
consulting services to Ciphergen and also grants Ciphergen
access on a continuing basis to certain equipment that will be
shared by the parties.
Sublease
Agreement
Pursuant to a sublease agreement, Bio-Rad will sublease a
portion of the premises currently occupied by Ciphergen until
July 31, 2008. Bio-Rad will pay market rates for the
subleased premises.
25
Stock
Purchase Agreement
As part of the asset purchase agreement, Bio-Rad agreed to
purchase $3 million of Ciphergen common stock pursuant to a
stock purchase agreement. The price per share will be $0.972,
which is the average closing price of Ciphergens common
stock on the five trading days immediately preceding
August 14, 2006, resulting in a purchase of
3,086,420 shares. The stock purchase agreement provides
certain registration rights whereby, if Ciphergen files a
registration statement under the Securities Act of 1933, as
amended, Bio-Rad may elect to include its shares in that
registration, subject to various conditions, as well as certain
representations and warranties by Ciphergen to Bio-Rad,
including, but not limited to, representations regarding due
organization of Ciphergen, the absence of litigation, the
absence of conflicts, the acquisition of a fairness opinion, and
the accuracy of financial statements. The purchase and sale of
the shares pursuant to the stock purchase agreement will be
consummated at the closing of the transactions contemplated by
the asset purchase agreement with Bio-Rad. If the proposed sale
of equity to Bio-Rad is completed, Ciphergen currently intends
to utilize the net proceeds to fund the development of our
emerging specialty diagnostics business and for other working
capital purposes.
Opinion
of our Financial Advisor
Pursuant to an engagement letter dated August 3, 2006,
Ciphergen retained Oppenheimer & Co. Inc. to render an
opinion to the board of directors of Ciphergen as to the
fairness, from a financial point of view, to Ciphergen of the
consideration to be received in the asset sale to Bio-Rad.
On August 14, 2006, Oppenheimer delivered its oral opinion
to the Ciphergen board, subsequently confirmed in writing as of
August 14, 2006, to the effect that and subject to the
various assumptions set forth therein, as of August 14,
2006, the consideration to be received in the asset sale was
fair, from a financial point of view, to Ciphergen. The full
text of the written opinion of Oppenheimer, dated
August 14, 2006, is attached as Annex C to this proxy
statement and is incorporated by reference into this proxy
statement. Holders of our common stock are urged to read the
opinion in its entirety for the assumptions made, procedures
followed, other matters considered and limits of the review by
Oppenheimer. The summary of the written opinion of Oppenheimer
set forth herein is qualified in its entirety by reference to
the full text of such opinion. Oppenheimers analyses and
opinion were prepared for and addressed to our board and are
directed only to the fairness, from a financial point of view,
of the consideration to be received in the asset sale to
Bio-Rad, and do not constitute an opinion as to the merits of
the asset sale to Bio-Rad or a recommendation to any stockholder
as to how to vote on the proposed asset sale to Bio-Rad. The
consideration received in the asset sale to Bio-Rad was
determined through negotiations between us and Bio-Rad and not
pursuant to recommendations of Oppenheimer.
In arriving at its opinion, Oppenheimer reviewed and considered
such financial and other matters as it deemed relevant,
including, among other things:
|
|
|
|
|
a final draft of the asset purchase agreement dated
August 14, 2006;
|
|
|
|
certain financial and other information on the assets of our
research tools business and certain other relevant financial and
operating data furnished to Oppenheimer by our management;
|
|
|
|
certain internal financial analyses, financial projections,
reports and other information concerning our research tools
business, prepared by our management;
|
|
|
|
certain internal financial analyses, financial projections,
reports and other information concerning our remaining
diagnostics business, as prepared by our management;
|
|
|
|
discussions Oppenheimer had with certain members of our
management including, but not limited to, the historical and
current business operations, financial conditions and prospects
of our research tools business and such other matters
Oppenheimer deemed relevant;
|
|
|
|
certain financial data, stock market performance data and
trading multiples of our research tools business as compared to
operating results and multiples of certain publicly traded
companies Oppenheimer deemed generally comparable;
|
26
|
|
|
|
|
certain publicly available information regarding recent purchase
price multiples of precedent transactions, if any, that
Oppenheimer deemed relevant;
|
|
|
|
based on the projections prepared by our management, the cash
flows generated by our research tools business on a stand-alone
basis to determine the present value of the discounted cash
flows; and
|
|
|
|
such other information, financial studies, analyses and
investigations and such other factors that Oppenheimer deemed
relevant for the purposes of its opinion.
|
In conducting its review and arriving at its opinion,
Oppenheimer, (i) with our consent, assumed and relied upon,
without independent investigation, the accuracy and completeness
of all financial and other information-provided to it by us, or
(ii) assumed and relied upon, without independent
investigation, the accuracy and completeness of all financial
and other information which was publicly available. Oppenheimer
did not undertake any responsibility for the accuracy,
completeness or reasonableness of, or independently verify, such
information. In addition, Oppenheimer did not conduct nor assume
any obligation to conduct any physical inspection of the
properties or facilities of our research tools business.
Oppenheimer further relied upon the assurance of our management
that they were unaware of any facts that would make the
information provided to Oppenheimer incomplete or misleading in
any material respect. Oppenheimer, with our consent, without
independent investigation, assumed that the financial
projections that it examined were reasonably prepared by our
management based on the best available estimates and good faith
judgment of management as to the future performance of our tools
and diagnostics businesses, and that such projections provided a
reasonable basis for its opinion.
Oppenheimer did not make or obtain any independent evaluations,
valuations or appraisals of the assets or liabilities of our
research tools business, nor was Oppenheimer furnished with such
materials. With respect to all legal matters relating to
Ciphergen, Oppenheimer relied on the advice of our legal
counsel. Oppenheimer was not requested to opine as to, and its
opinion does not in any manner address, our use of the proceeds
from the asset sale to Bio-Rad or our financial viability
following the asset sale to Bio-Rad. In addition, Oppenheimer
assumed in all respects material to its analysis that we would
not be subject to any claims pursuant to the indemnification
provisions of the asset purchase agreement. Oppenheimers
opinion was necessarily based upon economic and market
conditions and other circumstances as they existed and could be
evaluated by Oppenheimer on the date of its opinion. It should
be understood that although subsequent developments may affect
Oppenheimers opinion, Oppenheimer does not have any
obligation to update, revise or reaffirm its opinion and
Oppenheimer expressly disclaims any responsibility to do so.
In rendering its opinion, Oppenheimer assumed, in all respects
material to its analysis, that the representations and
warranties of each party contained in the asset purchase
agreement are true and correct, that each party will perform all
of the covenants and agreements required to be performed by it
under the asset purchase agreement and that all conditions to
the consummation of the asset sale to Bio-Rad will be satisfied
without waiver thereof. Oppenheimer assumed, in all respects
material to its analysis, that all governmental, regulatory and
other consents and approvals contemplated by the asset purchase
agreement would be obtained and that, in the course of obtaining
any of those consents, no restrictions will be imposed or
waivers made that would have an adverse effect on the
contemplated benefits of the asset sale to Bio-Rad.
Oppenheimers opinion does not constitute a recommendation
to any stockholder as to how the stockholder should vote on the
proposed asset sale to Bio-Rad or take any other action with
respect to the asset sale to Bio-Rad or otherwise. Oppenheimer
was not requested to opine as to, and its opinion does not in
any manner address, Ciphergens underlying business
decision to affect the asset sale to Bio-Rad. Oppenheimer did
not express any view as to the price or trading range for
Ciphergen common stock following consummation of the asset sale
to Bio-Rad or otherwise, which may vary depending on numerous
factors that generally influence the price of securities.
Oppenheimers opinion is limited to the fairness, from a
financial point of view, of the consideration to be received
pursuant to the asset purchase agreement.
The following is a summary of the principal financial analyses
performed by Oppenheimer to arrive at its opinion. Some of the
summaries of financial analyses include information presented in
tabular format. In order to fully understand the financial
analyses, the tables must be read together with the text of each
summary. The tables alone do not constitute a complete
description of the financial analyses. Considering the data set
forth in the tables
27
without considering the full narrative description of the
financial analyses, including the methodologies and assumptions
underlying the analyses, could create a misleading or incomplete
view of the financial analyses. Oppenheimer performed certain
procedures, including each of the financial analyses described
below, and reviewed with our management the assumptions on which
such analyses were based and other factors, including our
historical and projected financial results. No limitations were
imposed by our board of directors with respect to the
investigations made or procedures followed by Oppenheimer in
rendering its opinion.
Discounted Cash Flow
Analysis. Oppenheimer estimated a range of
values for our research tools business based upon the discounted
present value of the projected stand-alone, unlevered, after-tax
cash flows of our research tools business described in the
financial projections provided by our management for the
4th quarter of 2006 through the three fiscal years ending
December 31, 2009, and the discounted present value of the
terminal value of our research tools business based upon a
terminal revenue multiple. Stand-alone, unlevered, after-tax
cash flow was calculated by taking projected operating income
and subtracting from this amount projected cash taxes and
capital expenditures, adding back projected depreciation and
amortization and adding or subtracting, as the case may be,
changes in working capital. This analysis was based upon
projections supplied by our management along with certain other
assumptions. In performing this analysis, Oppenheimer utilized
discount rates ranging from 15% to 35%, representing 10% +/-
Ciphergens research tools business calculated weighted
average cost of capital. Oppenheimer utilized terminal revenue
multiples applied to estimated 2009 revenue ranging from .53x to
.76x, which represents the median of its peer group less a
discount. Utilizing this methodology, the implied enterprise
value reference range of our research tools business is
$2.2 million to $3.5 million, based on the financial
forecasts.
Comparable Company
Analysis. Oppenheimer compared selected
historical and projected, to the extent available, operating and
financial data for our research tools business to the
corresponding financial data and ratios of certain other
companies whose securities are publicly traded and which
Oppenheimer believes are comparable based on operating, market
valuation or other criteria which are similar to our research
tools business. In evaluating the peer group, Oppenheimer made
judgments and assumptions with regard to disaggregating selected
financial information from the genetic, proteomic, and molecular
diagnostics industry performance; general business; economic;
market; and financial conditions and many other matters,
including the impact of competition.
Oppenheimer compared certain trading multiple and valuation
statistics of a selected group of publicly traded companies in
the genetic, proteomic, and molecular diagnostics sectors.
Oppenheimer then separated them into three categories:
(i) large growing companies with growing or projected to
grow revenues, (ii) small growing companies with growing or
projected to grow revenues, and (iii) small declining
companies with declining or projected to decline revenues, which
in Oppenheimers judgment were generally comparable to the
assets of our research tools business for the purposes of this
analysis from both a financial and operational perspective.
28
There were twelve companies that met the full criteria, four
within the large growing category, five within the small growing
category and three in the small declining category. These
companies were:
|
|
|
|
|
Selected Companies.
|
|
Ticker
|
|
|
Large Growing Companies
|
|
|
|
|
Affymetrix
|
|
|
AFFX
|
|
Bruker Biosciences Corp.
|
|
|
BRKR
|
|
Illumina
|
|
|
ILMN
|
|
Luminex Corp.
|
|
|
LMNX
|
|
Small Growing Companies
|
|
|
|
|
Caliper Life Sciences, Inc.
|
|
|
CALP
|
|
Cepheid
|
|
|
CPHD
|
|
Lexicon Genetics
|
|
|
LEXG
|
|
Molecular Devices Corp.
|
|
|
MDCC
|
|
Nanogen
|
|
|
NGEN
|
|
Small Declining Companies
|
|
|
|
|
Orchid Cellmark
|
|
|
ORCH
|
|
Sequenom
|
|
|
SQNM
|
|
Transgenomic
|
|
|
TBIO
|
|
The data and ratios included the enterprise value (market equity
value, less cash, plus debt, minority interests and preferred
stock) of the selected companies as multiples of last twelve
months (LTM) revenue, gross profit and EBITDA (in each case, as
available from SEC filings, FirstCall Consensus, or if not so
available, research analyst reports).
The following table presents multiples implied by the ratio of
enterprise value to LTM revenue and gross profit for the
sub-group of small declining companies within the broader scope
of minimal or comparable companies. EBITDA multiples were not
meaningful as Ciphergen and the comparable companies have
negative EBITDA. The information in the table is based on
closing stock prices as of August 11, 2006. Consideration
to be received in the asset sale to Bio-Rad is adjusted for
purposes of this analysis to take into account the likelihood of
receipt of payment of certain contingent payments and time
value. With respect to figures presented in the column entitled
Multiple Implied by Consideration to be Received in the
asset sale to Bio-Rad, LTM revenue and gross profit are as
per our management.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multiple Implied by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration to be
|
|
|
|
Selected Company Multiples
|
|
|
Received in the asset sale to
|
|
|
|
Low
|
|
|
Average
|
|
|
Median
|
|
|
High
|
|
|
Bio-Rad
|
|
|
Enterprise Value as a ratio of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LTM Revenue
|
|
|
0.6x
|
|
|
|
0.8x
|
|
|
|
0.8x
|
|
|
|
1.2x
|
|
|
|
0.8x
|
|
LTM Gross Profit
|
|
|
1.2x
|
|
|
|
1.9x
|
|
|
|
2.2x
|
|
|
|
2.4x
|
|
|
|
1.6.x
|
|
Oppenheimer noted that the three companies that compose the
group of small declining companies with declining or projected
to decline revenues utilized in the comparable company analysis
were, as of August 14, 2006, sufficiently similar to
Ciphergen in terms of industry and financial and operational
perspective. No company utilized in the comparable company
analysis was identical to the stand-alone assets of
Ciphergens research tools business. Thus, Oppenheimer
concluded that, on a Comparable Company Analysis, based on the
current stand-alone assets of our research tools business, that
the range of enterprise value to LTM revenue multiples for the
small declining companies ranges from 0.6x to 1.2x, with an
average of 0.8x, yielding a value of $19.6 million.
Precedent Mergers and Acquisition Transactions
Analysis. Oppenheimer compared certain
publicly available statistics from SEC filings, company press
releases, publicly available research and other sources of
selected precedent mergers and acquisitions from January 1,
2004 to August 11, 2006 involving companies that
29
operate in the genomic, proteomic, and molecular research and
diagnostic device industry or in a similar industry, which
Oppenheimer deemed comparable to the transaction between our
research tools business and Bio-Rad.
Oppenheimer noted that the analysis of precedent transactions
necessarily involves complex considerations and judgments
concerning differences in financial and operating
characteristics, form of consideration, acquisition terms, sale
terms, and other factors that would necessarily affect the
purchase value of our research tools business versus the
acquisition value of any other comparable company in general and
the transactions Oppenheimer analyzed in particular. Oppenheimer
further noted that none of the precedent merger and acquisition
transactions were sufficiently similar to the sale of our
research tools business to Bio-Rad. Oppenheimer concluded that
this valuation method is not appropriate due to the lack of
truly comparable transactions and the declining and projected to
decline financial and operational nature of our research tools
business.
Implied Market Valuation
Analysis. Oppenheimer calculated the implied
equity value of the stand-alone assets of our research tools
business by subtracting the calculated equity value of our
stand-alone diagnostics business from our current market equity
value. Oppenheimer calculated the contribution of our combined
tools and diagnostics businesses, yielding an equity value of
$35.5 million, based on our closing stock price on
August 11, 2006. Oppenheimer then calculated the sum of the
net present value of our future pro forma free cash flows for
our stand-alone diagnostics business, plus the estimated present
value of the terminal equity value of our stand-alone
diagnostics business, which is based on the median price to
earnings ratio (PE) of certain diagnostic comparable companies.
The analysis showed that the present value of the stand-alone
diagnostics business exceeded our equity value of
$35.5 million, implying a negative equity value for our
research tools business.
The summary set forth above does not purport to be a complete
description of all the analyses performed by Oppenheimer. The
preparation of a fairness opinion involves various
determinations as to the most appropriate and relevant methods
of financial analyses and the application of these methods to
the particular circumstances and, therefore, such an opinion is
not readily susceptible to partial analysis or summary
description. Oppenheimer did not attribute any particular weight
to any analysis or factor considered by it, but rather made
qualitative judgments as to the significance and relevance of
each analysis and factor. Accordingly, notwithstanding the
separate factors summarized above, Oppenheimer believes, and has
advised our board of directors, that its analyses must be
considered as a whole and that selecting portions of its
analyses and the factors considered by it, without considering
all analyses and factors, could create an incomplete view of the
process underlying its opinion. In performing its analyses,
Oppenheimer made numerous assumptions with respect to industry
performance, business and economic conditions and other matters,
many of which are beyond our control. These analyses performed
by Oppenheimer are not necessarily indicative of actual values
or future results, which may be significantly more or less
favorable than suggested by such analyses. In addition, analyses
relating to the value of businesses do not purport to be
appraisals or to reflect the prices at which businesses or
securities may actually be sold. Accordingly, such analyses and
estimates are inherently subject to uncertainty, being based
upon numerous factors or events beyond the control of the
parties or their respective advisors. None of Ciphergen,
Oppenheimer, or any other person assumes responsibility if
future results are materially different from those projected.
Oppenheimer was selected by our board of directors to render an
opinion to it because Oppenheimer is an internationally
recognized investment banking firm and because, as part of its
investment banking business, Oppenheimer is continually engaged
in the valuation of businesses and their securities in
connection with mergers and acquisitions, negotiated
underwritings, secondary distributions of listed and unlisted
securities, private placements and valuations for corporate and
other purposes. In addition, in the ordinary course of its
business, Oppenheimer and its affiliates may trade the equity
securities of Ciphergen and Bio-Rad for their own account and
for the accounts of their customers, and, accordingly, may at
any time hold a long or short position in such securities.
Pursuant to the engagement letter, for Oppenheimers
services in providing the fairness opinion, we have agreed to
pay Oppenheimer a cash fee of $250,000, of which $50,000 is
payable upon signing of the engagement agreement, $150,000
payable upon delivery of the written opinion to Ciphergen and
the remaining balance of $50,000 payable upon closing of the
sale to Bio-Rad. Additionally, we have agreed to reimburse
Oppenheimer for its reasonable
out-of-pocket
expenses, including reasonable attorneys fees and expenses
and have agreed to indemnify Oppenheimer against certain
liabilities, including liabilities under the federal securities
laws. The terms of the fee arrangement with Oppenheimer, which
are customary in transactions of this nature, were negotiated at
30
arms length between us and Oppenheimer, and our board of
directors was aware of the arrangement, including the fact that
a portion of the fee payable to Oppenheimer is contingent upon
the completion of the asset sale to Bio-Rad. In addition,
Oppenheimer has been retained by Ciphergen to assist in other
investment-banking advisory services, for which Oppenheimer will
be paid its standard fees.
PROPOSAL NO. 2
PROPOSAL TO GRANT AUTHORITY TO ADJOURN OR POSTPONE THE
SPECIAL MEETING
This section of the proxy statement describes material aspects
of the proposed adjournment or postponement of the special
meeting. This summary may not contain all of the information
that is important to you. You should carefully read this proxy
statement for a more complete understanding of the adjournment
or postponement of the special meeting.
The
Ciphergen Adjournment Proposal
If, at the special meeting of stockholders on Thursday,
October 26, 2006, the number of shares of Ciphergen common
stock present or represented and voting in favor of adoption of
the asset sale to Bio-Rad is insufficient to adopt that proposal
under the Delaware General Corporation Law, proxy holder
Gail S. Page intend to move to adjourn the special meeting
in order to enable our board of directors to solicit additional
proxies in respect of such proposal. In that event, we will ask
our stockholders to vote only upon the adjournment proposal, and
not the proposal regarding the asset sale to Bio-Rad.
In this proposal, we are asking you to authorize the holder of
any proxy solicited by our board of directors to vote in favor
of granting discretionary authority to Gail S. Page to
adjourn or postpone the special meeting to another time and
place for the purpose of soliciting additional proxies. If the
stockholders approve the adjournment proposal, we could adjourn
the special meeting and any adjourned session of the special
meeting and use the additional time to solicit additional
proxies, including the solicitation of proxies from stockholders
that have previously voted. Among other things, approval of the
adjournment proposal could mean that, even if we had received
proxies representing a sufficient number of votes against the
approval of the asset sale to Bio-Rad to defeat that proposal,
we could adjourn the special meeting without a vote on the asset
sale proposal and seek to convince the holders of those shares
to change their votes to votes in favor of approval of the asset
sale.
Vote
Required and Board Recommendation
The Ciphergen adjournment proposal requires the approval of a
majority of the votes cast on the proposal. Broker non-votes and
abstentions will have no effect on the outcome of the vote on
the adjournment proposal. No proxy that is specifically marked
against adoption of the asset sale will be voted in
favor of the Ciphergen adjournment proposal, unless it is
specifically marked for the Ciphergen adjournment
proposal.
Our board of directors believes that, if the number of shares of
Ciphergen common stock present or represented at the special
meeting and voting in favor of adoption of the asset sale to
Bio-Rad is insufficient to approve that proposal, it is in the
best interests of our stockholders to enable our board of
directors to continue to seek to obtain a sufficient number of
additional votes in favor of adoption of the asset sale proposal
to bring about its approval.
Our board of directors recommends that you vote FOR
the Ciphergen adjournment proposal.
BENEFICIAL
INTERESTS
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of August 31, 2006,
certain information with respect to the beneficial ownership of
Ciphergens common stock by (i) each director ,
(ii) each of the executive officers , (iii) any person
(including any group as that term is used in
Section 13(d)(3) of the Exchange Act), known by Ciphergen
to be the beneficial owner of more than 5% of Ciphergens
common stock, and (iv) all executive officers, and
directors of Ciphergen as a group. Ciphergen does not know of
any arrangements, including any pledge by any person of
securities of Ciphergen, which may at a subsequent date result
in a change of control of Ciphergen. Unless
31
otherwise indicated, the address of each listed stockholder is
c/o Ciphergen Biosystems, Inc., 6611 Dumbarton Circle,
Fremont, California 94555.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
|
|
|
|
common stock
|
|
Name and Address of Beneficial Owner
|
|
Number of Shares
|
|
|
Outstanding(1)
|
|
|
5% STOCKHOLDERS, DIRECTORS,
NOMINEES FOR DIRECTOR AND NAMED EXECUTIVE OFFICERS
|
|
|
|
|
|
|
|
|
Quest Diagnostics Incorporated(2)
1290 Wall Street West
Lyndhurst, NJ 07071
|
|
|
7,416,069
|
|
|
|
19.9
|
%
|
Wellington Management Company, LLP
75 State Street
Boston, MA 02109
|
|
|
3,175,325
|
|
|
|
8.8
|
%
|
James L. Rathmann(3)
|
|
|
2,457,328
|
|
|
|
6.8
|
%
|
Falcon Technology Partners
600 Dorset Road
Devon, PA 19333
|
|
|
2,235,429
|
|
|
|
6.2
|
%
|
William E. Rich(4)
|
|
|
1,723,119
|
|
|
|
4.7
|
%
|
Michael J. Callaghan(5)
MDS Capital (USA) Corp.
435 Tasso Street, Suite 315
Palo Alto, CA
94301-1552
|
|
|
1,210,057
|
|
|
|
3.3
|
%
|
Gail S. Page(6)
|
|
|
535,412
|
|
|
|
1.5
|
%
|
John A. Young(7)
167 S. San Antonio Road, Suite 7
Los Altos, CA
94022-3055
|
|
|
386,539
|
|
|
|
1.1
|
%
|
Matthew J. Hogan(8)
|
|
|
257,997
|
|
|
|
*
|
|
William C. Sullivan(9)
|
|
|
113,287
|
|
|
|
*
|
|
Judy Bruner(10)
SanDisk Corporation
140 Caspian Court
Sunnyvale, CA 94087
|
|
|
101,832
|
|
|
|
*
|
|
Rajen K. Dalal(11)
|
|
|
91,999
|
|
|
|
*
|
|
Wendell Wierenga(12)
Neurocrine Biosciences, Inc.
10555 Science Center Drive
San Diego, CA 92121
|
|
|
74,500
|
|
|
|
*
|
|
James P. Merryweather(13)
|
|
|
68,497
|
|
|
|
*
|
|
James S. Burns(14)
Entremed, Inc.
9640 Medical Center Drive
Rockville, MD 20850
|
|
|
39,832
|
|
|
|
*
|
|
Kenneth J. Conway(15)
Firestar Ventures
15 Eagles Nest
Scituate, MA 02066
|
|
|
12,166
|
|
|
|
*
|
|
ALL DIRECTORS AND EXECUTIVE
OFFICERS AS A GROUP
(ten persons)(16)
|
|
|
5,016,949
|
|
|
|
13.4
|
%
|
|
|
|
* |
|
less than one percent of outstanding shares |
|
(1) |
|
Applicable percentage ownership is based on
36,075,017 shares of common stock outstanding as of
August 31, 2006 together with applicable options for such
stockholder. The table is based on information |
32
|
|
|
|
|
supplied by officers, directors and principal stockholders, and
Schedules 13G filed with the SEC. Beneficial ownership is
determined in accordance with the rules of the SEC and includes
voting or investment power with respect to securities, subject
to community property laws, where applicable. Shares of common
stock subject to options currently exercisable or exercisable
within 60 days after August 31, 2006, are deemed
outstanding for computing the percentage ownership of the person
holding such options, but are not deemed outstanding for
computing the percentage of any other person. |
|
(2) |
|
Includes 1,191,069 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of a warrant
to purchase up to 2,200,000 shares for $3.50 per share
which is exercisable at any time prior to July 22, 2010.
While the warrant is exercisable for up to
2,200,000 shares, Ciphergen and Quest Diagnostics have
clarified that the total number of shares of common stock
issuable upon exercise of the warrant could at no time cause
Quest Diagnostics total holdings of Ciphergens
common stock to exceed 19.9% of the total number of outstanding
shares of Ciphergen common stock (provided that Quest
Diagnostics may, prior to or concurrently with the exercise of
their warrant, sell such number of shares of Ciphergen common
stock so that, after the exercise of the warrant and such sale
of shares, Quest Diagnostics would not own more than 19.9% of
Ciphergens common stock). |
|
(3) |
|
Includes 213,299 shares in the name of Mr. Rathmann, a
director, issuable within 60 days of August 31, 2006
upon exercise of stock options, 8,600 shares currently
owned by Mr. Rathmann and 2,235,429 shares held by
Falcon Technology Partners, of which Mr. Rathmann is a
General Partner. |
|
(4) |
|
Includes 26,229 shares held in an Individual Retirement
Account by Lenita L. Rich and 4,300 shares held directly by
Lenita L. Rich, a former employee, who is Dr. Richs
spouse. Includes 804,000 shares of common stock issuable
within 60 days of August 31, 2006 upon exercise of
stock options. |
|
(5) |
|
Includes 113,866 shares issuable within 60 days of
August 31, 2006 upon exercise of stock option grants to
Michael J. Callaghan, 17,000 shares currently owned by
Mr. Callaghan and 1,079,191 shares owned by threefunds
managed or advised by MDS Capital Corp. Mr. Callaghan, a
director, is Managing Director, Private Equity, of MDS Capital
Corp. |
|
(6) |
|
Includes 510,412 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(7) |
|
Includes 139,440 shares of common stock held by family
trusts and 247,099 shares issuable within 60 days of
August 31, 2006 upon exercise of stock options granted to
Mr. Young. |
|
(8) |
|
Includes 255,497 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(9) |
|
Includes 113,287 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(10) |
|
Includes 101,832 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(11) |
|
Includes 91,999 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(12) |
|
Includes 74,500 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(13) |
|
Includes 68,497 shares of common stock issuable within
60 days of August 31, 2006 upon exercise of stock
options. |
|
(14) |
|
Includes 39,832 shares issuable within 60 days of
August 31, 2006 upon exercise of stock options. |
|
(15) |
|
Includes 2,000 shares currently owned by Mr. Conway
and 10,166 shares issuable within 60 days of
August 31, 2006 upon exercise of stock options. |
|
(16) |
|
Includes 1,510,289 shares issuable within 60 days of
August 31, 2006 upon exercise of stock options. |
33
OTHER
MATTERS
As of the date of this proxy statement, our board of directors
knows of no matters that will be presented for consideration at
the special meeting other than as described in this proxy
statement.
You should rely only on the information contained in this
document to vote your shares of common stock at the special
meeting. We have not authorized anyone to provide you with
information that is different from what is contained in this
document. This document is dated September 28, 2006. You
should not assume that the information contained in this
document is accurate as of any date other than that date, and
the mailing of this document to shareholders does not create any
implication to the contrary. This document does not constitute a
solicitation of a proxy in any jurisdiction where, or to or from
any person to whom, it is unlawful to make such solicitation in
that jurisdiction.
THE BOARD OF DIRECTORS
Fremont, California
September 28, 2006
34
ASSET PURCHASE AGREEMENT
CIPHERGEN
BIOSYSTEMS, INC.
BIO-RAD
LABORATORIES, INC.
A-1
ASSET
PURCHASE AGREEMENT
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE I
|
|
|
A-5
|
|
|
1.1
|
|
|
Defined Terms
|
|
|
A-5
|
|
|
1.2
|
|
|
Other Defined Terms
|
|
|
A-10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE II
|
|
|
A-11
|
|
|
2.1
|
|
|
Transfer of Assets
|
|
|
A-11
|
|
|
2.2
|
|
|
Assumption of Liabilities
|
|
|
A-11
|
|
|
2.3
|
|
|
Excluded Liabilities
|
|
|
A-11
|
|
|
2.4
|
|
|
Purchase Price
|
|
|
A-12
|
|
|
2.5
|
|
|
Closing Balance Sheet
|
|
|
A-12
|
|
|
2.6
|
|
|
Prorations
|
|
|
A-12
|
|
|
2.7
|
|
|
Closing Costs; Transfer Taxes and
Fees
|
|
|
A-13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE III
|
|
|
A-14
|
|
|
3.1
|
|
|
Closing
|
|
|
A-14
|
|
|
3.2
|
|
|
Conveyances at Closing
|
|
|
A-14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE IV
|
|
|
A-15
|
|
|
4.1
|
|
|
Organization of Seller
|
|
|
A-15
|
|
|
4.2
|
|
|
Subsidiaries
|
|
|
A-15
|
|
|
4.3
|
|
|
Authorization
|
|
|
A-15
|
|
|
4.4
|
|
|
Absence of Certain Changes or
Events
|
|
|
A-16
|
|
|
4.5
|
|
|
Assets
|
|
|
A-17
|
|
|
4.6
|
|
|
Facilities
|
|
|
A-17
|
|
|
4.7
|
|
|
Contracts and Commitments
|
|
|
A-18
|
|
|
4.8
|
|
|
Permits
|
|
|
A-19
|
|
|
4.9
|
|
|
No Conflict or Violation
|
|
|
A-19
|
|
|
4.10
|
|
|
Financial Statements
|
|
|
A-19
|
|
|
4.11
|
|
|
Books and Records
|
|
|
A-19
|
|
|
4.12
|
|
|
Litigation
|
|
|
A-19
|
|
|
4.13
|
|
|
Labor Matters
|
|
|
A-20
|
|
|
4.14
|
|
|
Liabilities
|
|
|
A-20
|
|
|
4.15
|
|
|
Compliance with Law
|
|
|
A-20
|
|
|
4.16
|
|
|
No Brokers
|
|
|
A-20
|
|
|
4.17
|
|
|
No Other Agreements to Sell the
Assets
|
|
|
A-20
|
|
|
4.18
|
|
|
Proprietary Rights
|
|
|
A-20
|
|
|
4.19
|
|
|
Transactions with Certain Persons
|
|
|
A-21
|
|
|
4.20
|
|
|
Tax Matters
|
|
|
A-21
|
|
|
4.21
|
|
|
Insurance
|
|
|
A-22
|
|
|
4.22
|
|
|
Inventory
|
|
|
A-22
|
|
|
4.23
|
|
|
Purchase Commitments and
Outstanding Bids
|
|
|
A-22
|
|
|
4.24
|
|
|
Payments
|
|
|
A-22
|
|
|
4.25
|
|
|
Customers, Distributors and
Suppliers
|
|
|
A-23
|
|
A-2
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
4.26
|
|
|
Compliance With Environmental Laws
|
|
|
A-23
|
|
|
4.27
|
|
|
Banking Relationships
|
|
|
A-24
|
|
|
4.28
|
|
|
Accounts Receivable
|
|
|
A-24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE V
|
|
|
A-25
|
|
|
5.1
|
|
|
Organization of Buyer
|
|
|
A-25
|
|
|
5.2
|
|
|
Authorization
|
|
|
A-25
|
|
|
5.3
|
|
|
No Conflict or Violation
|
|
|
A-25
|
|
|
5.4
|
|
|
Consents and Approvals
|
|
|
A-25
|
|
|
5.5
|
|
|
No Brokers
|
|
|
A-25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE VI
|
|
|
A-25
|
|
|
6.1
|
|
|
Further Assurances
|
|
|
A-25
|
|
|
6.2
|
|
|
No Solicitation
|
|
|
A-26
|
|
|
6.3
|
|
|
Notification of Certain Matters
|
|
|
A-27
|
|
|
6.4
|
|
|
Investigation by Buyer
|
|
|
A-27
|
|
|
6.5
|
|
|
Conduct of Business
|
|
|
A-28
|
|
|
6.6
|
|
|
Employee Matters
|
|
|
A-29
|
|
|
6.7
|
|
|
Subsidiary Transfer
|
|
|
A-29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE VII
|
|
|
A-29
|
|
|
7.1
|
|
|
Representations, Warranties and
Covenants
|
|
|
A-29
|
|
|
7.2
|
|
|
Consents; Regulatory Compliance
and Approval
|
|
|
A-30
|
|
|
7.3
|
|
|
No Actions or Court Orders
|
|
|
A-30
|
|
|
7.4
|
|
|
Opinion of Counsel
|
|
|
A-30
|
|
|
7.5
|
|
|
Certificates
|
|
|
A-30
|
|
|
7.6
|
|
|
Corporate Documents
|
|
|
A-31
|
|
|
7.7
|
|
|
Assumption Document
|
|
|
A-31
|
|
|
7.8
|
|
|
Ancillary Agreements
|
|
|
A-31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE VIII
|
|
|
A-31
|
|
|
8.1
|
|
|
Representations, Warranties and
Covenants
|
|
|
A-31
|
|
|
8.2
|
|
|
Consents; Regulatory Compliance
and Approval
|
|
|
A-31
|
|
|
8.3
|
|
|
No Actions or Court Orders
|
|
|
A-31
|
|
|
8.4
|
|
|
Opinion of Counsel
|
|
|
A-31
|
|
|
8.5
|
|
|
Certificates
|
|
|
A-32
|
|
|
8.6
|
|
|
Material Changes
|
|
|
A-32
|
|
|
8.7
|
|
|
Corporate Documents
|
|
|
A-32
|
|
|
8.8
|
|
|
Conveyancing Documents; Release of
Encumbrances
|
|
|
A-32
|
|
|
8.9
|
|
|
Permits
|
|
|
A-32
|
|
|
8.10
|
|
|
Other Agreements
|
|
|
A-32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE IX
|
|
|
A-32
|
|
|
9.1
|
|
|
Risk of Loss
|
|
|
A-32
|
|
|
9.2
|
|
|
Consents to Assignment
|
|
|
A-33
|
|
|
|
|
|
|
|
|
|
|
A-3
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE X
|
|
|
A-33
|
|
|
10.1
|
|
|
Collection of Accounts Receivable
and Letters of Credit
|
|
|
A-33
|
|
|
10.2
|
|
|
Books and Records; Tax Matters
|
|
|
A-33
|
|
|
10.3
|
|
|
Survival of Representations,
Etc.
|
|
|
A-34
|
|
|
10.4
|
|
|
Indemnifications
|
|
|
A-34
|
|
|
10.5
|
|
|
Bulk Sales
|
|
|
A-35
|
|
|
10.6
|
|
|
Covenant Not to Compete
|
|
|
A-36
|
|
|
10.7
|
|
|
Taxes
|
|
|
A-36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE XI
|
|
|
A-36
|
|
|
11.1
|
|
|
Termination
|
|
|
A-36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARTICLE XII
|
|
|
A-37
|
|
|
12.1
|
|
|
Assignment
|
|
|
A-37
|
|
|
12.2
|
|
|
Notices
|
|
|
A-38
|
|
|
12.3
|
|
|
Choice of Law
|
|
|
A-38
|
|
|
12.4
|
|
|
Entire Agreement; Amendments and
Waivers
|
|
|
A-38
|
|
|
12.5
|
|
|
Multiple Counterparts
|
|
|
A-38
|
|
|
12.6
|
|
|
Expenses
|
|
|
A-38
|
|
|
12.7
|
|
|
Invalidity
|
|
|
A-38
|
|
|
12.8
|
|
|
Titles; Gender
|
|
|
A-39
|
|
|
12.9
|
|
|
Public Statements and Press
Releases
|
|
|
A-39
|
|
|
12.10
|
|
|
Cumulative Remedies
|
|
|
A-39
|
|
|
12.11
|
|
|
Service of Process, Consent to
Jurisdiction
|
|
|
A-39
|
|
|
12.12
|
|
|
Attorneys Fees
|
|
|
A-39
|
|
A-4
ASSET
PURCHASE AGREEMENT
This Asset Purchase Agreement, dated as of August 14, 2006
(the Agreement) is entered into by and between
BIO-RAD LABORATORIES, INC., a Delaware corporation, with
offices at 1000 Alfred Nobel Drive, Hercules, California 94547
(Buyer), and CIPHERGEN BIOSYSTEMS, INC., a
Delaware corporation, with offices at 6611 Dumbarton Circle,
Fremont, California 94555 (Seller).
RECITALS
A. WHEREAS, Seller owns certain assets which it uses in the
conduct of the Business (as defined below); and
B. WHEREAS, Buyer desires to purchase from Seller, and
Seller desires to sell to Buyer, such assets upon the terms and
subject to the conditions of this Agreement.
AGREEMENT
NOW THEREFORE, in consideration of the respective covenants and
promises contained herein and for other good and valuable
consideration, the receipt and adequacy of which is hereby
acknowledged, the parties hereto agree as follows:
ARTICLE I
DEFINITIONS
1.1 Defined Terms. As used
herein, the terms below shall have the following meanings. Any
of such terms, unless the context otherwise requires, may be
used in the singular or plural, depending upon the reference.
Action shall mean any action, claim, suit,
litigation, proceeding, labor dispute, arbitral action,
governmental audit, inquiry, criminal prosecution, investigation
or unfair labor practice charge or complaint.
affiliate shall have the meaning set forth in
the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder.
Ancillary Agreements shall mean the
Indemnification Escrow Agreement, Sublease Agreement, Cross
License Agreement, Transition Services Agreement, Stock Purchase
Agreement and Manufacture and Supply Agreement, substantially in
the forms attached hereto as Exhibits I, J, K, L, M and N
respectively.
Assets shall mean all of Sellers right,
title and interest in and to the properties, assets and rights
owned by Seller, whether tangible, intangible, real or personal,
which represent all of the properties, assets and rights used or
held for use in connection with the Business or generated in the
conduct or operation of the Business, including without
limitation:
(a) all Contract Rights;
(b) all Leases;
(c) all Leasehold Estates;
(d) all Leasehold Improvements;
(e) all Fixtures and Equipment;
(f) all Inventory;
(g) all Books and Records;
(h) all Proprietary Rights relating to the Business;
(i) to the extent transferable, all Permits;
(j) all computers and software principally used in
connection with the Business;
A-5
(k) all Insurance Policies, to the extent assignable;
(l) all accounts and notes receivable (whether current or
noncurrent), refunds, deposits, prepayments or prepaid expenses
(including without limitation any prepaid insurance premiums) of
Seller relating to the Business;
(m) all available supplies, sales literature, promotional
literature, customer, supplier and distributor lists, art work,
display units, telephone and fax numbers and purchasing records
related to the Business;
(n) all rights under or pursuant to all warranties,
representations and guarantees made by suppliers in connection
with the Assets or services furnished to Seller pertaining to
the Business or affecting the Assets, to the extent such
warranties, representations and guarantees are
assignable; and
(o) all claims, causes of action, choses in action, rights
of recovery and rights of set-off of any kind, against any
person or entity pertaining to the Business, including without
limitation any liens, security interests, pledges or other
rights to payment or to enforce payment in connection with
products delivered by Seller on or prior to the Closing Date;
but excluding therefrom the Excluded Assets.
Balance Sheet shall mean the consolidated
balance sheet of Seller at the date indicated thereon, together
with the notes thereon.
Books and Records shall mean (a) all
records and lists of Seller pertaining to the Assets or the
Business, (b) all records and lists pertaining to the
Business, including customers, suppliers or personnel of Seller,
(c) all product, business and marketing plans of Seller
pertaining to the Assets or the Business and (d) all books,
ledgers, files, reports, plans, drawings and operating records
of every kind maintained by Seller relating to the Assets or the
Business, but excluding in each case the originals of
Sellers minute books, stock books and tax returns.
Business shall mean the Sellers
business commonly referred to as its tools business,
which is comprised of the development, manufacture and sale of
ProteinChip systems, arrays, readers, software and related
accessories and services.
Closing Date shall mean the date that is two
(2) business days following the satisfaction or waiver of
the conditions to closing of the parties set forth in
Articles VII and VIII hereof, or such other date as Buyer
and Seller shall mutually agree upon.
Code shall mean the Internal Revenue Code of
1986, as amended, and the rules and regulations thereunder.
Confidentiality Agreement shall mean that
certain Confidentiality Agreement dated as of the date hereof by
and between Seller and Buyer.
Contract shall mean any agreement, contract,
note, loan, evidence of indebtedness, purchase, order, letter of
credit, indenture, security or pledge agreement, franchise
agreement, undertaking, practice, covenant not to compete,
employment agreement, license, instrument, obligation or
commitment to which Seller is a party or is bound and which
relates to the Business or the Assets, whether oral or written,
but excluding all Leases.
Contract Rights shall mean all of
Sellers rights and obligations under the Contracts listed
on Schedule 4.7 and under any Contracts not so listed which
Buyer and Seller agree in writing that Buyer shall accept and
assume.
Copyrights shall mean registered copyrights,
copyright applications and unregistered copyrights.
Court Order shall mean any judgment,
decision, consent decree, injunction, ruling or order of any
federal, state or local court or governmental agency, department
or authority that is binding on any person or its property under
applicable law.
Default shall mean (a) a breach of or
default under any Contract or Lease, (b) the occurrence of
an event that with the passage of time or the giving of notice
or both would constitute a breach of or default under any
Contract or Lease, or (c) the occurrence of an event that
with or without the passage of time or the giving of notice or
both would give rise to a right of termination, renegotiation or
acceleration under any Contract or Lease.
A-6
Disclosure Schedule shall mean a schedule
executed and delivered by Seller to Buyer as of the date hereof
which sets forth the exceptions to the representations and
warranties contained in Article IV hereof and certain other
information called for by this Agreement. Unless otherwise
specified, each reference in this Agreement to any numbered
schedule is a reference to that numbered schedule which is
included in the Disclosure Schedule.
Encumbrance shall mean any claim, lien,
pledge, option, charge, easement, security interest, deed of
trust, mortgage,
right-of-way,
encroachment, building or use restriction, conditional sales
agreement, encumbrance or other right of third parties, whether
voluntarily incurred or arising by operation of law, and
includes, without limitation, any agreement to give any of the
foregoing in the future, and any contingent sale or other title
retention agreement or lease in the nature thereof.
Excluded Assets, notwithstanding any other
provision of this Agreement, shall mean the following assets of
Seller which are not to be acquired by Buyer hereunder:
(a) Inventory identified as excluded assets on
Schedule 4.22;
(b) all cash and cash equivalents held by Seller as of the
Closing Date;
(c) all Permits, to the extent not transferable; and
(d) all claims, causes of action, choses in action, rights
of recovery and rights of set-off of any kind against any person
or entity arising out of or relating to the Assets to the extent
related to the Excluded Liabilities.
Facilities shall mean all plants, offices,
manufacturing facilities, stores, warehouses, improvements,
administration buildings, and all real property and related
facilities which are identified or listed on
Exhibit A attached hereto.
Facility Leases shall mean all of the leases
of Facilities listed on Schedule 4.7.
Financial Statements shall mean the Year-End
Financial Statements and the Interim Financial Statements.
Fixtures and Equipment shall mean all of the
furniture, fixtures, furnishings, machinery, automobiles,
trucks, spare parts, supplies, equipment, tooling, molds,
patterns, dies and other tangible personal property owned by
Seller and used in connection with the Business, wherever
located and including any such Fixtures and Equipment in the
possession of any of Sellers suppliers, including all
warranty rights with respect thereto.
Former Facility shall mean each plant,
office, manufacturing facility, store, warehouse, improvement,
administrative building and all real property and related
facilities which was owned, leased or operated by Seller at any
time prior to the date hereof, but excluding any Facilities.
Insurance Policies shall mean the insurance
policies related to the Assets listed on Schedule 4.21.
Interim Balance Sheet shall mean the
unaudited Balance Sheet dated the Interim Balance Sheet Date.
Interim Balance Sheet Date shall mean
June 30, 2006.
Interim Financial Statements shall mean the
Interim Balance Sheet and the unaudited consolidated statements
of operations, changes in shareholders equity and cash
flow for the period ended on the Interim Balance Sheet Date.
Inventory shall mean all of Sellers
inventory held for resale and all of Sellers raw
materials, work in process, finished products, wrapping, supply
and packaging items and similar items used or held for use in
connection with the Business, in each case wherever the same may
be located.
Leased Real Property shall mean all leased
property described in the Facility Leases.
Leasehold Estates shall mean all of
Sellers rights and obligations as lessee under the Leases.
Leasehold Improvements shall mean all
leasehold improvements situated in or on the Leased Real
Property and owned by Seller.
A-7
Leases shall mean all of the existing leases
with respect to the personal or real property of Seller listed
on Schedule 4.7, and leases with respect to the personal
and real property of Seller which are not required to be listed
on Schedule 4.7.
Liabilities shall mean any direct or indirect
liability, indebtedness, obligation, commitment, expense, claim,
deficiency, guaranty or endorsement of or by any person of any
type, whether accrued, absolute, contingent, matured, unmatured
or other.
Material Adverse Effect shall mean with
respect to the Business or the Assets any effect or change which
is materially adverse to the operations, results of operations,
Liabilities or financial condition of operations of the Business
and/or the
Assets taken as a whole, or on the ability of Seller to
consummate the transactions contemplated hereby; provided,
however, that none of the following (individually or in
combination) shall be deemed to constitute, or shall be taken
into account in determining whether there has been, a Material
Adverse Effect or change: (1) any adverse effect to the
extent resulting from conditions generally affecting any
industry or industry sector in which Seller operates or
competes; (2) any adverse effect to the extent resulting
from changes or developments generally affecting the
U.S. or global economy; (3) any adverse effect to the
extent resulting from the announcement, execution or delivery of
this Agreement or the pendency or consummation of the
transactions set forth herein.
Mortgages shall mean all deeds of trust,
mortgages or other debt encumbrances on Owned Real Property.
Ordinary Course of Business shall mean the
ordinary course of the Business and consistent with
Sellers past practice.
Owned Real Property shall mean all real
property owned in fee by Seller, including without limitation
all rights, easements and privileges appertaining or relating
thereto, all buildings, fixtures, and improvements located
thereon and all Facilities thereon, if any.
Patents shall mean all U.S. and foreign
patents and patent applications and registered design and
registered design applications (including any division,
continuation, or
continuation-in-part,
reexamination, or reissue thereof).
Permits shall mean all licenses, permits,
franchises, approvals, authorizations, consents or orders of, or
filings with, any governmental authority, whether foreign,
federal, state or local, or any other person, necessary or
desirable for the present conduct of, or relating to the current
operation of, the Business.
Proprietary Rights shall mean all of
Sellers Copyrights, Patents, Trademarks, technology rights
and licenses, computer software (including without limitation
any source or object codes therefor or documentation relating
thereto), trade secrets, franchises, know-how, inventions,
designs, specifications, plans, drawings and intellectual
property rights relating to the Business.
Regulations shall mean any laws, statutes,
ordinances, regulations, rules, notice requirements, court
decisions, agency guidelines, principles of law and orders of
any foreign, federal, state or local government and any other
governmental department or agency, including without limitation
Environmental Laws, energy, motor vehicle safety, public
utility, zoning, building and health codes, occupational safety
and health and laws respecting employment practices, employee
documentation, terms and conditions of employment and wages and
hours.
Representative shall mean any officer,
director, principal, attorney, agent, employee or other
representative of a party.
Subsidiary shall mean (a) any
corporation in an unbroken chain of corporations beginning with
Seller if each of the corporations other than the last
corporation in the unbroken chain then owns stock possessing 50%
or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain,
(b) any partnership in which Seller is a general partner,
or (c) any partnership in which Seller possesses a 50% or
greater interest in the total capital or total income of such
partnership.
Superior Proposal shall mean a Proposed
Acquisition Transaction that is reasonably capable of being
consummated, taking into account all legal, financial,
regulatory, timing, and similar aspects of, and conditions to,
the proposal, the likelihood of obtaining necessary financing
and the corporation, partnership, person or other entity
A-8
or group making the proposal, and, which, if consummated, would
result in a transaction more favorable to the Companys
stockholders from a financial point of view than the
transactions contemplated hereby.
Tax shall mean any federal, state, local,
foreign or other tax, levy, impost, fee, assessment or other
government charge, including without limitation income,
estimated income, business, occupation, franchise, property,
payroll, personal property, sales, transfer, use, employment,
commercial rent, occupancy, franchise or withholding taxes, and
any premium, including without limitation interest, penalties
and additions in connection therewith.
Trademarks shall mean registered trademarks,
registered service marks, trademark and service mark
applications and unregistered trademarks and service marks.
Warrants shall mean (a) agreements,
rights to subscribe (including any preemptive rights), options,
warrants, calls, commitments or rights of any character to
purchase or otherwise acquire any common stock or other
securities of Seller, and (b) outstanding securities of
Seller that are convertible into or exchangeable for capital
shares or other securities of Seller.
Year-End Financial Statements shall mean the
audited Balance Sheets dated December 31, 2004 and
December 31, 2005, and the related audited consolidated
statements of operations, changes in shareholders equity
and cash flow for the year ended 2005.
A-9
1.2 Other Defined Terms. The
following terms shall have the meanings defined for such terms
in the Sections set forth below:
|
|
|
Term
|
|
Section
|
|
Assumed Liabilities
|
|
2.2
|
Assumption Documents
|
|
3.2(c)
|
Bulk Sales Act
|
|
10.6
|
Buyers Share of Property
Taxes
|
|
2.4(d)
|
Claim
|
|
10.4(d)
|
Claim Notice
|
|
10.4(d)
|
Closing
|
|
3.1
|
Closing Balance Sheet
|
|
2.5
|
Consultant
|
|
6.4(b)(i)
|
Cross License Agreement
|
|
3.2(d)
|
Damages
|
|
10.4(a)
|
Employee Plan
|
|
2.3(a)
|
Environmental Conditions
|
|
4.28(a)
|
Environmental Laws
|
|
4.28(a)
|
Escrow Account
|
|
2.4(b)
|
Escrow Agent
|
|
2.4(b)
|
Escrow Amount
|
|
2.4(b)
|
Escrow Indemnification Agreement
|
|
10.5
|
Excluded Liabilities
|
|
2.3
|
Hazardous Substance
|
|
4.28(a)
|
Holdback Amount
|
|
2.4(c)
|
Manufacture and Supply Agreement
|
|
3.2(g)
|
Permitted Encumbrances
|
|
4.6(a)
|
Property Taxes
|
|
2.6(d)
|
Proposed Acquisition Transaction
|
|
6.2(a)
|
Purchase Price
|
|
2.4(a)
|
Release
|
|
4.28(a)
|
Rehired Employees
|
|
6.6(a)
|
Seldi Patent
|
|
2.4(c)
|
Sellers Share of Property
Taxes
|
|
2.6(d)
|
Stock Purchase Agreement
|
|
3.2(f)
|
Straddle Period
|
|
2.6(d)
|
Sublease Agreement
|
|
3.2(c)
|
Term
|
|
10.6(b)
|
Transfer Taxes
|
|
2.7(b)
|
Transition Services Agreement
|
|
3.2(e)
|
A-10
ARTICLE II
PURCHASE AND SALE OF ASSETS
2.1 Transfer of Assets. Upon
the terms and subject to the conditions contained herein, at the
Closing, Seller will sell, convey, transfer, assign and deliver
to Buyer, and Buyer will acquire from Seller, the Assets, free
and clear of all Encumbrances.
2.2 Assumption of
Liabilities. Upon the terms and subject to
the conditions contained herein, at the Closing, Buyer shall
assume the following, and only the following, Liabilities of
Seller (the Assumed Liabilities): (a) the
following Liabilities of Seller specifically set forth on the
Closing Balance Sheet solely to the extent relating to the
Business and incurred in the Ordinary Course of Business as of
the Closing Date: (i) accounts payable, (ii) accrued
liabilities, (iii) deferred revenue (current), and
(iv) deferred revenue (long term), and (b) all
Liabilities accruing, arising out of, or relating to events or
occurrences happening after the Closing Date under (i) the
Contracts and Leases listed on Schedule 4.7, or under
Contracts or Leases which are not listed on Schedule 4.7
but which Buyer and Seller agree in writing that Buyer shall
accept and assume, but not including any Liability for any
Default under any such Contract occurring on or prior to the
Closing Date and (ii) under the Contract Rights, including
without limitation all service and warranty obligations relating
to the Contract Rights arising in the Ordinary Course of
Business.
2.3 Excluded
Liabilities. Notwithstanding any other
provision of this Agreement, except for the Assumed Liabilities
expressly specified in Section 2.2, Buyer shall not assume,
or otherwise be responsible for, any Liabilities of Seller,
whether liquidated or unliquidated, or known or unknown, whether
arising out of occurrences prior to, at or after the date hereof
(Excluded Liabilities), which Excluded Liabilities
include, without limitation:
(a) Except as otherwise provided in Section 6.6, any
Liability to or in respect of any employees or former employees
of Seller including without limitation (i) any employment
agreement, whether or not written, between Seller and any
person, (ii) any Liability under any employee benefit plan
(within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended, and the
rules and regulations promulgated thereunder) (an Employee
Plan) at any time maintained, contributed to or required
to be contributed to by or with respect to Seller under which
Seller may incur Liability, or any contributions, benefits or
Liabilities therefor, or any Liability with respect to
Sellers withdrawal or partial withdrawal from or
termination of any Employee Plan and (iii) any claim of an
unfair labor practice, or any claim under any state unemployment
compensation or workers compensation law or regulation or
under any federal or state employment discrimination law or
regulation, which shall have been asserted on or prior to the
Closing Date or is based on acts or omissions which occurred on
or prior to the Closing Date;
(b) Any Liability of Seller in respect of any Tax (except
as provided for in this Agreement);
(c) Any Liability arising from any injury to or death of
any person or damage to or destruction of any property, whether
based on negligence, breach of warranty, strict liability,
enterprise liability or any other legal or equitable theory
arising from defects in products manufactured or from services
performed by or on behalf of Seller or any other person or
entity on or prior to the Closing Date;
(d) Any Liability of Seller arising out of or related to
any Action against Seller or any Action which adversely affects
the Assets and which shall have been asserted on or prior to the
Closing Date or to the extent the basis of which shall have
arisen on or prior to the Closing Date, including, without
limitation, the litigation between Health Discovery and Seller
(Health Discovery Corporation v. Ciphergen Biosystems,
Inc. Case
No. 2:06-cv-00260-TJW
(U.S. District Court, Eastern District of Texas, Marshall
Division);
(e) Any Liability of Seller resulting from entering into,
performing its obligations pursuant to or consummating the
transactions contemplated by, this Agreement (including without
limitation any Liability of Seller pursuant to Article X
hereof); and
(f) Any Liability related to any Former Facility.
A-11
2.4 Purchase Price.
(a) Purchase Price. At the Closing, upon the terms and
subject to the conditions set forth herein, Buyer shall pay to
Seller for the sale, transfer, assignment, conveyance and
delivery of the Assets, the aggregate amount of Twenty Million
Dollars ($20,000,000) (the Purchase Price) less the
Escrow Amount and the Holdback Amount, by wire transfer of
immediately available funds to an account designated by Seller
and shall assume the Assumed Liabilities pursuant to this
Agreement. The Purchase Price shall be allocated among the
Assets in the manner required by Section 1060 of the Code
and regulations thereunder. Buyer will provide the allocation to
the Seller within thirty (30) calendar days after the Buyer
receives the Closing Balance Sheet from the Seller. If Seller
does not object to the allocation it shall be attached hereto as
Exhibit B. If Seller disagrees with the allocation, Seller
shall notify Buyer of such disagreement in writing specifying in
detail the particulars of such disagreement within fifteen
(15) business days after Sellers receipt of the
allocation. Buyer and Seller shall use their best efforts for a
period of thirty (30) calendar days after Buyers
delivery of such notice (or such longer period as Buyer and
Seller shall mutually agree upon) to resolve any disagreements
raised by Buyer with respect to the calculation of the
allocation. If, at the end of such period, Buyer and Seller are
unable to resolve such disagreements, PricewaterhouseCoopers LLP
and Deloitte & Touche LLP, independent auditors of
Seller and Buyer, respectively, shall jointly select a third
independent auditor of recognized national standing to resolve
any remaining disagreements. The determination by such third
independent auditor shall be final, binding and conclusive on
the parties. Buyer and Seller shall use their best efforts to
cause such third independent auditor to make its determination
within thirty (30) calendar days of accepting its
selection. Buyer and Seller agree to each prepare and file on a
timely basis with the Internal Revenue Service substantially
identical initial and supplemental Internal Revenue Service
Forms 8594 Asset Acquisition Statements Under
Section 1060 consistent with such allocation.
(b) The Escrow Amount shall be an amount equal
to Two Million Dollars ($2,000,000), which Buyer, at the
Closing, shall, pursuant to the Escrow Indemnification
Agreement, deliver to the Escrow Agent named therein, pending
the determination of Sellers indemnification obligations,
if any, as set forth in Section 10.4.. The Escrow
Indemnification Agreement shall instruct the Escrow Agent to
close the escrow established pursuant to the terms of that
agreement and this Agreement and to disburse funds as specified
therein and herein to Buyer
and/or
Seller, as appropriate. The parties agree and acknowledge that
the Escrow Amount shall not be Buyers exclusive method of
receiving indemnification from Seller pursuant to Article X.
(c) The Holdback Amount shall be an amount
equal to Two Million Dollars ($2,000,000), which Buyer shall
retain until the issuance of a Reexamination Certificate of
U.S. Patent No. 6,734,022 (the Seldi
Patent), confirming the patentability of all of the claims
as originally issued in such patent, or claims of equivalent
scope.
2.5 Closing Balance
Sheet. On or before the Closing Date, Seller
shall prepare and deliver to Buyer a Balance Sheet dated the
Closing Date (the Closing Balance Sheet).The Closing
Balance Sheet shall be prepared by Sellers personnel in
accordance with generally accepted accounting principles, as
applied in preparation of the Interim Balance Sheet, and shall
fairly and accurately present the consolidated assets,
Liabilities (including reserves) and financial position of
Seller, as of the Closing Date. The Closing Balance Sheet shall
be accompanied by reasonably detailed schedules indicating which
assets set forth thereon are Assets or Excluded Assets, which
Liabilities set forth thereon are Assumed Liabilities or
Excluded Liabilities and a calculation of the Net Book Value.
2.6 Prorations.
(a) Interest. On the Closing Date,
or as promptly as practicable following the Closing Date, but in
no event later than sixty (60) calendar days thereafter,
all prepaid interest and interest payable with respect to any
interest bearing obligations assumed by Buyer hereunder shall be
prorated between Buyer and Seller as of the Closing Date.
(b) Utilities. On the Closing
Date, or as promptly as practicable following the Closing Date,
but in no event later than sixty (60) calendar days
thereafter, the water, gas, electricity and other utilities,
common area maintenance reimbursements to lessors, local
business or other license fees, merchants association dues
and other similar periodic charges payable with respect to the
Assets or the Business shall be prorated between
A-12
Buyer and Seller effective as of the Closing Date. To the extent
practicable, utility meter readings for the Facilities shall be
determined as of the Closing Date. All such prorations shall be
based upon the most recent available assessed value of any
Facility prior to the Closing Date.
(c) Rents. Seller shall pay all
rent under the Leases through the end of the calendar month in
which the Closing Date occurs, and Buyer shall reimburse Seller
for such rent accrued from the Closing Date through the end of
such month as part of the post-Closing proration. Payments of
percentage rent, if any, due under the provisions of the Leases
shall be adjusted to the Closing Date as follows. Buyer shall
pay any percentage rent due for periods expiring after the
Closing Date, and Seller shall be responsible for that portion
of such percentage rent paid by Buyer and due under the Leases
based on sales from the commencement of the current lease year
through the Closing Date, and Buyer shall be responsible for
that portion due under the Lease based on sales from and after
the Closing Date. Within ninety (90) calendar days after
the Closing Date, Seller will furnish to Buyer records which
evidence the gross sales of Seller at each Facility to the
extent necessary to enable Buyer to comply with the percentage
rent provision of each Lease. Buyer shall provide to Seller,
within thirty (30) calendar days before the annual
settlement of percentage rent under any Lease for the partial
year in which Seller was operating such Facility, a statement
showing the manner of computation of all percentage rent due
under each Lease for such year. Any reimbursement due Buyer from
Seller in respect of its pro rata share of percentage rent shall
be paid within fifteen (15) calendar days after written
demand therefor by Buyer.
(d) Taxes. Any real or
personal property taxes applicable to the Assets or the Business
(Property Taxes) for a taxable period that includes
but does not end on the Closing Date (a Straddle
Period) shall be paid by the Buyer or the Seller as
required by applicable law. The portion of such Property Taxes
for which the Seller is liable under this Agreement (the
Sellers Share of Property Taxes) shall be
equal to the amount of such Property Taxes multiplied by a
fraction, the numerator of which is the number of days in such
Straddle Period that includes and ends on the Closing Date and
the denominator of which is the number of days in such Straddle
Period. The portion of such Property Taxes for which the Buyer
is liable under this Agreement shall be equal to the balance of
such Property Taxes (the Buyers Share of Property
Taxes). To the extent the Seller has paid any such
Property Taxes prior to the Closing Date, the Buyer shall make a
payment to the Seller on the Closing Date equal to the
Buyers Share of Property Taxes. Following the payment of
any such Property Taxes by the Seller after the Closing Date,
the Buyer shall, upon request, promptly pay to the Seller an
amount equal to the Buyers Share of Property Taxes.
Following the payment of any such Property Taxes by the Buyer
after the Closing Date, the Seller shall, upon request, promptly
pay to the Buyer an amount equal to the Sellers Share of
Property Taxes. The party required by law to file a tax return
with respect to Straddle Period Taxes shall do so within the
time period prescribed by law
2.7 Closing Costs; Transfer Taxes.
(a) Seller shall pay the fees and costs of recording or
filing all applicable conveyancing instruments described in
Section 3.2(a). Seller shall pay all costs of applying for
new Permits and obtaining the transfer of existing Permits which
may be lawfully transferred.
(b) Buyer shall promptly pay all applicable sales, use,
value added, goods and services, filing, recording,
registration, stamp, documentary and other similar taxes and
fees (together with any interest or penalties) (collectively
Transfer Taxes) that are payable in connection with
the transactions contemplated by this Agreement. To the extent
that Seller is required to pay any such Transfer Taxes under
applicable law, Buyer shall reimburse Seller for such Transfer
Taxes within three (3) days of receiving notice from Seller
of such payment. Buyer and Seller shall use their commercially
reasonable efforts to avail themselves of any and all available
exemptions or other opportunities to reduce or eliminate any
such Transfer Taxes. Such cooperation shall include, without
limitation, (i) the delivery of appropriate resale
certificates by Buyer to Seller, (ii) the parties hereto
obtaining applicable exemption certificates, and
(iii) Seller transferring the Assets to Buyer by remote
electronic transmission or other reasonable means of
transferring assets capable of being so transferred in other
than tangible form.
A-13
ARTICLE III
CLOSING
3.1 Closing. The Closing of
the transactions contemplated herein (the Closing)
shall be held at 10:00 a.m. local time on the Closing Date
at the offices of Buyer, 1000 Alfred Nobel Drive, Hercules,
California 94547, unless the parties hereto otherwise agree.
3.2 Conveyances at Closing.
(a) Instruments and Possession.
To effect the sale and transfer referred to in Section 2.1
hereof, Seller will, at the Closing, execute and deliver to
Buyer:
(i) one or more bills of sale, in the form attached hereto
as Exhibit C, conveying in the aggregate all of
Sellers owned personal property included in the Assets;
(ii) subject to Sections 9.2, Assignments of Lease in
the form attached hereto as Exhibit D with respect
to the Leases;
(iv) subject to Sections 9.2, Assignments of Contract
Rights, each in the form of Exhibit E attached
hereto, with respect to the Contract Rights;
(v) Assignments of Patents and Trademarks and other
Proprietary Rights each in the form attached hereto as
Exhibit F, in recordable form to the extent
necessary to assign such rights;; and
(vi) such other instruments as shall be reasonably
requested by Buyer to vest in Buyer title in and to the Assets
in accordance with the provisions hereof.
(b) Assumption Document. Upon the
terms and subject to the conditions contained herein, at the
Closing Buyer shall deliver to Seller an instrument of
assumption substantially in the form attached hereto as
Exhibit G, evidencing Buyers assumption,
pursuant to Section 2.2, of the Assumed Liabilities (the
Assumption Document).
(c) Sublease Agreement. Upon the
terms and subject to the conditions contained herein, at the
Closing, Seller and Buyer shall execute and deliver a sublease
substantially in the form attached hereto as
Exhibit J, pursuant to which Seller will sublease to
Buyer certain portions of its Facilities for use by Buyer in the
operation of the Business (the Sublease
Agreement).
(d) Cross License Agreement. Upon
the terms and subject to the conditions contained herein, at the
Closing, Seller and Buyer shall execute and deliver a cross
license agreement substantially in the form attached hereto as
Exhibit K, pursuant to which Buyer will grant back
to Seller from the Proprietary Rights an exclusive license to
certain intellectual property for use by Seller in connection
with its activities in the Clinical Diagnostics Market (as that
term is defined in such cross license agreement) and Seller will
grant back to Buyer a non-exclusive license to certain
intellectual property not included in the Proprietary Rights for
use in connection with the Business (the Cross License
Agreement).
(e) Transition Services
Agreement. Upon the terms and subject to the
conditions contained herein, at the Closing, Seller and Buyer
shall execute and deliver a transition services agreement
substantially in the form attached hereto as
Exhibit L (the Transition Services
Agreement).
(f) Stock Purchase Agreement. Upon
the terms and subject to the conditions contained herein, at the
Closing, Seller and Buyer shall execute and deliver a stock
purchase agreement substantially in the form attached hereto as
Exhibit M, pursuant to which Buyer will purchase
shares of Common Stock of Seller for a total purchase price of
Three Million Dollars ($3,000,000) on the terms set forth
therein (the Stock Purchase Agreement).
(g) Manufacture and Supply
Agreement. Upon the terms and subject to the
conditions stated herein, at the Closing, Seller and Buyer shall
execute and deliver a manufacture and supply agreement
substantially in the form attached hereto as
Exhibit N (the Manufacture and Supply
Agreement).
(h) Form of Instruments. To the
extent that the form of any document to be delivered hereunder
is not attached as an exhibit hereto, such documents shall be in
form and substance, and shall be executed and delivered in a
manner reasonably satisfactory to Buyer and Seller.
A-14
(i) Certificates; Opinions. Buyer
and Seller shall deliver the certificates, opinions of counsel
and other matters described in Articles VII and VIII.
(j) Consents. Subject to
Sections 9.2, Seller shall deliver all Permits and any
other third party consents required for the valid transfer of
the Assets as contemplated by this Agreement.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller hereby represents and warrants to Buyer as follows,
except as otherwise set forth on the Disclosure Schedule, which
representations and warranties are (i) as of the date
hereof, true and correct, and (ii) will be true and correct
in all material respects at and as of the Closing Date, other
than such failures to be true and correct that individually or
in the aggregate would not have a Material Adverse Effect,
except with respect to a representation
and/or
warranty that is itself qualified by materiality, in which case
such representation
and/or
warranty will be true and correct in all respects as of the
Closing Date:
4.1 Organization of
Seller. Seller is a corporation duly
organized, validly existing and in good standing under the laws
of the State of Delaware with full corporate power and authority
to conduct the Business as it is presently being conducted and
to own and lease its properties and assets. Seller is duly
qualified to do business as a foreign corporation and is in good
standing in each jurisdiction where the character of its
properties owned or leased or the nature of its activities make
such qualification necessary, except where the failure to be so
qualified or in good standing would not have a Material Adverse
Effect on the Assets or the Business. Copies of the Certificate
of Incorporation and Bylaws of Seller, and all amendments
thereto, heretofore delivered to Buyer are accurate and complete
as of the date hereof. Schedule 4.1 contains a true,
correct and complete list of all jurisdictions in which Seller
is qualified to do business as a foreign corporation.
4.2 Subsidiaries. Except as
set forth in Schedule 4.2, Seller does not have any
Subsidiaries which are used by Seller in the conduct of the
Business or which own any of the Assets. Seller has no direct or
indirect stock or other equity or ownership interest (whether
controlling or not) in any corporation, association,
partnership, joint venture or other entity which are used by
Seller in the conduct of the Business or which own any of the
Assets. Each of the Subsidiaries listed on Schedule 4.2, is
a corporation duly organized, validly existing and in good
standing (or appropriately recognized as legally in existence
and active under the laws of its jurisdiction) under the laws of
the jurisdiction identified on Schedule 4.2, has the
requisite power and authority to conduct its business as it is
presently being conducted and to own and lease its properties
and Assets, to permit Seller to enter into this Agreement, to
consummate the transactions contemplated hereby and to perform
its obligations hereunder. No other corporate proceedings on the
part of any Subsidiary are necessary to authorize this Agreement
and the transactions contemplated hereby. Schedule 4.2
contains a true, correct and complete list of all jurisdictions
in which each Subsidiary is qualified to do business as a
foreign corporation. Except as set forth on Schedule 4.2,
each of the Subsidiaries listed on Schedule 4.2 is duly
qualified to do business as a foreign corporation and is in good
standing in each jurisdiction where the character of its
properties owned or leased or the nature of its activities make
such qualification necessary, expect where the failure to be so
qualified or in good standing would not have a Material Adverse
Effect on such Subsidiary. Copies of the Certificate or Articles
of Incorporation and Bylaws (and/or similar incorporation
documents under the relevant law of any Subsidiary) of each
Subsidiary heretofore delivered to Buyer are accurate and
complete. Schedule 4.2 sets forth a description of all of
the issued and outstanding equity securities of each of the
Subsidiaries. Seller owns of record and beneficially all of the
issued and outstanding capital or other stock of each Subsidiary
listed on Schedule 4.2 free and clear of any Encumbrances,
except as set forth on Schedule 4.2. There are no Warrants
with respect to the equity securities of any Subsidiary listed
on Schedule 4.2.
4.3 Authorization. Seller
has all requisite power and authority, and has taken all
corporate action necessary, to execute and deliver this
Agreement and the Ancillary Agreements, to consummate the
transactions contemplated hereby and thereby and to perform its
obligations hereunder and thereunder. The execution and delivery
of this Agreement and the Ancillary Agreements by Seller and the
consummation by Seller of the transactions contemplated hereby
and thereby have been duly approved by the boards of directors
and shareholders of and Seller. No other corporate proceedings
on the part of Seller are necessary to authorize this Agreement
and the Ancillary
A-15
Agreements and the transactions contemplated hereby and thereby.
This Agreement has been duly executed and delivered by Seller
and is, and upon execution and delivery of the Ancillary
Agreements will be, legal, valid and binding obligations of
Seller enforceable against them in accordance with its terms.
4.4 Absence of Certain Changes or
Events. Since the Interim Balance Sheet Date,
there has not been any:
(a) change in the financial condition, working capital,
shareholders equity, assets, Liabilities, reserves,
revenues, income, earnings, prospects or Business of Seller,
which individually or in the aggregate would have a Material
Adverse Effect;
(b) change in accounting methods, principles or practices
by Seller affecting the Assets, its Liabilities or the Business;
(c) revaluation by Seller of any of the Assets, including
without limitation writing down the value of inventory or
writing off notes or accounts receivable;
(d) damage, destruction or loss (whether or not covered by
insurance) adversely affecting the Assets or the Business;
(e) cancellation of any indebtedness or waiver or release
of any right or claim of Seller relating to its activities or
properties which had or will have a Material Adverse Effect on
the Assets or the Business;
(f) declaration, setting aside, or payment of dividends or
distributions by Seller in respect of its shares or any
redemption, purchase or other acquisition of any of
Sellers securities;
(g) adverse change in employee relations which has or is
reasonably likely to have a Material Adverse Effect on the
productivity, the financial condition, results of operations or
Business of Seller or the relationships between the employees of
Seller and the management of Seller;
(h) amendment, cancellation or termination of any Contract,
commitment, agreement, Lease, transaction or Permit relating to
the Assets or the Business or entry into any Contract,
commitment, agreement, Lease, transaction or Permit which is not
in the Ordinary Course of Business, including without limitation
any employment or consulting agreements;
(i) mortgage, pledge or other encumbrance of any Assets,
except purchase money mortgages arising in the Ordinary Course
of Business;
(j) sale, assignment or transfer of any of the Assets,
other than in the Ordinary Course of Business;
(k) incurrence by Seller of Liabilities, except Liabilities
incurred in the Ordinary Course of Business, or increase or
change in any assumptions underlying or methods of calculating,
any doubtful account contingency or other reserves of Seller;
(l) payment, discharge or satisfaction of any Liabilities
of Seller other than the payment, discharge or satisfaction in
the Ordinary Course of Business of Liabilities set forth or
reserved for on the Interim Financial Statements or incurred in
the Ordinary Course of Business;
(m) capital expenditure by Seller, the execution of any
Lease by Seller or the incurring of any obligation by Seller to
make any capital expenditure or execute any Lease, in amounts in
excess of $25,000 in the aggregate, other than such transactions
with are in the Ordinary Course of Business;
(n) failure to pay or satisfy when due any Liability of
Seller, except where the failure would not have a Material
Adverse Effect on the Assets or the Business;
(o) failure of Seller to carry on diligently the Business
in the Ordinary Course of Business so as to keep available to
Buyer the services of Sellers employees, and to preserve
for Buyer the Assets and the Business and the goodwill of
Sellers suppliers, customers, distributors and others
having business relations with it;
(p) disposition or lapsing of any Proprietary Rights or any
disposition or disclosure to any person of any Proprietary
Rights not theretofore a matter of public knowledge;
A-16
(q) existence of any other event or condition which in any
one case or in the aggregate has or might reasonably be expected
to have a Material Adverse Effect on the Business;
(r) agreement by Seller to do any of the things described
in the preceding clauses (a) through (q) other than as
expressly provided for herein;
(s) increase in the rate of compensation payable or to
become payable to any of the Rehired Employees (as defined in
Section 6.6), including without limitation the making of
any loan to, or the payment, grant or accrual of any bonus,
incentive compensation, service award or other similar benefit
to, any such person, or the addition to, modification of, or
contribution to any Employee Plan, arrangement, or practice
described in the Disclosure Schedule.
4.5 Assets. Excluding the
Leased Real Property, Seller has and will transfer good and
marketable title to the Assets and upon the consummation of the
transactions contemplated hereby, Buyer will acquire good and
marketable title to all of the Assets, free and clear of any
Encumbrances. The Assets include all assets necessary for the
conduct or operation of the Business as the Business has been
conducted by Seller in the twelve (12) months prior to the
date of this Agreement on a commercially reasonable basis.
Schedule 4.5 contains accurate lists and summary
descriptions of all tangible Assets where the value of an
individual item exceeds $10,000 or where an aggregate of similar
items exceeds $20,000. All tangible assets and properties which
are part of the Assets are in good operating condition and
repair and are usable in the Ordinary Course of Business and
conform in all material respects to all applicable Regulations
(including Environmental Laws) relating to their construction,
use and operation.
4.6 Facilities. Schedule 4.6
contains a complete and accurate list of all Owned Real Property
used in connection with the Business
and/or the
Assets.
(a) Actions. There are no pending
or, to the best knowledge of Seller, threatened condemnation
proceedings or other Actions relating to any Facility.
(b) Leases or Other
Agreements. Except for Facility Leases listed
on Schedule 4.7, there are no leases, subleases, licenses,
occupancy agreements, options, rights, concessions or other
agreements or arrangements, written or oral, granting to any
person the right to purchase, use or occupy any Facility, or any
real property in connection with the Business or any portion
thereof or interest in any such Facility or real property.
(c) Facility Leases and Leased Real
Property. With respect to each Facility
Lease, Seller has and will have at the Closing an unencumbered
interest in the Leasehold Estate. Seller enjoys peaceful and
undisturbed possession of all the Leased Real Property, subject
to the rights of the fee owners.
(d) Certificate of Occupancy. All
Facilities have received all required approvals of governmental
authorities (including without limitation Permits and a
certificate of occupancy or other similar certificate permitting
lawful occupancy of the Facilities) required in connection with
the operation thereof and have been operated and maintained in
all material respects in accordance with applicable Regulations.
(f) Utilities. All Facilities are
supplied with utilities (including without limitation water,
sewage, disposal, electricity, gas and telephone) and other
services necessary for the operation of such Facilities as
currently operated, and there is no condition which would
reasonably he expected to result in the termination of the
present access from any Facility to such utility services.
(g) Improvements, Fixtures and
Equipment. To the Sellers knowledge,
the improvements constructed on the Facilities, including
without limitation all Leasehold Improvements, and all Fixtures
and Equipment and other tangible assets owned, leased or used by
Seller at the Facilities are (i) insured to the extent and
in a manner customary in the industry, (ii) structurally
sound with no known material defects, (iii) in good
operating condition and repair, subject to ordinary wear and
tear, (iv) not in need of maintenance, repair or correction
except for ordinary routine maintenance and repair, the cost of
which would not be material, (v) sufficient for the
operation of the Business as presently conducted and
(vi) in conformity , in all material respects, with all
applicable Regulations.
A-17
(h) No Special Assessment. Seller
has not received notice of any special assessment relating to
any Facility or any portion thereof and there is no pending or
threatened special assessment.
4.7 Contracts and Commitments.
(a) Contracts. Schedule 4.7
sets forth a complete and accurate list of all Contracts of the
following categories:
(i) Contracts not made in the Ordinary Course of Business
involving payments in excess of $25,000;
(ii) Employment contracts and severance agreements,
including without limitation Contracts (A) to employ or
terminate executive officers or other personnel and other
contracts with present or former officers, directors or
shareholders of Seller or (B) that will result in the
payment by, or the creation of any Liability to pay on behalf of
Buyer or Seller any severance, termination, golden
parachute, or other similar payments to any present or
former personnel following termination of employment or
otherwise as a result of the consummation of the transactions
contemplated by this Agreement;
(iii) Labor or union contracts;
(iv) Distribution, franchise, license, technical
assistance, sales, commission, consulting, agency or advertising
contracts related to the Assets or the Business, excluding
agreements entered into by Seller in the Ordinary Course of
Business to purchasers of its products;
(v) Options with respect to any property, real or personal,
whether Seller shall be the grantor or grantee thereunder;
(vi) Contracts involving future expenditures or
Liabilities, actual or potential, in excess of $25,000 or
otherwise material to the Business or the Assets;
(vii) Contracts or commitments relating to commission
arrangements with others;
(viii) Promissory notes, loans, agreements, indentures,
evidences of indebtedness, letters of credit, guarantees, or
other instruments relating to an obligation to pay money,
individually in excess of or in the aggregate in excess of
$25,000, whether Seller shall be the borrower, lender or
guarantor thereunder or whereby any Assets are pledged
(excluding credit provided by Seller in the Ordinary Course of
Business to purchasers of its products);
(ix) Contracts containing covenants limiting the freedom of
Seller or any officer, director, shareholder or affiliate of
Seller, to engage in any line of business or compete with any
person;
(x) Any Contract with the United States, state or local
government or any agency or department thereof;
(xi) Leases of real property;
(xii) Leases of personal property not cancelable (without
Liability) within thirty (30) calendar days.
Seller has delivered to Buyer true, correct and complete copies
of all of the Contracts listed on Schedule 4.7, including
all amendments and supplements thereto.
(b) Absence of Defaults. All of
the Contracts and Leases to which Seller is party or by which it
or any of the Assets is bound or affected are valid, binding and
enforceable in accordance with their terms. Seller has
fulfilled, or taken all action necessary to enable it to fulfill
when due, all of its material obligations under each of such
Contracts and Leases, except where the failure to do so,
individually or in the aggregate, would not have a Material
Adverse Effect. To Sellers knowledge, parties to such
Contracts and Leases have complied in all material respects with
the provisions thereof, no party is in Default thereunder and no
notice of any claim of Default has been given to Seller, except
where noncompliance, individually or in the aggregate, would not
have a Material Adverse Effect. To Sellers knowledge, the
products and services called for by any unfinished Contract can
be supplied in accordance with the terms of such Contract,
including time specifications, and any unfinished Contract will
upon performance by Seller not result in a loss to Seller. With
respect to any Leases, Seller has not received any notice of
cancellation or termination under any option or right reserved
to the lessor, or any notice of Default, thereunder.
A-18
(c) Product Warranty. Seller has
committed no act or failed to take an action, which could
reasonably be expected to result in, and there has been no
occurrence which could reasonably be expected to give rise to,
product liability or Liability for breach of warranty (whether
covered by insurance or not) on the part of Seller, with respect
to products designed, manufactured, assembled, repaired,
maintained, delivered or installed or services rendered prior to
or on the Closing Date, which in the aggregate would be in
excess of the amount reserved for warranty claims on the Interim
Balance Sheet.
4.8 Permits. (a) Schedule 4.8
sets forth a complete list of all material Permits used in the
operation of the Business or otherwise held by Seller. Seller
has, and at all times has had, all Permits required under any
Regulation (including Environmental Laws) in the operation of
its Business or in the ownership of the Assets, and owns or
possesses such Permits free and clear of all Encumbrances.
Seller is not in Default, nor has it received any notice of any
claim of Default, with respect to any such Permit, except where
such Default or series of Defaults would not have a Material
Adverse Effect. Except as otherwise governed by law, all such
Permits are renewable by their terms or in the Ordinary Course
of Business without the need to comply with any special
qualification procedures or to pay any amounts other than
routine filing fees and except as set forth on
Schedule 4.8, will not be adversely affected by the
completion of the transactions contemplated by this Agreement.
No present or former shareholder, director, officer or employee
of Seller or any affiliate thereof, or any other person, firm,
corporation or other entity, owns or has any proprietary,
financial or other interest (direct or indirect) in any Permit
which Seller owns, possesses or uses.
(b) Except as disclosed on Schedule 4.8 hereto, no
notice to, declaration, filing or registration with, or Permit
from, any domestic or foreign governmental or regulatory body or
authority, or any other person or entity, is required to be made
or obtained by Seller in connection with the execution, delivery
or performance of this Agreement and the consummation of the
transactions contemplated hereby.
4.9 No Conflict or
Violation. Neither the execution, delivery or
performance of this Agreement nor the consummation of the
transactions contemplated hereby, nor compliance by Seller with
any of the provisions hereof, will (a) violate or conflict
with any provision of the Certificate of Incorporation or Bylaws
of Seller, (b) violate, conflict with, or result in or
constitute a Default under, or result in the termination of, or
accelerate the performance required by, or result in a right of
termination or acceleration under, or result in the creation of
any Encumbrance upon any of the Assets under, any of the terms,
conditions or provisions of any Contract, Lease or Permit,
(i) to which Seller is a party or (ii) by which the
Assets are bound, (c) violate any Regulation or Court
Order, (d) impose any Encumbrance on the Assets or the
Business.
4.10 Financial
Statements. Seller has heretofore delivered
to Buyer the Financial Statements. The Financial Statements
(a) are in accordance with the books and records of Seller,
(b) have been prepared in accordance with generally
accepted accounting principles consistently applied throughout
the periods covered thereby and (c) fairly and accurately
present the consolidated assets, Liabilities (including all
reserves) and financial position of Seller as of the respective
dates thereof and the consolidated results of operations and
changes in cash flows for the periods then ended (subject, in
the case of the Interim Financial Statements, to normal year-end
adjustments). The Year-End Financial Statements have been
examined by PricewaterhouseCoopers LLP, independent certified
public accountants, whose report thereon is included with such
Year-End Financial Statements. At the respective dates of the
Financial Statements, there were no Liabilities of Seller,
which, in accordance with generally accepted accounting
principles, should have been set forth or reserved for in the
Financial Statements or the notes thereto, which are not set
forth or reserved for in the Financial Statements or the notes
thereto.
4.11 Books and
Records. Seller has made and kept (and given
Buyer access to) Books and Records and accounts, which, in
reasonable detail, accurately and fairly reflect the activities
of Seller. Seller has not engaged in any transaction, maintained
any bank account or used any corporate funds except for
transactions, bank accounts and funds which have been and are
reflected in the normally maintained books and records of Seller
4.12 Litigation. Except as
set forth on Schedule 4.12, there are no Actions pending,
or to the best of Sellers knowledge, threatened or
anticipated (a) against, related to or affecting
(i) Seller, the Business or the Assets (including with
respect to Environmental Laws), (ii) any officers or
directors of Seller as such, or (iii) any shareholder of
Seller in such shareholders capacity as a shareholder of
Seller, (b) seeking to delay, limit or enjoin the
transactions contemplated by this Agreement (c) that
involve the risk of criminal liability, or (d) in which
Seller is a plaintiff, including any derivative suits brought by
or on behalf of Seller. Seller is not in Default with respect to
A-19
or subject to any Court Order, and there are no unsatisfied
judgments against Seller, the Business or the Assets. There is
not a reasonable likelihood of an adverse determination of any
pending Actions. There are no Court Orders or agreements with,
or liens by, any governmental authority or quasi-governmental
entity relating to any Environmental Law which regulate,
obligate, bind or in any way affect Seller or any Facility or
Former Facility.
4.13 Labor Matters. Seller
is not a party to any labor agreement with respect to its
employees with any labor organization, union, group or
association and there are no employee unions (nor any other
similar labor or employee organizations) under local statutes,
custom or practice. Seller has not experienced any attempt by
organized labor or its representatives to make Seller conform to
demands of organized labor relating to its employees or to enter
into a binding agreement with organized labor that would cover
the employees of Seller. There is no labor strike or labor
disturbance pending or, to the best of Sellers knowledge,
threatened against Seller nor is any grievance currently being
asserted, and Seller has not experienced a work stoppage or
other labor difficulty, and is not and has not engaged in any
unfair labor practice. Without limiting the foregoing, Seller is
in compliance with the Immigration Reform and Control Act of
1986 and maintains a current
Form I-9,
as required by such Act, in the personnel file of each employee
hired after November 9, 1986. Schedule 4.13 sets forth
the names and current annual salary rates or current hourly
wages of all present employees of Seller related to the Business
whose annual cash compensation for the 2005 fiscal year exceeds
$35,000, and also sets forth the earnings for each of such
employees for the 2004 calendar year.
4.14 Liabilities. Other than
Excluded Liabilities, Seller has no Liabilities due or to become
due, except (a) Liabilities which are set forth or reserved
for on the Interim Balance Sheet, which have not been paid or
discharged since the Interim Balance Sheet Date,
(b) Liabilities arising in the Ordinary Course of Business
under Contracts, Leases, Permits and other business arrangements
described in the Disclosure Schedule (and under those Contracts,
Leases and Permits which are not required to be disclosed on the
Disclosure Schedule) and (c) Liabilities incurred since the
Interim Balance Sheet Date in the Ordinary Course of Business
and in accordance with this Agreement (none of which relates to
any Default under any Contract or Lease, breach of warranty,
tort, infringement or violation of any Regulation or Court Order
or arose out of any Action) and none of which, individually or
in the aggregate, has or would have a Material Adverse Effect on
the Business or the Assets.
4.15 Compliance with
Law. Seller and the conduct of the Business
have not violated and are in compliance with all Regulations and
Court Orders relating to the Assets or the Business or
operations of Seller. Seller has not received any notice to the
effect that, or otherwise been advised that, it is not in
compliance with any such Regulations or Court Orders, and Seller
has no reason to anticipate that any existing circumstances are
likely to result in violations of any of the foregoing.
4.16 No Brokers. Neither
Seller nor any of its respective officers, directors, employees,
shareholders or affiliates have employed or made any agreement
with any broker, finder or similar agent or any person or firm
which will result in the obligation of Buyer or any of its
affiliates to pay any finders fee, brokerage fees or
commission or similar payment in connection with the
transactions contemplated hereby.
4.17 No Other Agreements to Sell the
Assets. Neither Seller nor any of its
respective officers, directors, shareholders or affiliates have
any commitment or legal obligation, absolute or contingent, to
any other person or firm other than the Buyer to sell, assign,
transfer or effect a sale of any of the Assets (other than
inventory in the Ordinary Course of Business), to sell or effect
a sale of the capital stock of Seller, to effect any merger,
consolidation, liquidation, dissolution or other reorganization
of Seller, or to enter into any agreement or cause the entering
into of an agreement with respect to any of the foregoing.
4.18 Proprietary Rights.
(a) Proprietary
Rights. Schedule 4.18 lists all of
Sellers Proprietary Rights. Schedule 4.18 also sets
forth: (i) for each Patent, the number, normal expiration
date and subject matter for each country in which such Patent
has been issued, or, if applicable, the application number, date
of filing and subject matter for each country, (ii) for
each Trademark, the application serial number or registration
number, the class of goods covered and the expiration date for
each country in which a Trademark has been registered and
(iii) for each Copyright, the number and date of filing for
each country in which a Copyright has been filed. The
Proprietary Rights listed in the Disclosure Schedule are all
those used by Seller in connection with the Business. True and
correct copies of all Patents (including all pending
A-20
applications) owned, controlled, created or used by or on behalf
of Seller or in which Seller has any interest whatsoever have
been provided to Buyer.
(b) Royalties and Licenses. Except
as set forth in Schedule 4.18, Seller does not have any
obligation to compensate any person for the use of any such
Proprietary Rights nor has Seller granted to any person any
license, option or other rights to use in any manner any of its
Proprietary Rights, whether requiring the payment of royalties
or not (except as provided by Seller in the Ordinary Course of
Business to purchasers of its products) .
(c) Ownership and Protection of Proprietary
Rights. Seller owns or has a valid right to
use each of the Proprietary Rights, and the Proprietary Rights
will not cease to be valid rights of Seller by reason of the
execution, delivery and performance of this Agreement or the
consummation of the transactions contemplated hereby. All of the
pending Patent applications have been duly filed. Seller has not
received any notice of invalidity or infringement of any rights
of others with respect to such Trademarks. Seller has taken all
reasonable and prudent steps to protect the Proprietary Rights
from infringement by any other person. No other person
(i) has the right to use any of Sellers Trademarks on
the goods on which they are now being used either in identical
form or in such near resemblance thereto as to be likely, when
applied to the goods of any such person, to cause confusion with
such Trademarks or to cause a mistake or to deceive,
(ii) has notified Seller that it is claiming any ownership
of or right to use such Proprietary Rights, or (iii) to the
best of Sellers knowledge, is infringing upon any such
Proprietary Rights in any way. Sellers use of the
Proprietary Rights does not and will not conflict with, infringe
upon or otherwise violate the valid rights of any third party,
and no Action has been instituted against or notices received by
Seller that are presently outstanding alleging that
Sellers use of the Proprietary Rights infringes upon or
otherwise violates any rights of a third party in or to such
Proprietary Rights. There are not, and it is reasonably expected
that after the Closing there will not be, any restrictions on
Sellers, or Buyers, as the case may be, right to
sell products manufactured by Seller or Buyer, as the case may
be, in connection with the Business.
4.19 Transactions with Certain
Persons. No officer, director or employee of
Seller nor, to Sellers knowledge, any member of any such
persons immediate family is presently, or within the past
three (3) years has been, a party to any transaction with
Seller, including without limitation, any material contract,
agreement or other arrangement (a) providing for the
furnishing of services by, (b) providing for the rental of
real or personal property from, or (c) otherwise requiring
payments to (other than for services as officers, directors or
employees of Seller) any such person or corporation,
partnership, trust or other entity in which any such person has
an interest as a shareholder, officer, director, trustee or
partner.
4.20 Tax Matters.
(a) Filing of Tax Returns. To the
extent that failure to do so would adversely affect the Assets
or the Business, Seller has timely filed with the appropriate
taxing authorities all material returns in respect of Taxes
required to be filed through the date hereof and will timely
file any such returns required to be filed on or prior to the
Closing Date, and such returns are complete and accurate in all
material respects.
(b) Payment of Taxes. To the
extent that failure to do so would adversely affect the Assets
or the Business, all Taxes, in respect of periods beginning
before the Closing Date, have been timely paid, or will be
timely paid, or an adequate reserve has been established
therefor, as set forth in the Disclosure Schedule or the
Financial Statements.
(c) Audits, Investigations or
Claims. Except as set forth in the Disclosure
Schedule, there are no pending or, to the best of Sellers
knowledge, threatened audits, investigations or claims for or
relating to any material additional Liability in respect of
Taxes, and there are no matters under discussion with any
governmental authorities with respect to Taxes that in the
reasonable judgment of Seller, or its counsel, is likely to
result in a Material Adverse Effect on the Assets or the
Business.
(d) Lien. There are no liens for
Taxes (other than for current Taxes not yet due and payable) on
the Assets.
(e) Safe Harbor Lease Property. None
of the Assets is property that is required to be treated as
being owned by any other person pursuant to the so-called safe
harbor lease provisions of former Section 168(f)(8) of the
Code.
(f) Security for Tax-Exempt
Obligations. None of the Assets directly or
indirectly secures any debt the interest on which is tax-exempt
under Section 103(a) of the Code.
A-21
(g) Tax-Exempt Use Property. None
of the Assets is tax-exempt use property within the
meaning of Section 168(h) of the Code.
(h) Foreign Person. Seller is not
a person other than a United States person within the meaning of
the Code.
4.21 Insurance. Schedule 4.21
contains a complete and accurate list of all policies or binders
of fire, liability, title, workers compensation, product
liability (which list shall be for the past three
(3) years) and other forms of insurance (showing as to each
policy or binder the carrier, policy number, coverage limits,
expiration dates, annual premiums, a general description of the
type of coverage provided, loss experience history by line of
coverage) maintained by Seller on the Business, the Assets or
its employees. All insurance coverage applicable to Seller, the
Business and the Assets is in full force and effect, insures
Seller in reasonably sufficient amounts against all risks
usually insured against by persons operating similar businesses
or properties of similar size in the localities where such
businesses or properties are located, provides coverage as may
be required by applicable Regulation and by any and all
Contracts to which Seller is a party and has been issued by
insurers of recognized responsibility. There is no Default under
any such coverage nor has there been any failure to give notice
or present any claim under any such coverage in a due and timely
fashion. There are no outstanding unpaid premiums except in the
Ordinary Course of Business and no notice of cancellation or
nonrenewal of any such coverage has been received. There are no
provisions in such insurance policies for retroactive or
retrospective premium adjustments. All products liability,
general liability and workers compensation insurance
policies maintained by Seller have been occurrence policies and
not claims made policies. There are no outstanding performance
bonds covering or issued for the benefit of the Seller. There
are no facts upon which an insurer might be justified in
reducing coverage or increasing premiums on existing policies or
binders. No insurer has advised Seller that it intends to reduce
coverage, increase premiums or fail to renew existing policy or
binder.
4.22 Inventory. The
Disclosure Schedule contains a complete and accurate list of all
Inventory set forth on the Interim Balance Sheet and the
addresses at which the Inventory is located. The Inventory as
set forth on the Interim Balance Sheet or arising since the
Interim Balance Sheet Date was acquired and has been maintained
in accordance with the regular business practices of Seller,
consists of new and unused items of a quality and quantity
usable or saleable in the Ordinary Course of Business within the
past six months, and is valued at reasonable amounts based on
the normal valuation policy of Seller at prices equal to the
lower of cost or market value on a
first-in-first-out
basis. None of such Inventory is obsolete, unusable,
slow-moving, damaged or unsalable in the Ordinary Course of
Business, except for such items of Inventory which have been
written down to realizable market value, or for which adequate
reserves have been provided, in the Interim Balance Sheet.
4.23 Purchase Commitments and Outstanding
Bids. As of the date of this Agreement, the
aggregate of all accepted and unfulfilled orders for the sale of
merchandise in connection with the Business entered into by
Seller is at least $150,000, and the aggregate of all orders or
commitments for the purchase of supplies by Seller does not
exceed $460,000, all of which orders and commitments were made
in the Ordinary Course of Business. As of the date of this
Agreement, there are no claims against Seller to return
merchandise by reason of alleged overshipments, defective
merchandise or otherwise, or of merchandise in the hands of
customers under an understanding that such merchandise would be
returnable. No outstanding purchase or outstanding lease
commitment of Seller presently is in excess of the normal,
ordinary and usual requirements of the Business or was made at
any price in excess of the now current market price or contains
terms and conditions more onerous than those usual and customary
in the Business. There is no outstanding bid, proposal, Contract
or unfilled order which relates to the Assets which will or
would, if accepted, have a Material Adverse Effect, individually
or in the aggregate, on the Business or the Assets or will or
would, if accepted, reasonably be expected to result in a net
consolidated loss to Seller.
4.24 Payments. Seller has
not, directly or indirectly, paid or delivered any fee,
commission or other sum of money or item or property, however
characterized, to any finder, agent, client, customer, supplier,
government official or other party, in the United States or any
other country, which is in any manner related to the Business,
Assets or operations of Seller, which is, or may be with the
passage of time or discovery, illegal under any federal, state
or local laws of the United States (including without limitation
the U.S. Foreign Corrupt Practices Act) or any other
country having jurisdiction; and Seller has not participated,
directly or indirectly, in any boycotts or other similar
practices affecting any of its actual or potential customers and
has at all times done business in an open and ethical manner.
A-22
4.25 Customers, Distributors and
Suppliers. Schedule 4.25 sets forth a
complete and accurate list of the names and addresses of
Sellers (i) customers, distributors and other agents
and representatives with annual sales greater than $10,000
during Sellers last fiscal year, showing the approximate
total sales in dollars by Seller to each such customer during
such fiscal year; and (ii) suppliers with purchases greater
than $10,000 during Sellers last fiscal year, showing the
approximate total purchases in dollars by Seller from each such
supplier during such fiscal year. Since the Interim Balance
Sheet Date, there has been no change in the business
relationship of Seller with any customer, distributor or
supplier named on Schedule 4.25 which, individually or in
the aggregate, would have a Material Adverse Effect. Seller has
not received any communication from any customer, distributor or
supplier named on Schedule 4.25 of any intention to
terminate or materially reduce purchases from or supplies to
Seller.
4.26 Compliance With Environmental
Laws.
(a) Definitions. The following
terms, when used in this Section 4.26, shall have the
following meanings. Any of these terms may, unless the context
otherwise requires, used in the singular or the plural depending
on the reference.
(i) Seller. For purposes of this
Section, the term Seller shall include (i) all
affiliates of Seller, (ii) all partnerships, joint ventures
and other entities or organizations in which Seller was at any
time or is a partner, joint venturer, member or participant and
(iii) all predecessor or former corporations, partnerships,
joint ventures, organizations, businesses or other entities,
whether in existence as of the date hereof or at any time prior
to the date hereof, the assets or obligations of which have been
acquired or assumed by Seller or to which Seller has succeeded.
(ii) Release shall mean and
include any spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, dumping or
disposing into the environment or the workplace of any Hazardous
Substance, and otherwise as defined in any Environmental Law.
(iii) Hazardous Substance shall
mean any pollutants, contaminants, chemicals, waste and any
toxic, infectious, carcinogenic, reactive, corrosive, ignitible
or flammable chemical or chemical compound or hazardous
substance, material or waste, whether solid, liquid or gas,
including without limitation any quantity of asbestos in any
form, urea formaldehyde, PCBs, radon gas, crude oil or any
fraction thereof, all forms of natural gas, petroleum products
or by-products or derivatives, radioactive substance, waste
waters, sludges, slag and any other substance, material or waste
that is subject to regulation, control or remediation under any
Environmental Laws.
(iv) Environmental Laws shall
mean all Regulations which regulate or relate to the protection
or clean-up
of the environment, the use, treatment, storage, transportation,
generation, manufacture, processing, distribution, handling or
disposal of, or emission, discharge or other release or
threatened release of, Hazardous Substances or otherwise
dangerous substances, wastes, pollution or materials (whether,
gas, liquid or solid), the preservation or protection of
waterways, groundwater, drinking water, air, wildlife, plants or
other natural resources, or the health and safety of persons or
property, including without limitation protection of the health
and safety of employees. Environmental Laws shall include
without limitation the Federal Water Pollution Control Act,
Resource Conservation & Recovery Act
(RCRA), Clean Water Act, Safe Drinking Water Act,
Atomic Energy Act, Occupational Safety and Health Act, Toxic
Substances Control Act, Clean Air Act, Comprehensive
Environmental Response, Compensation and Liability Act
(CERCLA), Hazardous Materials Transportation Act and
all analogous or related federal, state or local law, each as
amended.
(v) Environmental Conditions
means the introduction into the environment of any pollution,
including without limitation any contaminant, irritant or
pollutant or other Hazardous Substance (whether or not upon any
Facility or Former Facility or other property and whether or not
such pollution constituted at the time thereof a violation of
any Environmental Law as a result of any Release of any kind
whatsoever of any Hazardous Substance) as a result of which
Seller has or may become liable to any person or by reason of
which any Facility, Former Facility or any of the Assets may
suffer or be subjected to any lien.
(b) Facilities. The Facilities
are, and at all times have been, and all Former Facilities were
at all times when owned, leased or operated by Seller, owned,
leased and operated in compliance with all Environmental Laws
and in a manner that will not give rise to any Liability under
any Environmental Laws. Without limiting the foregoing,
(i) there is not and has not been any Hazardous Substance
used, generated, treated, stored, transported, disposed of,
handled or otherwise existing on, under, about or from any
Facility or any Former Facility, except for quantities of
A-23
any such Hazardous Substances stored or otherwise held on, under
or about any such Facility in full compliance with all
Environmental Laws and necessary for the operation of the
Business, (ii) Seller has at all times used, generated,
treated, stored, transported, disposed of or otherwise handled
its Hazardous Substances in compliance with all Environmental
Laws and in a manner that will not result in Liability of Seller
under any Environmental Law, (iii) there is not now and has
not been at any time in the past any underground or above-ground
storage tank or pipeline at any Facility or Former Facility
where the installation, use, maintenance, repair, testing,
closure or removal of such tank or pipeline was not in
compliance with all Environmental Laws and there has been no
Release from or rupture of any such tank or pipeline, including
without limitation any Release from or in connection with the
filling or emptying of such tank, (iv) Seller does not
manufacture or distribute any product in the State of California
which requires the warning mandated by the California Safe
Drinking Water and Toxic Enforcement Act of 1986
(Proposition 65), and (v) Seller has not made
and has never been required to make any filing under the New
Jersey Industrial Site Recovery Act or any other state law of
similar effect.
(c) Notice of Violation. Seller
has not received any notice of alleged, actual or potential
responsibility for, or any inquiry or investigation regarding,
(i) any Release or threatened Release of any Hazardous
Substance at any location, whether at the Facilities, the Former
Facilities or otherwise or (ii) an alleged violation of or
non-compliance with the conditions of any Permit required under
any Environmental Law or the provisions of any Environmental
Law. Seller has not received any notice of any other claim,
demand or Action by any individual or entity alleging any actual
or threatened injury or damage to any person, property, natural
resource or the environment arising from or relating to any
Release or threatened Release of any Hazardous Substances at,
on, under, in, to or from any Facilities or Former Facilities,
or in connection with any operations or activities thereat.
(d) Environmental
Conditions. There are no present or past
Environmental Conditions in any way relating to the Business or
at any Facility or Former Facility.
(e) Environmental Audits or
Assessments. True, complete and correct
copies of the written reports, and all parts thereof, including
any drafts of such reports if such drafts are in the possession
or control of Seller, of all environmental audits or assessments
which have been conducted at any Facility or Former Facility
within the past five years, either by Seller or any attorney,
environmental consultant or engineer engaged for such purpose,
have been delivered to Buyer and a list of all such reports,
audits and assessments and any other similar report, audit or
assessment of which Seller has knowledge is included on the
Disclosure Schedule.
(f) Indemnification
Agreements. Seller is not a party, whether as
a direct signatory or as successor, assign or third party
beneficiary, or otherwise bound, to any Lease or other Contract
(excluding insurance policies disclosed on the Disclosure
Schedule) under which Seller is obligated by or entitled to the
benefits of, directly or indirectly, any representation,
warranty, indemnification, covenant, restriction or other
undertaking concerning environmental conditions.
(g) Releases or Waivers. Seller
has not released any other person from any claim under any
Environmental Law or waived any rights concerning any
Environmental Condition.
(h) Notices, Warnings and
Records. Seller has given all notices and
warnings, made all reports, and has kept and maintained all
records required by and in compliance with all Environmental
Laws.
4.27 Banking
Relationships. Schedule 4.27 sets forth
a complete and accurate description of all arrangements that
Seller has with any banks, savings and loan associations or
other financial institutions providing for checking accounts,
safe deposit boxes, borrowing arrangements, and certificates of
deposit or otherwise, indicating in each case account numbers,
if applicable, and the person or persons authorized to act or
sign on behalf of Seller in respect of any of the foregoing.
4.28 Accounts
Receivable. The accounts receivable set forth
on the Interim Balance Sheet, and all accounts receivable
arising since the Interim Balance Sheet Date, represent bona
fide claims of Seller against debtors for sales, services
performed or other charges arising on or before the date hereof,
and all the goods delivered and services performed which gave
rise to said accounts were delivered or performed in accordance
with the applicable orders or Contracts. Said accounts
receivable are subject to no defenses, counterclaims or rights
of setoff and are fully collectible in the Ordinary Course of
Business without cost in collection efforts therefor, except to
the extent of the appropriate reserves for bad debts on accounts
receivable as set forth on the Interim Balance Sheet and, in the
A-24
case of accounts receivable arising since the Interim Balance
Sheet Date, to the extent of a reasonable reserve rate for bad
debts on accounts receivable which is not greater than the rate
reflected by the reserve for bad debts on the Interim Balance
Sheet.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer hereby represents and warrants to Seller as follows, which
representations and warranties are, as of the date hereof, and
will be, as of the Closing Date, true and correct:
5.1 Organization of
Buyer. Buyer is a corporation duly organized,
validly existing and in good standing under the laws of the
State of Delaware.
5.2 Authorization. Buyer has
all requisite corporate power and authority, and has taken all
corporate action necessary, to execute and deliver this
Agreement and the Ancillary Agreements, to consummate the
transactions contemplated hereby and thereby and to perform its
obligations hereunder and thereunder. The execution and delivery
of this Agreement and the Ancillary Agreements by Buyer and the
consummation by Buyer of the transactions contemplated hereby
and thereby have been duly approved by the board of directors of
Buyer. No other corporate proceedings on the part of Buyer are
necessary to authorize this Agreement and the Ancillary
Agreements and the transactions contemplated hereby and thereby.
This Agreement has been duly executed and delivered by Buyer and
is, and upon execution and delivery the Ancillary Agreements
will be, legal, valid and binding obligations of Buyer,
enforceable against Buyer in accordance with their terms.
5.3 No Conflict or
Violation. Neither the execution, delivery or
performance of this Agreement nor the consummation of the
transactions contemplated hereby, nor compliance by Buyer with
any of the provisions hereof, will (a) violate or conflict
with any provision of the Certificate of Incorporation or Bylaws
of Buyer, (b) violate, conflict with, or result in or
constitute a Default under, or result in the termination of, or
accelerate the performance required by, or result in a right of
termination or acceleration under, or result in the creation of
any Encumbrance upon any of Buyers assets under, any of
the terms, conditions or provisions of any contract,
indebtedness, note, bond, indenture, security or pledge
agreement, commitment, license, lease, franchise, permit,
agreement, authorization, concession, or other instrument or
obligation to which Buyer is a party, (c) violate any
Regulation or Court Order, except, in the case of each of
clauses (a), (b) and (c) above, for such
violations, Defaults, terminations, accelerations or creations
of Encumbrances which, in the aggregate, would not have a
Material Adverse Effect on the business of Buyer or its ability
to consummate the transactions contemplated hereby.
5.4 Consents and
Approvals. Except as set forth on
Exhibit H hereto, no notice to, declaration, filing
or registration with, or authorization, consent or approval of,
or permit from, any domestic or foreign governmental or
regulatory body or authority, or any other person or entity, is
required to be made or obtained by Buyer in connection with the
execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby.
5.5 No Brokers. Neither
Buyer nor any of its officers, directors, employees,
shareholders or affiliates has employed or made any agreement
with any broker, finder or similar agent or any person or firm
which will result in the obligation of Seller or any of their
respective affiliates to pay any finders fee, brokerage
fees or commission or similar payment in connection with the
transactions contemplated hereby.
ARTICLE VI
COVENANTS OF SELLER AND BUYER
Seller and Buyer each covenant with the other as follows:
6.1 Further Assurances. Upon
the terms and subject to the conditions contained herein, the
parties agree, both before and after the Closing, (i) to
use all reasonable efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary,
proper or advisable to consummate and make effective the
transactions contemplated by this Agreement, (ii) to
execute any documents, instruments or conveyances of any kind
which may
A-25
be reasonably necessary or advisable to carry out any of the
transactions contemplated hereunder, and (iii) to cooperate
with each other in connection with the foregoing. Without
limiting the foregoing, the parties agree to use their
respective best efforts (A) to obtain all necessary
waivers, consents and approvals from other parties to the
Contracts and Leases to be assumed by Buyer; provided,
however that Buyer shall not be required to make any
payments, commence litigation or agree to modifications of the
terms thereof in order to obtain any such waivers, consents or
approvals, (B) to obtain all necessary Permits as are
required to be obtained under any Regulations, (C) to
defend all Actions challenging this Agreement or the
consummation of the transactions contemplated hereby,
(D) to lift or rescind any injunction or restraining order
or other Court Order adversely affecting the ability of the
parties to consummate the transactions contemplated hereby,
(E) to give all notices to, and make all registrations and
filings with third parties, including without limitation
submissions of information requested by governmental
authorities, and (F) to fulfill all conditions to this
Agreement. In addition, each party will commence all action
required under this Section 6.1 as promptly as possible
after the date of this Agreement to allow the transactions
contemplated hereunder to be consummated by the Closing Date.
6.2 No Solicitation.
(a) No Solicitation. From the date
hereof through the Closing or the earlier termination of this
Agreement, Seller shall not, and shall cause its Representatives
(including without limitation investment bankers, attorneys and
accountants), not to, directly or indirectly, enter into,
solicit, initiate or continue any discussions or negotiations
with, or encourage or respond to any inquiries or proposals by,
or participate in any negotiations with, or provide any
information to, or otherwise cooperate in any other way with,
any corporation, partnership, person or other entity or group,
other than Buyer and its Representatives, concerning any sale of
all or a portion of the Assets or the Business, or all or
substantially all the shares of capital stock of Seller, or any
merger, consolidation, liquidation, dissolution or similar
transaction involving Seller (each such transaction being
referred to herein as a Proposed Acquisition
Transaction). Seller and its subsidiaries shall not,
directly or indirectly, through any officer, director, employee,
representative, agent or otherwise, solicit, initiate or
encourage the submission of any proposal or offer from any
person (including, without limitation, a person as
defined in Section 13(d)(3) of the Securities Exchange Act
of 1934, as amended) or entity relating to any Proposed
Acquisition Transaction or participate in any negotiations
regarding, or furnish to any other person any information with
respect to Seller or any of its subsidiaries for the purposes
of, or otherwise cooperate in any way with, or assist or
participate in, facilitate or encourage, any effort or attempt
by any other person to seek or effect a Proposed Acquisition
Transaction. Notwithstanding the foregoing, prior to the Closing
the Company may (A) provide access to its properties and
Books and Records in response to a request therefor by a
corporation, partnership, person or other entity or group which
has made an unsolicited bona fide written proposal regarding a
Proposed Acquisition Transaction or (B) engage in any
negotiations or discussions with any corporation, partnership,
person or other entity or group which has made an unsolicited
bona fide written proposal regarding a Proposed Acquisition
Transaction, if and only to the extent that prior to taking any
of the actions set forth in clauses (A) or
(B) with respect to an Proposed Acquisition Transaction,
(x) the Companys Board of Directors shall have
determined in good faith, after consultation with its outside
legal counsel and financial advisors, that the failure to take
such action would violate the fiduciary duties of the
Companys Board of Directors under applicable law and that
such Proposed Acquisition Transaction constitutes or is
reasonably likely to result in a Superior Proposal from the
party that made the proposal for a Proposed Acquisition
Transaction and (y) the Company shall have informed the
Buyer promptly following the taking by it of any such action.
Seller hereby represents that it is not now engaged in
discussions or negotiations with any party other than Buyer with
respect to any Proposed Acquisition Transaction. Seller shall
notify Buyer promptly (orally and in writing) if any written
proposal for a Proposed Acquisition Transaction, or any inquiry
or contact with any person with respect thereto, is made and
shall provide Buyer with a copy of such offer and shall keep
Buyer informed of the status of any negotiations regarding such
offer. Nothing contained in this Agreement shall prohibit the
Company or the Companys Board of Directors from taking and
disclosing to the Companys stockholders a position with
respect to a tender or exchange offer by a third party pursuant
to
Rules 14d-9
and 14e-2(a)
promulgated under the Securities Exchange Act of 1934, as
amended, or from making any disclosure required by applicable
law with regard to a Proposed Acquisition Transaction. Seller
agrees not to release any third party from, or waive any
provision of, any confidentiality or standstill agreement to
which Seller is a party.
A-26
(b) Notification. Seller will
immediately notify Buyer if any discussions or negotiations are
sought to be initiated, any inquiry or proposal is made, or any
information is requested with respect to any Proposed
Acquisition Transaction and notify Buyer of the terms of any
proposal which it may receive in respect of any such Proposed
Acquisition Transaction, including without limitation the
identity of the prospective purchaser or soliciting party.
6.3 Notification of Certain
Matters. From the date hereof through the
Closing, Seller shall give prompt notice to Buyer of
(a) the occurrence, or failure to occur, of any event which
occurrence or failure would be likely to cause any
representation or warranty contained in this Agreement or in any
exhibit or schedule hereto to be untrue or inaccurate in any
material respect and (b) any failure of Seller, any of its
affiliates or Representatives to comply with or satisfy any
covenant, condition or agreement to be complied with or
satisfied by it under this Agreement or any exhibit or schedule
hereto; provided, however, that such disclosure
shall not be deemed to cure any breach of a representation,
warranty, covenant or agreement or to satisfy any condition.
Seller shall promptly notify Buyer of any Default, the threat or
commencement of any Action that occurs before the Closing that
Seller reasonably expects to have a material adverse affect on
the Assets or the Business.
6.4 Investigation by Buyer.
Subject to the Confidentiality Agreement, from the date hereof
through the Closing Date:
(a) Seller shall, and shall cause its officers, directors,
employees and agents to, afford the Representatives of Buyer and
its affiliates complete access at all reasonable times to the
Assets for the purpose of inspecting the same, and to the
officers, employees, agents, attorneys, accountants, properties,
Books and Records and Contracts of Seller, and shall furnish
Buyer and its Representatives all financial, operating and other
data and information as Buyer or its affiliates, through their
respective Representatives, may reasonably request, including an
unaudited consolidated balance sheet and the related statements
of income, retained earnings and cash flow for each month from
the date hereof through the Closing Date within fourteen
(14) calendar days after the end of each month which
financial statements shall (a) be true, correct and
complete, (b) be in accordance with the books and records
of Seller and (c) accurately set forth the assets,
Liabilities and financial condition, results of operations and
other information purported to be set forth therein in
accordance with generally accepted accounting principles
consistently applied.
(b)(i) Buyer shall have the right, at its sole cost and expense
to (A) conduct tests of the soil surface or subsurface
waters and air quality at, in, on, beneath or about the Owned
Real Property and the Leased Real Property, and such other
procedures as may be recommended by an independent environmental
consultant selected by Buyer (the Consultant) based
on its reasonable professional judgment, in a manner consistent
with good engineering practice, (B) inspect records,
reports, permits, applications, monitoring results, studies,
correspondence, data and any other information or documents
relevant to environmental conditions or environmental
noncompliance, and (C) inspect all buildings and equipment
at the Owned Real Property and the Leased Real Property,
including without limitation the visual inspection of the
Facilities for asbestos-containing construction materials;
provided, in each case, such tests and inspections shall
be conducted only (1) during regular business hours; and
(2) in a manner which will not unduly interfere with the
operation of the Business
and/or the
use of, access to or egress from the Owned Real Property and the
Leased Property.
(ii) Buyers right to conduct tests, inspect records
and other documents, and visually inspect all buildings and
equipment at the Owned Real Property and the Leased Real
Property shall also be subject to the following terms and
conditions:
(A) All testing performed on Buyers behalf shall be
conducted by the Consultant;
(B) Seller shall have the right to accompany the Consultant
as it performs testing;
(C) Except as otherwise required by law, any information
concerning the Owned Real Property and the Leased Real Property
gathered by Buyer or the Consultant as the result of, or in
connection with, the testing shall be kept confidential in
accordance with subsection (D) below and shall not be
revealed to, or discussed with, anyone other than
Representatives of Buyer or Representatives of Seller who agree
to comply with the provisions of subsection
(D) below; and
A-27
(D) In the event that any party to this Agreement or any
party set forth in subsection (C) above is requested
or required to disclose information described in
subparagraph (b)(i), Buyer shall provide Seller or Seller
shall provide Buyer, as the case may be, with prompt notice of
such request so that Seller or Buyer, as the case may be, may
seek an appropriate protective order or waiver by the other
partys compliance with this Agreement. If, in the absence
of a protective order or the receipt of a waiver hereunder, such
party is nonetheless, in the opinion of its counsel, compelled
to disclose such information to any tribunal or else stand
liable for contempt or suffer other censure or penalty, such
party will furnish only that portion of the information which is
legally required and will exercise its reasonable efforts to
obtain reliable assurance that confidential treatment will be
afforded to the disclosed information. The requirements of this
subparagraph shall not apply to information in the public domain
or lawfully acquired on a nonconfidential basis from others.
6.5 Conduct of
Business. From the date hereof through the
Closing, Seller shall, except as contemplated by this Agreement,
or as consented to by Buyer in writing, operate the Business in
the Ordinary Course of Business and in accordance with past
practice and will not take any action inconsistent with this
Agreement or with the consummation of the Closing. Without
limiting the generality of the foregoing, Seller shall not, and
shall cause each of the Subsidiaries listed on Schedule 4.2
not to, except as specifically contemplated by this Agreement or
as consented to by Buyer in writing, which consent shall not be
unreasonably withheld:
(a) change or amend the Certificate of Incorporation or
Bylaws of Seller;
(b) enter into, extend, materially modify, terminate or
renew any Contract or Lease, except in the Ordinary Course of
Business;
(c) sell, assign, transfer, convey, lease, mortgage, pledge
or otherwise dispose of or encumber any material amount of the
Assets, or any interests therein, except in the Ordinary Course
of Business and, without limiting the generality of the
foregoing, Seller will produce, maintain and sell inventory
consistent with its past practices;
(d) (i) for any of the Rehired Employees (as defined
in Section 6.6), take any action with respect to the grant
of any bonus, severance or termination pay (otherwise than
pursuant to policies or agreements of Seller in effect on the
date hereof that are described on the Disclosure Schedule) or
with respect to any increase of benefits payable under its
severance or termination pay policies or agreements in effect on
the date hereof or increase in any manner the compensation or
fringe benefits of any employee or pay any benefit not required
by any existing Employee Plan or policy;
(ii) adopt, enter into or amend any Employee Plan,
agreement (including without limitation any collective
bargaining or employment agreement), trust, fund or other
arrangement for the benefit or welfare of any employee, except
for any such amendment as may be required to comply with
applicable Regulations; or
(iii) fail to maintain all Employee Plans in accordance
with applicable Regulations;
(e) declare, set aside, make or pay any dividend or other
distribution in respect of Sellers capital stock;
(f) fail to expend funds for budgeted capital expenditures
or commitments of the Business;
(g) willingly allow or permit to be done, any act by which
any of the Insurance Policies may be suspended, impaired or
canceled;
(h) fail to pay its accounts payable and any debts owed or
obligations due to it, or pay or discharge when due any
Liabilities related to the Business, in the Ordinary Course of
Business;
(i) fail to maintain the Assets in substantially their
current state of repair, excepting normal wear and tear or fail
to replace consistent with Sellers past practice
inoperable, worn-out or obsolete or destroyed Assets;
(j) fail to comply in any material respect with all
Regulations applicable to the Assets or the Business;
(k) intentionally do any other act which would cause any
representation or warranty of Seller in this Agreement to be or
become untrue in any material respect;
A-28
(l) fail to use its reasonable commercial efforts to
(i) retain the Sellers employees involved in the
Business and (ii) maintain the Business so that such
employees will remain available to Seller on and after the
Closing Date, (iii) maintain existing relationships with
suppliers, customers and others having business dealings with
Seller related to the Business and (iv) otherwise to
preserve the goodwill of the Business so that such relationships
and goodwill will be preserved on and after the Closing Date;
(m) enter into any agreement, or otherwise become
obligated, to do any action prohibited hereunder;
(n) enter into, renew, modify or revise any agreement or
transaction with any of the Subsidiaries listed on
Schedule 4.2; or
(o) make any payment of any kind whatsoever to or on behalf
of any of the Subsidiaries listed on Schedule 4.2 or any
officer or director of any of such Subsidiaries, pursuant to any
agreement between Seller and any of such Subsidiaries or
otherwise.
6.6 Employee Matters.
(a) Buyer shall extend offers of employment to those of
Sellers employees whom it desires to hire, which are
identified on Schedule 4.13 (such employees are hereinafter
referred to as the Rehired Employees), which Buyer
shall determine in its sole discretion. Seller shall terminate
the employment of all Rehired Employees immediately prior to the
Closing and shall cooperate with and use its reasonable
commercial efforts to assist Buyer in its efforts to secure
satisfactory employment arrangements with those employees of
Seller to whom Buyer makes offers of employment.
(b) Seller shall be solely responsible for all of the
Benefit Plans and all obligations and liabilities thereunder.
Buyer shall not assume any of the Benefit Plans or any
obligation or liability thereunder.
(c) Nothing contained in this Agreement shall confer upon
any Rehired Employee any right with respect to continuance of
employment by Buyer, nor shall anything herein interfere with
the right of Buyer to terminate the employment of any of the
Rehired Employees at any time, with or without cause, or
restrict Buyer in the exercise of its independent business
judgment in modifying any of the terms and conditions of the
employment of the Rehired Employees.
(d) No provision of this Agreement shall create any third
party beneficiary rights in any Rehired Employee, any
beneficiary or dependents thereof, or any collective bargaining
representative thereof, with respect to the compensation, terms
and conditions of employment and benefits that may be provided
to any Rehired Employee by Buyer or under any benefit plan which
Buyer may maintain.
(e) For a period of one (1) year after the Closing
Date, neither party shall, directly or indirectly, hire or offer
employment to or seek to hire or offer employment to any
employee of the other party whose employment is continued by
such party after the Closing Date, unless such party first
terminates the employment of such employee or gives its written
consent to such employment or offer of employment.
6.7 Subsidiary
Transfers. Seller shall, and shall cause all
of the Subsidiaries listed on Schedule 4.2 to, transfer all
right, title and interest held by such Subsidiary in all assets
used or held for use in connection with the Business of Seller
to be transferred to Seller for inclusion in the Assets prior to
the Closing.
ARTICLE VII
CONDITIONS TO SELLERS OBLIGATIONS
The obligations of Seller to consummate the transactions
provided for hereby are subject, in the discretion of Seller, to
the satisfaction, on or prior to the Closing Date, of each of
the following conditions, any of which may be waived by Seller:
7.1 Representations, Warranties and
Covenants. All representations and warranties
of Buyer contained in this Agreement shall be true and correct
in all material respects at and as of the date of this Agreement
and at and as of the Closing Date, except as and to the extent
that the facts and conditions upon which such representations
and warranties are based are expressly required or permitted to
be changed by the terms hereof, and Buyer shall have
A-29
performed and satisfied in all material respects all agreements
and covenants required hereby to be performed by it prior to or
on the Closing Date.
7.2 Consents; Regulatory Compliance and
Approval; Stockholder Approval. All consents,
approvals and waivers from governmental authorities and other
parties necessary to permit Seller to transfer the Assets to
Buyer as contemplated hereby shall have been obtained (including
without limitation all required third-party consents to the
assignment of the Leases, Contracts and other Assets to be
assigned to Buyer as set forth herein). Seller shall be
satisfied that all approvals required under any Regulations to
carry out the transactions contemplated by this Agreement shall
have been obtained and that the parties shall have complied with
all Regulations applicable to the Acquisition. Seller shall have
obtained the requisite consent of its stockholders to the
transactions contemplated by this Agreement at a duly convened
special meeting of stockholders.
7.3 No Actions or Court
Orders. No Action by any governmental
authority or other person shall have been instituted or
threatened which questions the validity or legality of the
transactions contemplated hereby and which could reasonably be
expected to damage Seller, the Assets or the Business materially
if the transactions contemplated hereby are consummated,
including without limitation any Material Adverse Effect on the
right or ability of Buyer to own, operate, possess or transfer
the Assets after the Closing. There shall not be any Regulation
or Court Order that makes the purchase and sale of the Business
or the Assets contemplated hereby illegal or otherwise
prohibited.
7.4 Opinion of
Counsel. Buyer shall have delivered to Seller
an opinion of Buyers counsel, dated as of the Closing
Date, in form and substance attached hereto as
Exhibit O, substantially to the effect that:
(a) Incorporation. Buyer is a
corporation duly incorporated, validly existing and in good
standing under the laws of the State of Delaware;
(b) Corporate Power and
Authority. Buyer has the necessary corporate
power and authority to enter into this Agreement and the
Ancillary Agreements and to consummate the transactions
contemplated hereby and thereby;
(c) Corporate Action and
Enforceability. The execution, delivery and
performance of this Agreement and the Ancillary Agreements by
Buyer have been duly authorized by all necessary corporate
action of Buyer, and no approval of the stockholders of Buyer is
required in connection therewith or, if required, such approval
has been duly obtained in accordance with the provisions of
Buyers Certificate of Incorporation and Bylaws and
applicable law, and this Agreement and the Ancillary Agreements
have been duly executed and delivered by Buyer, and constitute
legally valid and binding obligations of Buyer, enforceable
against Buyer in accordance with their terms, except as limited
by (i) bankruptcy, insolvency, reorganization, moratorium
or other similar laws relating to creditors rights
generally or by equitable principles (whether considered in an
action at law or in equity), (ii) limitations imposed by
federal or state law or equitable principles upon the
availability of specific performance, injunctive relief or other
equitable remedies, or (iii) other customary limitations;
(d) No Breach of
Contracts. Neither the execution and delivery
of this Agreement or the Ancillary Agreements by Buyer nor the
consummation of the transactions contemplated hereby or thereby
will (i) violate the Certificate of Incorporation or Bylaws
of Buyer, (ii) cause a Default under any term or provision
of any material contract to which Buyer is a party listed in
such opinion, or (iii) to the knowledge of such counsel,
violate any Court Order applicable to Buyer; and
(e) No Violation of Law. Neither
the execution and performance of this Agreement or the Ancillary
Agreements by Buyer nor the consummation of the transactions
contemplated hereby or thereby will violate or result in a
failure to comply with any Regulation or Court Order, applicable
to Buyer.
In rendering such opinions, such counsel may rely as they deem
advisable (a) as to matters governed by the laws of
jurisdictions other than states in which they maintain offices,
upon opinions of local counsel satisfactory to such counsel, and
(b) as to factual matters, upon certificates and assurances
of public officials and officers of Buyer.
7.5 Certificates. Buyer
shall furnish Seller with such certificates of its officers and
others to evidence compliance with the conditions set forth in
this Article VII as may be reasonably requested by Seller.
A-30
7.6 Corporate
Documents. Seller shall have received from
Buyer resolutions adopted by the board of directors of Buyer
approving this Agreement, the Ancillary Agreements and the
transactions contemplated hereby or thereby, certified by
Buyers corporate secretary.
7.7 Assumption
Document. Buyer shall have executed the
Assumption Document.
7.8 Ancillary
Agreements. Buyer shall have executed and
delivered the Ancillary Agreements to which Buyer is a party.
ARTICLE VIII
CONDITIONS
TO BUYERS OBLIGATIONS
The obligations of Buyer to consummate the transactions provided
for hereby are subject, in the discretion of Buyer, to the
satisfaction, on or prior to the Closing Date, of each of the
following conditions, any of which may be waived by Buyer:
8.1 Representations, Warranties and
Covenants. All representations and warranties
of Seller contained in this Agreement shall be true and correct
in all material respects at and as of the date of this Agreement
and at and as of the Closing Date, other than such failures to
be true and correct that individually or in the aggregate would
not have a Material Adverse Effect and except as and to the
extent that the facts and conditions upon which such
representations and warranties are based are expressly required
or permitted to be changed by the terms hereof, and Seller shall
have performed and satisfied in all material respects all
agreements and covenants required hereby to be performed by it
prior to or on the Closing Date.
8.2 Consents; Regulatory Compliance and
Approval. All Permits, consents, approvals
and waivers from governmental authorities and other parties
necessary to the consummation of the transactions contemplated
hereby and for the operation of the Business by Buyer
(including, without limitation, all required third party
consents to the assignment of the Leases and Contracts to be
assumed by Buyer) shall have been obtained. Buyer shall be
satisfied that all approvals required under any Regulations to
carry out the transactions contemplated by this Agreement shall
have been obtained and that the parties shall have complied with
all Regulations applicable to the Acquisition.
8.3 No Actions or Court
Orders. No Action by any governmental
authority or other person shall have been instituted or
threatened which questions the validity or legality of the
transactions contemplated hereby and which could reasonably be
expected to damage Buyer, the Assets or the Business materially
if the transactions contemplated hereby are consummated,
including without limitation any Material Adverse Effect on the
right or ability of Buyer to own, operate, possess or transfer
the Assets after the Closing. There shall not be any Regulation
or Court Order that makes the purchase and sale of the Business
or the Assets contemplated hereby illegal or otherwise
prohibited.
8.4 Opinion of
Counsel. Seller shall have delivered to Buyer
an opinion of outside counsel, counsel to Seller, dated as of
the Closing Date, in form attached hereto as
Exhibit P, substantially to the effect that:
(a) Incorporation. Seller is a
corporation duly incorporated, validly existing and in good
standing under the laws of the State of Delaware; Seller is duly
qualified to do business as a foreign corporation and is in good
standing in each jurisdiction where the ownership or leasing of
its property or nature of the Business requires such
qualification, except where the failure to be so qualified would
not have a Material Adverse Effect on the Business or the Assets;
(b) Corporate Power and
Authority. Seller has the necessary corporate
power and authority to enter into this Agreement and the
Ancillary Agreements and to consummate the transactions
contemplated hereby and thereby; and Seller has the necessary
corporate power and authority to own, lease and operate the
Assets and its other properties and to conduct the Business as
presently conducted;
(c) Corporate Action and
Enforceability. The execution, delivery and
performance of this Agreement and the Ancillary Agreements by
Seller have been duly authorized by all necessary corporate
action of Seller, and this Agreement and the Ancillary
Agreements have been duly executed and delivered by Seller, and
no approval of the stockholders of Seller is required in
connection therewith or, if required, such approval has
A-31
been duly obtained in accordance with the provisions of
Sellers Certificate of Incorporation and Bylaws and
applicable law, and this Agreement and each Ancillary Agreement
constitute legally valid and binding obligations of Seller,
enforceable against Seller in accordance with their terms,
except as limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to
creditors rights generally or by equitable principles
(whether considered in an action at law or in equity),
(ii) limitations imposed by federal or state law or
equitable principles upon the availability of specific
performance, injunctive relief or other equitable remedies, or
(iii) other customary limitations;
(d) No Breach of
Contracts. Neither the execution and delivery
of this Agreement or the Ancillary Agreements by Seller nor the
consummation of the transactions contemplated hereby or thereby
will (i) violate the Certificate of Incorporation or Bylaws
of Seller, (ii) cause a Default under any term or provision
of any material Contract or Lease listed in such opinion to
which Seller is a party or by which the Assets are bound, or
(iii) to the knowledge of such counsel, violate any Court
Order applicable to Seller; and
(e) No Violation of Law. Neither
the execution and performance of this Agreement or the Ancillary
Agreements by Seller nor the consummation of the transactions
contemplated hereby or thereby will violate or result in a
failure to comply with any Regulation or Court Order known to
such counsel, applicable to Seller.
In rendering such opinions, such counsel may rely as they deem
advisable (a) as to matters governed by the laws of
jurisdictions other than states in which they maintain offices,
upon opinions of local counsel satisfactory to such counsel, and
(b) as to factual matters, upon certificates and assurances
of public officials and officers of Seller.
8.5 Certificates. Seller
shall furnish Buyer with such certificates of its officers and
others to evidence compliance with the conditions set forth in
this Article VIII as may be reasonably requested by Buyer.
8.6 Material Changes. Since
the date of this Agreement, there shall not have occurred any
event which shall have a Material Adverse Effect on the Business
or the Assets.
8.7 Corporate
Documents. Buyer shall have received from
Seller resolutions adopted by the board of directors of Seller
approving this Agreement and the Ancillary Agreements and the
transactions contemplated hereby and thereby, certified by
Sellers corporate secretary, as applicable.
8.8 Conveyancing Documents; Release of
Encumbrances. Seller shall have executed and
delivered each of documents described in Section 3.2 hereof
so as to effect the transfer and assignment to Buyer of all
right, title and interest in and to the Assets and Seller shall
have filed (where necessary) and delivered to Buyer all
documents necessary to release the Assets from all Encumbrances,
which documents shall be in a form reasonably satisfactory to
Buyers counsel.
8.9 Permits. Buyer shall
have obtained or been granted the right to use all Permits
necessary to its operation of the Business.
8.10 Other
Agreements. Seller shall have executed and
delivered the Ancillary Agreements in the forms attached as
exhibits hereto.
ARTICLE IX
RISK OF
LOSS; CONSENTS TO ASSIGNMENT
9.1 Risk of Loss. From the
date hereof through the Closing Date, all risk of loss or damage
to the property included in the Assets shall be borne by Seller,
and thereafter shall be borne by Buyer. If any portion of the
Assets is destroyed or damaged by fire or any other cause on or
prior to the Closing Date, other than use, wear or loss in the
Ordinary Course of Business, Seller shall give written notice to
Buyer as soon as practicable after, but in any event within five
(5) calendar days of, discovery of such damage or
destruction and estimated interruption of the Business, the
amount of insurance, if any, covering such Assets
and/or
interruption of the Business and the amount, if any, which
Seller is otherwise entitled to receive as a consequence. Prior
to the Closing, Buyer shall have the option, which shall be
exercised by written notice to Seller within ten
(10) calendar days after receipt of Sellers notice or
if there is not ten (10) calendar days prior to the Closing
Date, as soon as practicable prior to the Closing Date, of
(a) accepting such Assets in their destroyed or damaged
condition in which event Buyer shall be entitled to the
A-32
proceeds of any insurance or other proceeds payable with respect
to such loss (including for the interruption of the Business, if
any) and subject to Section 10.4(f), to such
indemnification for any uninsured portion of such loss pursuant
to Section 10.4, and the full Purchase Price shall be paid
for such Assets, (b) excluding such Assets from this
Agreement, in which event the Purchase Price shall be reduced by
the amount allocated to such Assets, as mutually agreed between
the parties or (c) if such destroyed or damaged Assets
and/or
interruption of the Business has an aggregate value of greater
than $5,000,000, terminating this Agreement in accordance with
Section 11.1. If Buyer accepts such Assets, then after the
Closing, any insurance or other proceeds shall belong, and shall
be assigned to, Buyer without any reduction in the Purchase
Price; otherwise, such insurance proceeds shall belong to Seller.
9.2 Consents to
Assignment. Anything in this Agreement to the
contrary notwithstanding, this Agreement shall not constitute an
agreement to assign any Contract, Lease, Permit or any claim or
right or any benefit arising thereunder or resulting therefrom
if an attempted assignment thereof, without the consent of a
third party thereto, would constitute a Default thereof or in
any way adversely affect the rights of Buyer thereunder. If such
consent is not obtained, or if an attempted assignment thereof
would be ineffective or would affect the rights thereunder so
that Buyer would not receive all such rights, Seller will
cooperate with Buyer, in all reasonable respects, to provide to
Buyer the benefits under any such Contract, Lease, Permit or any
claim or right, including without limitation enforcement for the
benefit of Buyer of any and all rights of Seller against a third
party thereto arising out of the Default or cancellation by such
third party or otherwise. Nothing in this Section 9.2 shall
affect Buyers right to terminate this Agreement under
Sections 8.2 and 11.1 in the event that any consent or
approval to the transfer of any Asset is not obtained.
ARTICLE X
ACTIONS
BY SELLER AND BUYER
AFTER THE
CLOSING
10.1 Collection of Accounts Receivable and
Letters of Credit. At the Closing, Buyer will
acquire hereunder, and thereafter Buyer or its designee shall
have the right and authority to collect for Buyers or its
designees account, all receivables, letters of credit and
other items which constitute a part of the Assets, and Seller
shall within two (2) business days after receipt of any
payment in respect of any of the foregoing, properly endorse and
deliver to Buyer any letters of credit, documents, cash or
checks received on account of or otherwise relating to any such
receivables, letters of credit or other items. Seller shall
promptly transfer or deliver to Buyer or its designee any cash
or other property that Seller may receive in respect of any
deposit, prepaid expense, claim, contract, license, lease,
commitment, sales order, purchase order, letter of credit or
receivable of any character, or any other item, constituting a
part of the Assets.
10.2 Books and Records; Tax Matters.
(a) Books and Records. Each party
agrees that it will cooperate with and make available to the
other party, during normal business hours, all Books and
Records, information and employees (without substantial
disruption of employment) retained and remaining in existence
after the Closing which are necessary or useful in connection
with any tax inquiry, audit, investigation or dispute, any
litigation or investigation or any other matter requiring any
such Books and Records, information or employees for any
reasonable business purpose. The party requesting any such Books
and Records, information or employees shall bear all of the
out-of-pocket
costs and expenses (including without limitation attorneys
fees, but excluding reimbursement for salaries and employee
benefits) reasonably incurred in connection with providing such
Books and Records, information or employees. All information
received pursuant to this Section 10.2(a) shall be subject
to the terms of the Confidentiality Agreement.
(b) Cooperation and Records
Retention. Seller and Buyer shall
(i) each provide the other with such assistance as may
reasonably be requested by any of them in connection with the
preparation of any return, audit, or other examination by any
taxing authority or judicial or administrative proceedings
relating to Liability for Taxes, (ii) each retain and
provide the other with any records or other information that may
be relevant to such return, audit or examination, proceeding or
determination, and (iii) each provide the other with any
final determination of any such audit or examination,
proceeding, or determination that affects any amount required
A-33
to be shown on any tax return of the other for any period.
Without limiting the generality of the foregoing, Buyer and
Seller shall each retain, until the applicable statutes of
limitations (including any extensions) have expired, copies of
all tax returns, supporting work schedules, and other records or
information that may be relevant to such returns for all tax
periods or portions thereof ending on or before the Closing Date
and shall not destroy or otherwise dispose of any such records
without first providing the other party with a reasonable
opportunity to review and copy the same.
10.3 Survival of Representations,
Etc. All of the representations, warranties,
covenants and agreements made by each party in this Agreement or
in any attachment, Exhibit, the Disclosure Schedule,
certificate, document or list delivered by any such party
pursuant hereto shall survive the Closing for a period of (and
claims based upon or arising out of such representations,
warranties, covenants and agreements may be asserted at any time
before the date which shall be) [three (3)] years following
the Closing (except with respect to the representations and
warranties set forth Sections 4.20 and 4.26, which shall
survive until the expiration of the applicable statute of
limitations (with extensions) with respect to the matters
addressed in such sections). Each party hereto shall be entitled
to rely upon the representations and warranties of the other
party set forth in this Agreement. The termination of the
representations and warranties provided herein shall not affect
the rights of a party in respect of any Claim made by such party
in a writing received by the other party prior to the expiration
of the applicable survival period provided herein.
10.4 Indemnifications.
(a) By Seller. Seller shall
indemnify, save and hold harmless and defend Buyer, its
affiliates and subsidiaries, and its and their respective
Representatives, from and against any and all costs, losses
(including without limitation diminution in value), Taxes,
Liabilities, obligations, damages, lawsuits, deficiencies,
claims, demands, and expenses (whether or not arising out of
third-party claims), including without limitation interest,
penalties, costs of mitigation, losses in connection with any
Environmental Law (including without limitation any
clean-up or
remedial action), lost profits and other losses resulting from
any shutdown or curtailment of operations, damages to the
environment, attorneys fees and all amounts paid in
investigation, defense or settlement of any of the foregoing
(herein, Damages), incurred in connection with,
arising out of, resulting from or incident to (i) any
breach of any representation or warranty or the inaccuracy of
any representation, made by Seller in or pursuant to this
Agreement; (ii) any breach of any covenant or agreement
made by Seller in or pursuant to this Agreement; (iii) any
Excluded Liability (iv) any Liability imposed upon Buyer by
reason of Buyers status as transferee of the Business or
the Assets directly resulting from any breach of any
representation, warranty, covenant or agreement made by Seller
in or pursuant to this Agreement; or (v) any Liability
imposed upon Buyer related to the United States Patent Nos.
5,504,326, 5,510,613, 5,712,479, 5,625,184, 5,627,369,
5,760,393, 6,002,127, 6,057,543, 5,641,959, and 5,654,545,
including any division, continuation,
continuation-in-part,
reexamination, reissue, or foreign equivalent or counterpart
thereof, or any other patent asserted by Bruker Daltonics, Inc.,
Indiana University, or Applera Corp. relating to Space-Velocity
Correlation Focusing or Delayed Extraction, or (vi) any
Liability imposed upon Buyer related to any Patent in which a
claim of infringement is made against the making, using,
selling, or importation of the laser incorporated within the
ProteinChip System, Series 4000 instrument as of the
Closing Date.
The term Damages as used in this Section 10.4
is not limited to matters asserted by third parties against
Seller or Buyer, but includes Damages incurred or sustained by
Seller or Buyer in the absence of third party claims. Payments
by Buyer of amounts for which Buyer is indemnified hereunder,
and payments by Seller of amounts for which Seller is
indemnified, shall not be a condition precedent to recovery.
Sellers obligation to indemnify Buyer, and Buyers
obligation to indemnify Seller, shall not limit any other
rights, including without limitation rights of contribution
which either party may have under statute or common law.
(b) By Buyer. Buyer shall
indemnify and save and hold harmless and defend Seller, its
respective affiliates and subsidiaries, and its respective
Representatives from and against any and all Damages incurred in
connection with, arising out of, resulting from or incident to
(i) any breach of any representation or warranty or the
inaccuracy of any representation, made by Buyer in or pursuant
to this Agreement; (ii) any breach of any covenant or
agreement made by Buyer in or pursuant to this Agreement; or
(iii) from and after the Closing, any Assumed Liability or
the operations of the Business by Buyer.
(c) Cooperation. The indemnified
party shall cooperate in all reasonable respects with the
indemnifying party and such attorneys in the investigation,
trial and defense of such lawsuit or action and any appeal
arising
A-34
therefrom; provided, however, that the indemnified
party may, at its own cost, participate in the investigation,
trial and defense of such lawsuit or action and any appeal
arising therefrom. The parties shall cooperate with each other
in any notifications to insurers.
(d) Defense of Claims. If a claim
for Damages (a Claim) is to be made by an
indemnified party hereunder against the indemnifying party, the
indemnified party shall give written notice (a Claim
Notice) to the indemnifying party as soon as practicable
after the indemnified party becomes aware of any fact, condition
or event which may give rise to Damages for which
indemnification may be sought under this Section 10.4. If
any lawsuit or enforcement action is filed against any party
entitled to the benefit of indemnity hereunder, written notice
thereof shall be given to the indemnifying party as promptly as
practicable (and in any event within fifteen (15) calendar
days after the service of the citation or summons). The failure
of any indemnified party to give timely notice hereunder shall
not affect rights to indemnification hereunder, except to the
extent that the indemnifying party demonstrates actual damage
caused by such failure. The indemnifying party shall be
entitled, if it so elects at its own cost, risk and expense,
(i) to take control of the defense and investigation of
such lawsuit or action, (ii) to employ and engage attorneys
of its own choice to handle and defend the same unless the named
parties to such action or proceeding include both the
indemnifying party and the indemnified party and the indemnified
party has been advised in writing by counsel that there may be
one or more legal defenses available to such indemnified party
that are different from or additional to those available to the
indemnifying party, in which event the indemnified party shall
be entitled, at the indemnifying partys cost, risk and
expense, to separate counsel of its own choosing, and
(iii) to compromise or settle such claim, which compromise
or settlement shall be made only with the written consent of the
indemnified party, such consent not to be unreasonably withheld,
unless the indemnifying party shall agree to pay the full amount
of such settlement. If the indemnifying party fails to assume
the defense of such claim within fifteen (15) calendar days
after receipt of the Claim Notice, the indemnified party against
which such claim has been asserted will (upon delivering notice
to such effect to the indemnifying party) have the right to
undertake, at the indemnifying partys cost and expense,
the defense, compromise or settlement of such claim on behalf of
and for the account and risk of the indemnifying party, provided
that any such settlement of claim shall be made only with the
written consent of the indemnifying party unless the indemnified
party shall agree to pay the full amount of such settlement. In
the event the indemnified party assumes the defense of the
claim, the indemnified party will keep the indemnifying party
reasonably informed of the progress of any such defense,
compromise or settlement.
(e) Product and Warranty
Liability. The provisions of this
Section 10.4 shall cover, without limitation, all
Liabilities of whatsoever kind, nature or description relating,
directly or indirectly, to product liability, litigation or
claims against Buyer or Seller in connection with, arising out
of, or relating to products sold or shipped from the Facilities
by Buyer or Seller, respectively.
(f) Brokers and Finders. Pursuant
to the provisions of this Section 10.4, each of Buyer and
Seller shall indemnify, hold harmless and defend the other party
from the payment of any and all brokers and finders
expenses, commissions, fees or other forms of compensation which
may be due or payable from or by the indemnifying party, or may
have been earned by any third party acting on behalf of the
indemnifying party in connection with the negotiation and
execution hereof and the consummation of the transactions
contemplated hereby.
(g) Representatives. No individual
Representative of any party shall be personally liable for any
Damages under the provisions contained in this
Section 10.4. Nothing herein shall relieve either party of
any Liability to make any payment expressly required to be made
by such party pursuant to this Agreement.
(h) Limitation on
Indemnity. Notwithstanding the foregoing, the
maximum aggregate amount of Damages Seller shall be liable
pursuant to this Section 10.4 shall be Twenty Million
Dollars ($20,000,000) in the aggregate; provided,
however, that the maximum aggregate amount of Damages
Seller shall be liable pursuant to this Section 10.4 with
respect to the Seldi Patent shall be Ten Million Dollars
($10,000,000).
10.5 Bulk Sales. It may not
be practicable to comply or attempt to comply with the
procedures of the Bulk Sales Act or similar law of
any or all of the states in which the Assets are situated or of
any other state which may be asserted to be applicable to the
transactions contemplated hereby. Accordingly, to induce Buyer
to waive any requirements for compliance with any or all of such
laws, Seller hereby agrees that the indemnity provisions of
Section 10.4 hereof shall apply to any Damages of Buyer
arising out of or resulting from the failure of Seller or Buyer
to comply with any such laws.
A-35
10.6 Covenant Not to Compete.
(a) Recitals. Seller acknowledges
and agree that Seller has technical expertise associated with
the Business and is well known in the life sciences industry. In
addition, Seller has valuable business contacts with clients and
potential clients of the Business and with professionals in the
life sciences industry. Sellers reputation and goodwill
are an integral part of its business success throughout the
areas where it conducts the Business. If Seller deprives Buyer
of any of Sellers goodwill or in any manner uses its
reputation and goodwill in competition with the Business, Buyer
will be deprived of the benefits it has bargained for pursuant
to this Agreement. Since Seller has the ability to compete with
Buyer in the operation of the Business, Buyer therefore desires
that Seller enter into this Covenant Not To Compete. But for
Sellers entry into this Covenant Not to Compete, Buyer
would not have entered into the Purchase Agreement with Seller.
(b) Covenant Not to
Compete. Seller agrees that for a period of
five (5) years after the Closing Date (the
Term), neither Seller nor any of its respective
Subsidiaries, unless acting in accordance with Buyers
prior written consent, shall, directly or indirectly, own,
manage, join, operate or control, or participate in the
ownership, management, operation or control of, or be connected
as a partner, consultant or otherwise with, or permit their
names to be used by or in connection with, any profit or
non-profit business or organization which produces, designs,
conducts research on, provides, sells, distributes or markets
products, goods, equipment or services which, directly competes
with the Business, as conducted by Seller immediately prior to
the Closing, anywhere in the world other than in the Clinical
Diagnostics Market (as that term is defined in the Cross-License
Agreement); it being understood that the foregoing shall not
limit Seller from (a) acquiring control of any company or
business which derives less than 2% of its revenues from a
business which competes directly with the Business as conducted
by Seller immediately prior to the Closing or (b) making
passive investments of less than 2% of the outstanding equity
securities in any entity listed for trading on a national stock
exchange or quoted on any recognized automatic quotation system.
(c) Severability of Provisions. If
any covenant set forth in this agreement is determined by any
court to be unenforceable by reason of its extending for too
great a period of time or over too great a geographic area, or
by reason of its being extensive in any other respect, such
covenant shall be interpreted to extend only for the longest
period of time and over the greatest geographic area, and to
otherwise have the broadest application as shall be enforceable.
The invalidity or unenforceability of any particular provision
of this agreement shall not affect the other provisions hereof,
which shall continue in full force and effect. Without limiting
the foregoing, the covenants contained herein shall be construed
as separate covenants, covering their respective subject
matters, with respect to each of the separate cities, counties
and states of the United States, and each other country, and
political subdivision thereof, in which any of Seller or its
successors now transacts any business.
(d) Injunctive Relief. Seller
acknowledges that (i) the provisions of
Section 10.6(b) and (c) are reasonable and necessary
to protect the legitimate interests of Buyer, and (ii) any
violation of paragraphs (b) or (c) of this
Section 10.6 will result in irreparable injury to Buyer,
the exact amount of which will be difficult to ascertain, and
that the remedies at law for any such violation would not be
reasonable or adequate compensation to Buyer for such a
violation. Accordingly, Seller agrees that if Seller violates
the provisions of Section 10.6(b) or (c), in addition to
any other remedy which may be available at law or in equity,
Buyer shall be entitled to specific performance and injunctive
relief, without posting bond or other security, and without the
necessity of proving actual damages.
10.7 Taxes. Subject to
Section 2.6, Seller shall pay, or cause to be paid, when
due all Taxes for which Seller is or may be liable or that are
or may become payable with respect to all taxable periods ending
on or prior to the Closing Date.
ARTICLE XI
TERMINATION
11.1 Termination.
(a) Termination. This Agreement
may be terminated at any time prior to Closing:
(i) By mutual written consent of Buyer and Seller; or
(ii) By Buyer or Seller if the Closing shall not have
occurred on or before November 1, 2006; provided, however,
that this right to terminate this Agreement shall not be
available to any party whose failure to fulfill
A-36
any obligation under this Agreement has been the primary cause
of, or resulted in, the failure of such consummation to occur on
or before such date;
(iii) By Buyer or Seller, if Sellers stockholders
vote not to approve the transactions contemplated by this
Agreement at a duly convened special meeting of stockholders
called for the purpose of approving such transactions(or any
adjournment or postponement thereof); or
(iv) By Seller, if prior to the Closing and after
compliance in all material respects with the applicable
provisions of Section 6.2, the Company elects to enter into
a binding agreement with respect to a Superior Proposal.
(b) In the Event of
Termination. In the event of termination of
this Agreement:
(i) Each party will redeliver all documents, work papers
and other material of any other party relating to the
transactions contemplated hereby, whether so obtained before or
after the execution hereof, to the party furnishing the same;
(ii) The provisions of the Confidentiality Agreement shall
continue in full force and effect;
(iii) Buyer agrees, in consideration of Seller entering
into this Agreement, that in the event that (A) Seller
terminates this Agreement in accordance with
Section 11.1(a)(ii) as a result of the conditions to
Sellers obligations to close specified in Article VII
not having been satisfied (provided that at such time all of the
conditions to Buyers obligation to close specified in
Article VIII have been satisfied by Seller or validly
waived), or (B) Buyer terminates this Agreement
(i) for any reason prior to November 1, 2006, or
(ii) for any reason after November 1, 2006 (provided
that at such time all of the conditions to Buyers
obligation to close specified in Article VIII have been
satisfied by Seller or validly waived), Buyer shall, within two
(2) days after such termination, pay Seller an amount equal
to Two Million Dollars ($2,000,000); and
(iv) Seller agrees, in consideration of Buyer entering into
this Agreement, that in the event that (A) (i) Buyer
terminates this Agreement in accordance with
Section 11.1(a)(ii) as a result of the conditions to
Buyers obligations to close specified in Article VIII
not having been satisfied (provided that at such time all of the
conditions to Sellers obligation to close specified in
Article VII have been satisfied by Buyer or validly
waived), or (ii) Seller terminates this Agreement
(a) for any reason prior to November 1, 2006, or
(b) for any reason after November 1, 2006 (provided
that, except in the case of termination by Seller for the reason
set forth in Section 11.1(a)(iv), at such time all of the
conditions to Sellers obligation to close specified in
Article VII have been satisfied by Buyer or validly
waived), or (B) Buyer or Seller terminates this Agreement
in accordance with Section 11.1(a)(iii) and within
9 months thereafter Seller closes a transaction in which it
sells or otherwise transfers all or substantially all of the
assets comprising the Business to a third party, then (if any of
the events set forth in (A) or (B) occur) Seller
shall, within two (2) days after such termination or
closing, as applicable, pay Buyer an amount equal to Two Million
Dollars ($2,000,000).
ARTICLE XII
MISCELLANEOUS
12.1 Assignment. Neither
this Agreement nor any of the rights or obligations hereunder
may be assigned by either party without the prior written
consent of the other party. Subject to the foregoing, this
Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted
assigns, and no other person shall have any right, benefit or
obligation under this Agreement as a third party beneficiary or
otherwise.
A-37
12.2 Notices. All notices,
requests, demands and other communications which are required or
may be given under this Agreement shall be in writing and shall
be deemed to have been duly given when received if personally
delivered; when transmitted if transmitted by telecopy,
electronic or digital transmission method; the day after it is
sent, if sent for next day delivery to a domestic address by
recognized overnight delivery service (e.g., Federal
Express); and upon receipt, if sent by certified or registered
mail, return receipt requested. In each case notice shall be
sent to:
|
|
|
If to Seller, addressed to:
|
|
|
|
|
|
Ciphergen Biosystems, Inc.
|
|
|
6611 Dumbarton Circle
|
|
|
Fremont, California 94555
|
|
|
Attention: President and CEO;
and
Vice President of Business Development
|
|
|
|
With a copy to:
|
|
|
|
|
|
Wilson Sonsini Goodrich &
Rosati
|
|
|
650 Page Mill Road
|
|
|
Palo Alto, California 94304
|
|
|
Attention: Michael J.
ODonnell, Esq.
|
|
|
|
If to Buyer, addressed to:
|
|
|
|
|
|
Bio-Rad Laboratories, Inc.
|
|
|
1000 Alfred Nobel Drive
|
|
|
Hercules, California 94547
|
|
|
Attention: General Counsel
|
or to such other place and with such other copies as either
party may designate as to itself by written notice to the party.
12.3 Choice of Law. This
Agreement shall be construed, interpreted and the rights of the
parties determined in accordance with the laws of the State of
California (without reference to the choice of law provisions),
except with respect to matters of law concerning the internal
corporate affairs of any corporate entity which is a party to or
the subject of this Agreement.
12.4 Entire Agreement; Amendments and
Waivers. This Agreement, the Ancillary
Agreements, together with all exhibits and schedules hereto and
thereto (including the Disclosure Schedule), and the
Confidentiality Agreement constitutes the entire agreement
between the parties pertaining to the subject matter hereof and
supersedes all prior agreements, understandings, negotiations
and discussions, whether oral or written, of the parties. This
Agreement may not be amended except by an instrument in writing
signed on behalf of each of the parties hereto. No amendment,
supplement, modification or waiver of this Agreement shall be
binding unless executed in writing by the party to be bound
thereby. No waiver of any of the provisions of this Agreement
shall be deemed or shall constitute a waiver of any other
provision hereof (whether or not similar), nor shall such waiver
constitute a continuing waiver unless otherwise expressly
provided.
12.5 Multiple
Counterparts. This Agreement may be executed
in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the
same instrument.
12.6 Expenses. Except as
otherwise specified in this Agreement, each party hereto shall
pay its own legal, accounting,
out-of-pocket
and other expenses incident to this Agreement and to any action
taken by such party in preparation for carrying this Agreement
into effect.
12.7 Invalidity. In the
event that any one or more of the provisions contained in this
Agreement or in any other instrument referred to herein, shall,
for any reason, be held to be invalid, illegal or unenforceable
in any respect, then to the maximum extent permitted by law,
such invalidity, illegality or unenforceability shall not affect
any other provision of this Agreement or any other such
instrument.
A-38
12.8 Titles; Gender. The
titles, captions or headings of the Articles and Sections
herein, and the use of a particular gender, are for convenience
of reference only and are not intended to be a part of or to
affect or restrict the meaning or interpretation of this
Agreement.
12.9 Public Statements and Press
Releases. The parties hereto covenant and
agree that, except as provided for hereinbelow, each will not
from and after the date hereof make, issue or release any public
announcement, press release, statement or acknowledgment of the
existence of, or reveal publicly the terms, conditions and
status of, the transactions provided for herein, without the
prior written consent of the other party as to the content and
time of release of and the media in which such statement or
announcement is to be made; provided, however,
that in the case of announcements, statements, acknowledgments
or revelations which either party is required by law to make,
issue or release, the making, issuing or releasing of any such
announcement, statement, acknowledgment or revelation by the
party so required to do so by law shall not constitute a breach
of this Agreement if such party shall have given, to the extent
reasonably possible, not less than two (2) calendar days
prior notice to the other party, and shall have attempted, to
the extent reasonably possible, to clear such announcement,
statement, acknowledgment or revelation with the other party.
Each party hereto agrees that it will not unreasonably withhold
any such consent or clearance. Notwithstanding the foregoing,
the parties agree to issue a mutually agreed upon joint press
release on or about the date of execution of this Agreement
announcing the existence of this Agreement and the transactions
contemplated herein.
12.10 Cumulative
Remedies. All rights and remedies of either
party hereto are cumulative of each other and of every other
right or remedy such party may otherwise have at law or in
equity, and the exercise of one or more rights or remedies shall
not prejudice or impair the concurrent or subsequent exercise of
other rights or remedies.
12.11 Service of Process, Consent to
Jurisdiction.
(a) Service of Process. Each
parties hereto irrevocably consents to the service of any
process, pleading, notices or other papers by the mailing of
copies thereof by registered, certified or first class mail,
postage prepaid, to such party at such partys address set
forth herein, or by any other method provided or permitted under
California law.
(b) Consent and Jurisdiction. Each
party hereto irrevocably and unconditionally (1) agrees
that any suit, action or other legal proceeding arising out of
this Agreement may be brought in the United States District
Court for the Northern District of California or, if such court
does not have jurisdiction or will not accept jurisdiction, in
any court of general jurisdiction in Contra Costa County,
California; (2) consents to the jurisdiction or any such
court in any such suit, action or proceeding; and
(3) waives any objection which such party may have to the
laying of venue of any such suit, action or proceeding in any
such court.
12.12 Attorneys
Fees. If any party to this Agreement brings
an action to enforce its rights under this Agreement, the
prevailing party shall be entitled to recover its costs and
expenses, including without limitation reasonable
attorneys fees, incurred in connection with such action,
including any appeal of such action.
A-39
IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed on their respective behalf, by
their respective officers thereunto duly authorized, all as of
the day and year first above written.
|
|
|
CIPHERGEN BIOSYSTEMS, INC.
|
|
BIO-RAD LABORATORIES, INC.
|
|
|
|
|
|
By: /s/ /s/ Sanford
Wadler
|
|
|
|
|
|
|
|
|
|
|
|
Title: Vice President and
General Counsel
|
A-40
ANNEX B:
NEW BUSINESS STRATEGY
Overview
Ciphergen is dedicated to the discovery, development and
commercialization of specialty diagnostic tests that help
physicians manage their patients and that improve patient
outcomes. We intend to do this using translational proteomics,
which is the process of answering clinical questions by
utilizing advanced protein separation tools to identify
combinations of biomarkers (or, better, to resolve variants of
specific biomarkers), developing assays, and commercializing
tests.
Through collaborations with leading academic and research
institutions, including The Johns Hopkins School of Medicine,
The University of Texas M. D. Anderson Cancer Center, University
College London, and The University of Texas Medical Branch,
Ciphergen plans to develop diagnostic tests in the fields of
cancer, cardiovascular disease, and womens health. The
clinical questions we are addressing include early disease
detection, treatment response, monitoring of disease
progression, prognosis and others. In July 2005, we entered into
a strategic alliance agreement with Quest Diagnostics
Incorporated covering a three year period during which the
parties have agreed to develop and commercialize up to three
diagnostic tests based on SELDI technology.
Our most advanced program is in the field of ovarian cancer.
Commonly known as the silent killer, ovarian cancer
leads to approximately 14,000 deaths each year in the United
States. Approximately 23,000 new cases are diagnosed each year,
with the majority in patients with late stage disease, where the
cancer has spread beyond the ovary. Unfortunately, the prognosis
is poor in these patients, leading to the high mortality from
this disease. One unmet clinical need is a diagnostic test that
can provide adequate predictive value to stratify patients with
a pelvic mass into high risk of invasive ovarian cancer versus
those with a low risk. We believe that there are at least
5 million testing opportunities each year addressing this
need. Ciphergen has developed a panel of biomarkers that we
believe provides risk stratification information for ovarian
cancer based on a series of studies involving over 2,000
clinical samples from more than five sites. We recently reported
the results of a prospective clinical trial involving over 200
consecutive women to test specifically the performance of this
marker panel in a realistic patient population, and achieved 80%
positive predictive value (the likelihood that a positive test
result is truly invasive epithelial ovarian cancer) which is
better than other available diagnostic modalities in this
patient cohort, such as CA125. Ciphergen is currently working
with Quest Diagnostics in their efforts to commercialize this
marker set under the analyte specific reagent, or ASR,
regulations. In addition, Ciphergen is simultaneously
undertaking a prospective clinical trial to support submission
to the FDA for approval as an in vitro diagnostic
test.
The
Diagnostics Market Opportunity
The economics of health care demand improved allocation of
resources. Improved allocation of resources can be derived
through disease prevention, early detection of disease leading
to early intervention, and from diagnostic tools that can triage
patients to more appropriate therapy and intervention. According
to the Lewin Group, the worldwide market for diagnostics in 2005
was approximately $29 billion.
We have chosen to focus primarily in the areas of oncology,
cardiovascular disease, and womens health. Demographic
trends suggest that, as the population ages, the burden from
these diseases will increase, and the demand for quality
diagnostic, prognostic, and predictive tests will increase. In
addition, these areas generally lack quality diagnostic tests
and therefore we believe patient outcomes can be significantly
improved by the development of novel diagnostic and risk
stratification tests.
Cancer represents the second leading cause of death in the
United States. Over 500,000 Americans die of cancer each year.
While many cancer types are preventable, others are not. Even
among patients with clear risk factors (for example, HPV
infection for cervical cancer), health care providers still
generally lack the ability to distinguish those who will get
cancer from those who will not. Consequently, there is a clear
unmet need to stratify these individuals. Breast cancer is the
second most common non-skin cancer among women, with
approximately 270,000 new cases of invasive and in situ cancer
diagnosed in 2005. Breast cancer kills more women than any other
cancer except for lung cancer, with approximately 40,000 deaths
from breast cancer in 2005. While much less common than breast
cancer, ovarian cancer is the most lethal gynecological
malignancy, with approximately 15,300
B-1
deaths due to ovarian cancer in 2005. Prostate cancer is the
most common non-skin cancer among men, with approximately
230,000 cases in 2005.
Cardiovascular disease is the leading cause of morbidity and
mortality in industrial countries. Over 64 million
Americans are affected by at least one type of cardiovascular
disease, and close to 1 million die from cardiovascular
disease each year more than from all the cancers
combined. The prevalence of cardiovascular disease is expected
to increase, not just because of the aging population, but also
because of the rapid increase in obesity. More health care
dollars are spent on cardiovascular disease than on any other
disease, and the estimated annual cost of cardiovascular disease
(both indirect and direct) is $368 billion, twice that of
cancer. Cardiovascular disease represents a prime opportunity
for new diagnostic tests, particularly those that can monitor
cardiovascular health or that can predict poor prognosis.
Prevention and surveillance are accepted paradigms in
cardiovascular medicine; therefore, market acceptance of these
types of tests is likely to be high. There is no non-invasive
test currently available to distinguish between coronary artery
disease and peripheral arterial disease. Such a test would allow
physicians to prescribe the appropriate type of treatment.
In the field of womens health, outside of gynecologic
malignancies, the field of reproductive health contains many
potential opportunities. For example, as women wait longer to
have children, the reliance on assisted reproductive
technologies, or ART, increases and the potential for obstetric
complications increases. Tests aimed at assessing the viability
of oocytes during the process of ART may help patients and
physicians improve the efficiency of the process, as well as
decrease the likelihood of multiple births. In 2003,
approximately 90,000 cycles of ART were initiated, resulting in
approximately 25,000 live-birth deliveries. More than a third of
pregnancies contained multiple fetuses.
Our focus on proteomics enables us to address the market for
diagnostic tests that measure multiple protein biomarkers,
simultaneously. A protein biomarker is a protein or protein
variant that is present in a greater or lesser amount in a
disease state versus a normal condition. Conventional proteomic
tests measure a single protein biomarker whereas most diseases
are complex. We believe that efforts to diagnose cancer and
other complex diseases have failed in large part because the
disease is heterogeneous at the causative level (i.e., most
diseases can be traced to multiple potential etiologies) and at
the human response level (i.e. each individual afflicted with a
given disease can respond to that ailment in a specific manner).
Consequently, measuring a single protein biomarker when multiple
protein biomarkers may be altered in a complex disease is
unlikely to provide meaningful information about the disease
state. Our approach, using mass spectrometry, allows us to
create diagnostic tests with sufficient sensitivity and
specificity to aid the physician considering treatment options
for patients with complex diseases.
Scientific
Background
Genes are the hereditary coding system of living organisms.
Genes encode proteins that are responsible for cellular
functions. The study of genes and their functions has led to the
discovery of new targets for drug development. Industry sources
estimate that within the human genome there are approximately
30,000 genes. The initial structure of a protein is determined
by a single gene. The final structure of a protein is frequently
altered by interactions with additional genes or proteins. These
subsequent modifications result in hundreds of thousands of
different proteins. In addition, proteins may interact with one
another to form complex structures that are ultimately
responsible for cellular functions.
Genomics allows researchers to establish the relationship
between gene activity and disease. However, many diseases are
manifested not at the genetic level, but at the protein level.
The complete structure of modified proteins cannot be determined
by reference to the encoding gene alone. Thus, while genomics
provides some information about diseases, it does not provide a
full understanding of disease processes.
The
Relationship Between Proteins and Diseases
The entire genetic content of any organism, known as its genome,
is encoded in strands of deoxyribonucleic acid, or DNA. Cells
perform their normal biological functions through the genetic
instructions encoded in their DNA, which results in the
production of proteins. The process of producing proteins from
DNA is known as gene expression or protein expression.
Differences in living organisms result from variability in their
genomes, which can affect the types of genes expressed and the
levels of gene expression. Each cell of an organism expresses
only
B-2
approximately 10% to 20% of the genome. The type of cell
determines which genes are expressed and the amount of a
particular protein produced. For example, liver cells produce
different proteins from those produced by cells found in the
heart, lungs, skin, etc. Proteins play a crucial role in
virtually all biological processes, including transportation and
storage of energy, immune protection, generation and
transmission of nerve impulses and control of growth.
Diseases may be caused by a mutation of a gene that alters a
protein directly or indirectly, or alters the level of protein
expression. These alterations interrupt the normal balance of
proteins and create disease symptoms. A protein biomarker is a
protein or protein variant that is present in a greater or
lesser amount in a disease state versus a normal condition. By
studying changes in protein biomarkers, researchers may identify
diseases prior to the appearance of physical symptoms.
Historically, researchers discovered protein biomarkers as a
byproduct of basic biological disease research. This has
resulted in the validation by researchers of approximately 200
protein biomarkers that are being used in commercially available
clinical diagnostic products.
Limitations
of Existing Diagnostic Approaches and Ciphergens
Solution
The in vitro diagnostics industry manufactures and
distributes products that are used to detect thousands of
individual components present in human derived specimens.
However, the vast majority of these assays are used specifically
to identify single protein biomarkers. The development of new
diagnostic products has been limited by the complexity of
disease states, which may be caused or characterized by several
or many proteins or post-translationally modified protein
variants. Diagnostic assays that are limited to the detection of
a single protein often have limitations in clinical specificity
(true negatives) and sensitivity (true positives) due to the
complex nature of many diseases and the inherent biological
diversity among populations of people. Diagnostic products that
are limited to the detection of a single protein may lack the
ability to detect more complex diseases, and thus produce
results that are unacceptable for practical use.
The heterogeneity of disease and of the human response to
disease underlie the shortcoming of single markers to diagnose
accurately and to predict many diseases. Our studies,
particularly in ovarian cancer, have given us a better
understanding of both the disease pathophysiology and the host
response. By using multiple markers, we are better able to
encompass the disease and host response heterogeneity. In
addition, by examining specific analytes with greater
resolution, for example, post-translational modifications, we
believe we can improve the specificity of our diagnostic markers
because these modifications reflect both the pathophysiology and
host response. We utilize translational proteomics, i.e., the
process of answering clinical questions by utilizing advanced
protein separation tools to identify combinations of biomarkers
(or better to resolve variants of specific biomarkers),
developing assays, and commercializing tests.
Ciphergen is applying proteomics research and development tools
and methods to analyze biological information in an attempt to
discover associations between proteins, protein variants, and
protein-protein interaction and diseases. Ciphergen intends to
develop new diagnostic tests based on known and newly-identified
protein markers to help physicians predict an individuals
predisposition in order better to characterize, monitor
progression of, and select appropriate therapy for, diseases.
Our goals are to:
|
|
|
|
|
Develop high-value diagnostic tests that address unmet medical
needs, particularly in stratifying patients according to the
risk of developing a disease, having a disease, or failing a
specific therapy for a disease
|
|
|
|
Facilitate more efficient clinical trials of new therapeutics by
providing biomarkers that stratify patients according to
likelihood of response
|
|
|
|
Identify biomarkers that can form the basis of molecular imaging
targets
|
B-3
Our
Solution
|
|
|
Problem
|
|
Ciphergens solution
|
|
Heterogeneity of disease
|
|
Emphasis on multi-marker panels
|
Poorly validated markers
|
|
Expertise in study design incorporating internal and external validation
|
|
|
Large multi-site studies
|
Protein post-translational
modifications that reduce specificity of assays
|
|
Assay development using mass spectrometry to quantitate disease-specific forms
|
Absence of product pipeline
|
|
Potential test candidates derived from internally driven programs with leading collaborators and in-licensing efforts directed to the SELDI-installed base
|
Addressing
the heterogeneity of disease
Ciphergens strategy is to create a paradigm of diagnostics
that is based on risk stratification, multiple-marker testing,
and information integration. This strategy is based on the
belief that any specific disease is heterogeneous and therefore
relying on a single disease marker to provide a simple
yes-no answer is likely to fail. We believe that
efforts to diagnose cancer and other complex diseases have
failed in large part because the disease is heterogeneous at the
causative level, meaning that most diseases can be traced to
multiple potential etiologies, and at the human response level,
meaning that each individual afflicted with a given disease can
respond to that ailment in a specific manner. A better
understanding of heterogeneity of disease and human response is
necessary for improved diagnosis and treatment of many diseases.
Validation
of markers through proper study design
Analysis of peer-reviewed publications reveals almost daily
reports of novel biomarkers or biomarker combinations associated
with specific diseases. Few of these are used clinically. As
with drug discovery, preliminary research results fail to
canvass sufficient variation in study populations or laboratory
practices and, therefore, the vast majority of candidate
biomarkers fail to be substantiated in subsequent studies.
Recognizing that validation is the point at which most
biomarkers fail, Ciphergens strategy is to reduce the
attrition rate between discovery and clinical implementation by
building validation into the discovery process. Biomarkers fail
to validate for a number of reasons, which can be broadly
classified into pre-analytical and analytical factors.
Pre-analytical factors include study design that does not mimic
actual clinical practice, inclusion of the wrong types of
control individuals, and demographic bias (usually seen in
studies in which samples are collected from a single
institution). Analytical factors include poor control over
laboratory protocols, inadequate randomization of study samples,
and instrumentation biases (for example, higher signal early in
the experimental run compared to later in the experimental run).
Finally, the manner in which the data are analyzed can have a
profound impact on the reliability of the statistical
conclusions.
When designing clinical studies, Ciphergen begins with the
clinical question, since this drives the downstream clinical
utility of the biomarkers. With this as a starting point,
Ciphergen is able to design a study that includes the
appropriate cases and control groups. Ciphergen further
incorporates an initial validation component even within the
discovery component. Therefore, Ciphergen places an emphasis on
multi-institutional studies, inclusion of clinically relevant
controls, and partitioning of training from validation data. For
example, in the 2004 Cancer Research paper describing the
first three markers in the ovarian cancer panel, more than 600
samples taken from five hospitals were analyzed. These samples
were divided into individual training sets, followed by a first
round of validation samples and then a second round of
independent validation samples. Subsequently, Ciphergen has
analyzed more than 2,000 samples from five additional medical
centers. Ciphergen has examined over 300 samples in its breast
cancer program and over 400 samples in its prostate cancer
program. In analyzing the complex proteomics data, Ciphergen
takes an agnostic view of statistical methodologies, choosing to
use a variety of approaches and looking for concordance between
approaches, taking the view that markers deemed significant by
multiple statistical algorithms are more likely to reflect
biological conditions rather than mathematical artifacts.
B-4
Exploiting
the power of mass spectrometry to improve assay
specificity
An important characteristic of proteins is that their functional
activity is often modulated by changes in their structure.
Conventional approaches to assay proteins have variable ability
to detect these changes, and may depend on the specificity of
the antibody to the original or altered forms of the proteins.
Additionally, a conventional assay may inadvertently measure
only one form of a protein while many exist. Ciphergen has
developed programs for biomarkers in which mass spectrometry
provides an advantage over traditional assays in characterizing
and quantitating disease markers. Mass spectrometrys
advantages over traditional assay approaches in these instances
is a result of its ability to distinguish two or more highly
related protein species based on molecular mass, or in
combination with chromatographic separation tools, such as with
ProteinChip arrays, based on biochemical properties. Because
most traditional assay approaches rely strictly on using
antibodies to capture the intended analyte, protein forms with a
common epitope are not readily distinguished. A few examplar
proteins that are candidates for this approach include von
Willebrands factor, human chorionic gonadotropin, albumin,
c-reactive protein, and serum amyloid A. One disease that
Ciphergen is specifically addressing is TTP, a disease that
affects mostly women and is a result of a deficiency in the
enzyme ADAMTS13, which cleaves von Willebrands factor.
Current assays rely on unwieldy Western Blots, which are both
low throughput and poorly quantitative. Ciphergens assay
measures directly the product of the enzymatic reaction for
ADAMTS13, and provides the level of quantitation necessary to
distinguish TTP from other thrombocytopenic diseases.
Creating
and maintaining a viable product pipeline
Ciphergen can develop potential tests based on biomarkers
discovered in its sponsored programs with academic
collaborators, and also has the opportunity to in-license tests
from an installed base of hundreds of academic SELDI customers.
Ciphergens strategy of selling its SELDI proteomics
platform to researchers in academia, pharmaceutical companies,
and biotechnology companies may provide Ciphergen with access to
biomarkers that could potentially lead to additional diagnostic
tests. Going forward, Bio-Rad and Ciphergen have agreed to
continue to identify SELDI users that could provide additional
biomarker discoveries for Ciphergens diagnostics pipeline.
In addition, Ciphergen has the opportunity to identify
additional markers discovered on other platforms that complement
its existing product pipeline.
Ciphergen has entered into collaboration, research, and material
transfer agreements with more than 16 companies and
academic institutions to support its large-scale clinical
studies, including ongoing studies as well as studies Ciphergen
plans to conduct in the future. Some of Ciphergens major
collaborations in the areas of cancer and womens health
are described in greater detail here.
|
|
|
|
|
The Johns Hopkins University School of
Medicine: Led by Dr. Daniel Chan, Director
of the clinical laboratories, this collaboration focuses on
oncology (in particular, breast, prostate, and ovarian cancer).
Under our Collaboration Agreement with Johns Hopkins, we provide
research funding, ProteinChip Systems and ProteinChip Arrays.
Johns Hopkins provides laboratory space and equipment, clinical
samples and scientists to perform the research. Johns Hopkins
has granted us an option to take a royalty-bearing, exclusive,
worldwide license to commercialize any inventions resulting from
the research. Our royalty obligations include minimum annual
royalties, as well as running royalties on sales of products and
services. The collaboration agreement with John Hopkins is
effective through September 30, 2006, and we are currently
negotiating an amended agreement, with an extended term.
|
|
|
|
The University of Texas M. D. Anderson Cancer
Center: Led by Dr. Robert C. Bast, Jr.,
who discovered the tumor marker for ovarian cancer (CA125), this
collaboration focuses on ovarian cancer. Under our Research and
License Agreement with M. D. Anderson, we provide research
funding, ProteinChip Arrays and other consumables. M. D.
Anderson provides clinical samples for research purposes. Both
we and M. D. Anderson perform designated portions of the
research. M. D. Anderson has granted us an option to negotiate
and acquire a royalty-bearing, exclusive, worldwide license to
commercialize any inventions resulting from the research. We are
currently in the process of negotiating license terms with M. D.
Anderson with respect to certain patents covering biomarkers
discovered under the collaboration.
|
|
|
|
University College London: Led by Professor
Ian Jacobs, this collaboration provides us with access to the
largest ovarian cancer screening trial in the world (UKCTOCS).
This collaboration is aimed at ovarian and
|
B-5
|
|
|
|
|
breast cancer. Pursuant to our Collaborative Research Agreement
with UCL, we provide research funding, ProteinChip Arrays and
associated consumables, bioinformatics, software and data
analysis and other research support. UCL provides clinical
samples. Both parties perform designated portions of the
research. UCL has granted us an option to acquire a
royalty-bearing, exclusive, worldwide license to commercialize
inventions resulting from the research in the field of
diagnostics and therapeutics for cancer.
|
|
|
|
|
|
The University of Texas Medical Branch: Led by
Dr. John Petersen, this collaboration is focused on the
discovery and development of new products for personalized, or
targeted medicine, particularly in the field of liver disease.
Under our Research and License Agreement with UTMB, UTMB
provides clinical samples for research purposes. Both we and
UTMB perform designated portions of the research. UTMB has
granted us an option to negotiate and acquire a royalty-bearing,
exclusive, worldwide license to commercialize any inventions
resulting from the research subject to the terms of a license
agreement to be negotiated by the parties.
|
Ciphergen, together with its collaborators, is currently
conducting large-scale protein biomarker studies in the
following areas: oncology, womens health, and
cardiovascular disease. Most of these studies involve the
analysis of large numbers of samples from healthy and diseased
individuals, or comparing patients with the disease of interest
to those with related diseases for which clinical distinction is
necessary. The goal of most of these studies is to identify sets
of proteins that serve as biomarkers for a specific disease.
B-6
|
|
|
|
|
|
|
|
|
2005 Estimated
|
|
|
|
|
|
|
Treatment Decisions
|
|
|
|
|
Disease field
|
|
in the United States
|
|
Specific clinical question
|
|
Product Stage
|
|
Ovarian cancer
|
|
5,000,000
|
|
Screening and risk
stratification of women with a suspicious pelvic mass
|
|
Final clinical evaluation(1)
|
|
|
65,000
|
|
Prediction of
recurrence/response to chemotherapy
|
|
Discovery and initial clinical
evaluation(2)
|
|
|
10,000,000
|
|
Surveillance of
high-risk women
|
|
Initial discovery(3)
|
|
|
|
|
|
|
|
Breast cancer
|
|
54,000,000(4)
|
|
Triage to imaging
modality
|
|
Initial clinical evaluation
|
|
|
100,000
|
|
Enhanced response to
chemotherapy
|
|
Initial discovery
|
|
|
|
|
|
|
|
Prostate cancer
|
|
30,000,000(5)
|
|
Screening and
detection in conjunction with PSA
|
|
Initial clinical evaluation
|
|
|
230,000
|
|
Risk of recurrence
|
|
Initial clinical evaluation
|
|
|
|
|
|
|
|
Peripheral arterial disease
|
|
>12,000,000
|
|
Determination of risk
of PAD
|
|
Final clinical evaluation
|
|
|
|
|
Distinguishing between
PAD and CAD
|
|
Initial discovery
|
|
|
|
|
|
|
|
Thrombotic thrombocytopenic purpura
|
|
100,000
|
|
Diagnosis
|
|
Assay development(6)
|
|
|
|
|
Monitoring of to
therapy
|
|
|
|
|
|
|
|
|
|
Assisted reproductive technology
|
|
90,000
|
|
Prediction of
likelihood of successful implantation
|
|
Initial clinical evaluation
|
|
|
|
(1) |
|
Final clinical evaluation means that a specific
marker set has undergone a multi-site evaluation and assay
development, and is undergoing final clinical evaluation tests
prior to product launch. |
|
|
(2) |
|
Initial clinical evaluation means that a specific
marker set is being evaluated in independent sample sets,
generally from multiple medical centers. In some instances,
candidate markers have been discovered and are undergoing
clinical evaluation experiments while additional markers are
being sought to improve the clinical performance. This process
may expedite commercialization if such markers are found. |
|
|
(3) |
|
Initial discovery means that studies, generally
retrospective case control, are being conducted to discover and
identify biomarkers. These studies are usually relatively small
(< 200) and examine samples from 1-2 medical centers,
and a specific set of markers for commercialization has not yet
been determined. |
|
|
(4) |
|
Number of women aged 40-70, according to US Census estimates. |
|
|
(5) |
|
Number of men aged 50-75, according to US Census estimates. |
|
|
(6) |
|
Assay development means the process of creating
reproducible and quantitative assays, as well as ascertaining
pre-analytical variables that affect reproducibility such that
the test can be run in a clinical laboratory. |
B-7
Further details regarding important developments in several of
Ciphergens large-scale studies are set forth below.
Ovarian cancer. Commonly known as the
silent killer, ovarian cancer leads to approximately
14,000 deaths each year in the United States. Approximately
23,000 new cases are diagnosed each year, with the majority in
patients with late stage disease, i.e., when the cancer has
spread beyond the ovary. Unfortunately, the prognosis is poor in
these patients, leading to the high mortality from this disease.
While the diagnosis of ovarian cancer in its earliest stages has
a profound positive impact on the likelihood of survival of the
disease, another factor that predicts survival from ovarian
cancer is the specialty training of the surgeon who operates on
the patient with ovarian cancer, with patients being treated by
the gynecologic oncologist having better outcomes than those
treated by the general surgeon. Accordingly, an unmet clinical
need is a diagnostic test that can provide adequate predictive
value to stratify patients with a pelvic mass into high risk of
invasive ovarian cancer versus those with a low risk. No blood
test currently exists to address properly this clinical
question, although CA125 is commonly used. CA125, which is
cleared by the FDA only for monitoring for recurrence of ovarian
cancer, is absent in up to 50% of early stage ovarian cancer
cases, and can be elevated in diseases other than ovarian
cancer, including benign ovarian tumors and endometriosis. These
shortcomings limit CA125s utility in distinguishing benign
from malignant ovarian tumors or for use in detection of early
stage ovarian cancer. Transvaginal ultrasound is another
diagnostic modality used with patients with ovarian tumors.
Attempts at defining specific morphological criteria that can
aid in a benign versus malignant diagnosis have led to the
morphology index and the risk of malignancy index, with reports
of 40-70% predictive value. However, ultrasound interpretation
can be variable and dependent on the experience of the operator.
In August 2004, Ciphergen along with collaborators at Johns
Hopkins, University College London, and M. D. Anderson Cancer
Center reported the discovery of three markers that, when
combined, provided higher diagnostic accuracy for early stage
ovarian cancer than other markers, for example, CA125. The three
markers that Ciphergen reported in 2004 form the basis of an
expanded panel of biomarkers that together have been
demonstrated to provide risk stratification information in a
series of studies involving over 2,000 clinical samples from 5
sites. The most recent data, presented at the annual meeting of
the American Society of Clinical Oncology in June 2006,
demonstrate the portability of this marker panel among different
clinical groups, indicating its potential validity across
various testing populations. Ciphergen and collaborators at
Rigshospitalet (Copenhagen) also reported the results of a
prospective clinical trial involving over 200 consecutive women
specifically to test the performance of this marker panel in a
realistic patient population, and achieved 80% positive
predictive value (likelihood that a positive test result is
truly invasive epithelial ovarian cancer), better than other
available diagnostic modality in this patient cohort. Ciphergen
is continuing to investigate the role of these markers, as well
as discovering additional biomarkers, that may be used to
identify early stage ovarian cancer.
Prostate cancer. Approximately 250,000 men are
expected to be diagnosed with prostate cancer in the United
States each year, approximately 195,000 of whom will need to
make critical decisions on whether or not to undergo local
therapy, such as surgery or radiation, and on whether or not to
have additional treatment after local therapy. Because the side
effects of surgery and local radiation therapy can be serious, a
need exists for a reliable test to determine the likelihood of
progression. There is also a need for a reliable test to
determine the likelihood of recurrence after local treatment,
because hormonal therapy and chemotherapy have significant side
effects as well. It has become clear that prostate cancer
suffers from over-diagnosis in that many men with prostate
cancer will not die of the disease, but it is unclear which
patients will have an adverse outcome directly related to
prostate cancer versus those who will not. In May 2006,
Ciphergen and Johns Hopkins reported the discovery of two
biomarkers that, when combined with PSA, were highly predictive
of likelihood of recurrence of prostate cancer. The results
arose from two studies, one examining over 400 men with prostate
cancer, and the other examining 50 pairs of men followed for
5 years with prostate cancer matched for age, cancer stage,
and other clinical parameters. These results suggest the
potential to aid in the stratification of risk of highly
aggressive prostate cancer, independent of other clinical
variables, reduce overtreatment of prostate cancer cases not
likely to be lethal, and shift treatment to those cases that are
particularly likely to be lethal.
Breast cancer. Detection of early stage breast
cancer holds the potential to improve outcomes for women with
this disease. No blood markers currently exist that can
accurately detect ductal carcinoma in situ, or DCIS, which is
one of the earliest stages of breast cancer, and it is likely
that imaging modalities such as mammography, ultrasound, and
magnetic resonance imaging will improve detection accuracy when
combined with blood markers
B-8
or molecular imaging targets. Ciphergen in collaboration with
Johns Hopkins has performed two independent studies to identify
blood markers for DCIS and stage I breast cancer. The first
study examined 169 women with varying stages of breast cancer,
benign disease, and healthy women, and the second study examined
176 women from a different medical center as independent
validation. Ciphergen is currently performing a 350 woman
multi-center validation study to confirm the two markers
identified in the previous studies.
Peripheral arterial disease. This disease
affects 12 million Americans and is underdiagnosed and
undertreated. With the rising incidence of diabetes, the
incidence of peripheral arterial disease, or PAD, is expected to
increase concomitantly. The absence of a good blood test
contributes to the underdiagnosis of PAD. Ciphergen in
collaboration with Stanford University has performed both an
initial discovery study and a first validation study that has
resulted in the identification of a novel biomarker for PAD.
Ongoing efforts are aimed at further validating this marker in
combination with additional cardiovascular biomarkers.
Thrombotic thrombocytopenic purpura. This
disease affects approximately 1,000 Americans annually and is
life threatening in the absence of appropriate treatment, which
is usually plasmaphoresis. Undertreatment can lead to increased
mortality from the disease while overtreatment wastes precious
resources. In addition, patients with TTP need to be monitored
for clinical response to therapy. Because the pathophysiology of
TTP is known to be a result of a defect in the activity of the
enzyme ADAMTS13, mass spectrometry was a logical approach to
develop an accurate and quantitative assay to measure this
enzymatic activity. Final assay development is under way.
Assisted reproductive technology. There has
been increased use of ART to facilitate pregnancies, either in
women who are infertile or who have waited to have babies.
Currently, it is difficult to predict which embryos will lead to
viable fetuses and successful live births. Therefore, women may
go through multiple cycles of induction and implantation
and/or may
have multiple embryos implanted. Implantation cycles are
expensive, and multiple implantations often result in multiple
gestations. Therefore a test that can improve the probability
that an implanted embryo will result in a live birth will reduce
overall costs associated with ART and may reduce the number of
multiple gestations. SELDI-TOF-MS profiling of conditioned media
derived from cultured embryos has revealed a series of proteins
that may improve in discriminating between embryos that are more
likely to successfully implant versus those that are not. These
results are currently undergoing validation.
Commercialization
If we are successful at discovering biomarkers and panels of
biomarkers that have diagnostic utility, our commercialization
strategy includes partnering with other parties to assist in the
development and commercialization of our initial tests. In July,
2005, we entered into a strategic alliance agreement with Quest
Diagnostics covering a three year period during which the
parties have agreed to develop and commercialize up to three
diagnostic tests based on SELDI technology. In connection with
this strategic alliance, Quest Diagnostics invested
$15 million in Ciphergen and received a warrant to invest
an additional $7.7 million. In addition, Quest Diagnostics
agreed to loan Ciphergen up to $10 million to pay
certain costs and expenses related to the strategic alliance,
which loan is forgiveable based upon the achievement of certain
milestones related to the development of diagnostic tests.
We expect to commercialize and sell diagnostic tests in two
phases. The first phase (the ASR phase) will involve
the sale of analyte specific reagents (ASR) to
certain customers coupled with the grant to such customer of a
sublicense to perform the laboratory test using the methodology
covered by the relevant license obtained from our
collaborator(s), e.g., a test for ovarian cancer covered by
licenses from Johns Hopkins and the M. D. Anderson Cancer
Center. ASRs are the raw materials which we will resell or make
ourselves and which are utilized by clinical laboratories to
develop and perform homebrew laboratory tests in
CLIA-regulated laboratories (i.e., laboratories regulated under
the federal Clinical Laboratory Improvement Amendments of 1988
[CLIA]). During the second phase (the IVD
phase), we plan to assemble and sell in vitro
diagnostic, or IVD, test kits, which have been cleared by
the FDA, to customers together with SELDI instruments which we
expect to purchase from Bio-Rad.
Under our strategic alliance agreement, Quest Diagnostics has
the exclusive right to perform up to three ASR laboratory tests
and, once we begin manufacturing a test kit for each of such
tests, we expect that Quest Diagnostics will cease producing the
homebrew tests and will purchase FDA-cleared IVD test kits from
Ciphergen. Quest Diagnostics will have the exclusive right to
perform such test and market test kits purchased from Ciphergen
in the United States, Mexico, the United Kingdom and other
countries, such as Brazil, where Quest Diagnostics operates a
B-9
clinical laboratory for up to five years following
commercialization of each respective test (referred to as the
Exclusive Period) with non-exclusive rights to commercialize
these tests in the rest of the world, subject to a royalty
payable to Ciphergen. Upon expiration of the Exclusive Period,
Quest Diagnostics exclusive rights will become
non-exclusive.
During the ASR phase for a given test, and so long as the
Exclusive Period continues, we will sell ASRs and grant rights
to perform such tests to Quest Diagnostics and to other
reference laboratories, hospitals and medical clinics in
countries where Quest diagnostics does not operate a clinical
laboratory. Once the IVD phase begins for a given test, and so
long as the Exclusive Period continues for that particular test,
we will sell test kits and instruments to Quest Diagnostics. At
the end of the Exclusive Period with respect to any test kit,
Quest Diagnostics exclusive right to perform tests using
such test kit will become non-exclusive. In addition to
continuing to sell test kits to Quest Diagnostics, we will then
also sell test kits to commercial clinical laboratories in the
United States, Mexico, the United Kingdom and other countries
which were exclusive to Quest Diagnostics during the Exclusive
Period. In addition to working through Quest Diagnostics,
Ciphergen intends to seek partnerships for commercialization
purposes with traditional in vitro diagnostic
companies
and/or with
clinical reference labs in territories where Quest Diagnostics
does not have exclusive rights.
Customers
Ciphergen expects that Quest Diagnostics and future
commercialization partners, reference laboratories, hospitals
and medical clinics that perform diagnostic testing will be the
primary users of instruments, chips and future diagnostic
products which we may develop and that those customers, along
with our collaborators, will continue to be the primary users of
instruments and arrays that we may develop or sell. Pursuant to
the manufacture and supply agreement with Bio-Rad, Bio-Rad has
agreed to supply Ciphergen with SELDI instruments and
ProteinChip arrays previously manufactured by us. If Bio-Rad
develops new products using SELDI technology, Bio-Rad has agreed
to supply those products to Ciphergen to sell to its customers.
Ciphergen can also request that Bio-Rad develop and manufacture
new products to written specifications and the parties will
negotiate in good faith the terms of purchasing such products.
Competition
The diagnostics industry in which Ciphergen operates is
competitive and evolving. There is intense competition among
healthcare, biotechnology, and diagnostic companies attempting
to discover candidates for potential new diagnostic products.
These companies may:
|
|
|
|
|
develop new diagnostic products in advance of Ciphergen or its
collaborators;
|
|
|
|
develop diagnostic products which are more effective or more
cost-effective than those developed by Ciphergen or its
collaborators;
|
|
|
|
obtain regulatory clearance or approval of their diagnostic
products more rapidly than Ciphergen or its
collaborators; or
|
|
|
|
obtain patent protection or other intellectual property rights
that would limit Ciphergens or its collaborators
ability to develop and commercialize, or their customers
ability to use, Ciphergens, or its collaborators,
diagnostic products.
|
Ciphergen competes with companies in the U.S. and abroad that
are engaged in the development and commercialization of novel
biomarkers that may form the basis of novel diagnostic tests.
These companies may develop products that are competitive with
the products offered by Ciphergen or its collaborators, such as
analyte specific reagents or diagnostic test kits, that perform
the same or similar purposes as Ciphergens or its
collaborators products. Also, clinical laboratories may
offer testing services that are competitive with the products
sold by Ciphergen or its collaborators. For example, a clinical
laboratory can use either reagents purchased from manufacturers
other than Ciphergen, or use its own internally developed
reagents, to make diagnostic tests. If clinical laboratories
make tests in this manner for a particular disease, they could
offer testing services for that disease as an alternative to
products sold by Ciphergen used to test for the same disease.
The testing services offered by clinical laboratories may be
easier to develop and market than test kits developed by
Ciphergen or its
B-10
collaborators because the testing services are not subject to
the same clinical validation requirements that are applicable to
FDA-cleared or approved diagnostic test kits. The diagnostic
testing services market is estimated to be approximately
$40 billion. A substantial portion of all sales of
diagnostic products are made to a small number of clinical
reference laboratories such as Quest Diagnostics Incorporated
and Laboratory Corporation of America Holdings, which together
account for close to 20% of the testing services market.
Therefore, Ciphergen expects to rely on clinical reference
laboratories for a substantial portion of its sales.
Ciphergens inability to establish or maintain one or more
of these laboratories as a customer could adversely affect its
business, financial condition, and operating results.
Research
and Development
Ciphergens research and development efforts towards
developing novel high-value diagnostic tests focus on two
synergistic activities. First, Ciphergen is dedicated to
developing new approaches to investigate the human proteome.
Second, Ciphergen utilizes these new technologies to discover
biomarkers that can address unmet clinical needs. A major area
of our research and development activities centers around
efforts to discover and validate biomarkers and patterns of
biomarkers that can be developed into diagnostic assays. We do
this both through in-house programs and through collaborations
we have established with The Johns Hopkins School of Medicine,
The University of Texas M. D. Anderson Cancer Center and
University College London, among others.
In applied research, we are developing new applications and
reagents for quantitative differential protein expression
analysis, protein interaction assays and protein
characterization. Our efforts are particularly focused on
discovery and quantitative analysis of low-abundance proteins
present in complex samples such as plasma, serum and urine. We
have demonstrated that the surface chemistries immobilized on
ProteinChip Arrays have similar protein selectivity to those
chemistries immobilized on higher capacity bead formats,
facilitating the transition from discovery on arrays to small
scale purification on beads as well as orthogonal purification.
Using these approaches, we seek to improve the speed and
efficiency of designing protein separation strategies at any
scale based on the predictive information obtained using
ProteinChip Systems. We believe these methods will accelerate
the identification of discovered biomarkers.
Ciphergens activities in research and development will
maintain a strong focus in protein separation technologies, but
will be intently focused on development (i.e., taking research
tools and developing them into practical, usable tools for
biomarker discovery and assay). Research will initially focus on
three major tasks:
|
|
|
|
|
Making
Equalizertm
bead technology practical for biomarker discovery
|
|
|
|
Making multi-select technology practical for biomarker discovery
|
|
|
|
Clinical assay development using novel proteomics technologies
|
These objectives will maintain Ciphergens competitive edge
in biomarker discovery abilities, and will be critical in our
ability to improve on our current diagnostic tests under
development as well as to develop and foster a pipeline of
diagnostic tests. The new proteomic analysis tools that
Ciphergen has developed are intended to provide Ciphergen an
important advantage in the race to discover novel biomarkers.
The complexity of the human proteome has hindered efforts to
develop a comprehensive database of expressed proteins and their
post-translational modifications. Consequently, entities that
are able to leverage novel protein separation tools will have an
advantage in analyzing clinical samples to identify biomarkers
for disease. Ciphergen has focused on developing solutions to
the problem of separating proteins to increase the number of
proteins that can be detected and characterized while
maintaining a level of throughput that permits running enough
numbers of clinical samples to achieve statistical significance.
These novel solutions are embodied in tools such as Equalizer
Beads and multi-select and mini-select technologies. These tools
have been applied to clinical samples that may be used to
address diagnostic questions in hematology/oncology,
womens health, and cardiovascular disease, as described
above.
Intellectual
Property
Our intellectual property includes a portfolio of owned,
co-owned or licensed patents and patent applications. As of
July 31, 2006, our patent portfolio included 36 issued U.S.
patents, 100 pending U.S. patent applications and numerous
pending patent applications and issued patents outside the U.S.
These patents and patent applications are
B-11
directed to several areas of technology important to our
business, including the core SELDI technology and its
applications, protein biochips, instrumentation, software and
biomarkers. The issued patents covering the SELDI and Retentate
Chromatography mass spectrometry technologies expire at various
times from 2013 to 2019. Pursuant to the asset purchase
agreement, Bio-Rad acquired certain proprietary rights used in
the research tools business. At the closing of the asset
purchase, we will enter into a cross license agreement with
Bio-Rad pursuant to which we will retain the right to
commercially exploit those proprietary rights, including SELDI
technology, in the clinical diagnostics market. The clinical
diagnostics market includes laboratories engaged in the research
and development and/or manufacture of diagnostic tests using
biomarkers, commercial clinical laboratories, hospitals and
medical clinics that perform diagnostic tests. Ciphergen has
been granted exclusive rights to commercialize the proprietary
rights in the clinical diagnostics market during a five-year
exclusivity period. After the end of the five-year period, we
and Bio-Rad will share exclusive rights. Ciphergen and Bio-Rad
each have the right to engage in negotiations with the other
party for a license to any improvements in the proprietary
rights created by the other party.
The rights to the core SELDI technology are derived through
royalty-bearing sublicenses from Molecular Analytical Systems,
Inc., or MAS. MAS holds an exclusive license to patents directed
to the SELDI technology from the owner, Baylor College of
Medicine. MAS granted certain rights under these patents to our
wholly owned subsidiaries, IllumeSys Pacific, Inc. and Ciphergen
Technologies, Inc. in 1997. We obtained further rights under the
patents in 2003 through sublicenses and assignments executed as
part of the settlement of a lawsuit between Ciphergen, MAS,
LumiCyte and T. William Hutchens. Together, the sublicenses and
assignments provide all rights to develop, make and have made,
use, sell, import, market and otherwise exploit products and
services covered by the patents throughout the world in all
fields and applications, both commercial and non-commercial. The
sub licenses carry the obligation to pay MAS a royalty equal to
2% of SELDI-related revenues recognized between
February 21, 2003 and the earlier of (i) May 28,
2014, or (ii) the date on which the cumulative payments to
MAS have reached $10,000,000. Through June 30, 2006, we had
paid or accrued a total of approximately $2.5 million in
such royalties.
We hold licenses or options to license biomarkers developed
using SELDI technology, and related intellectual property. As of
July 31, 2006, 41 of our patent applications are directed
to biomarker inventions. These include applications in the areas
of cancer, cardiovascular disease, infectious disease,
neurodegenerative disease and womens health. We are
currently negotiating an extension of the term of our
collaboration agreement with The Johns Hopkins School of
Medicine to patent applications directed to biomarkers for
ovarian cancer that we intend to commercialize as an ovarian
cancer diagnostic test. Other institutions and companies from
which we hold options to license intellectual property related
to biomarkers include University College London (England), The
University of Texas M. D. Anderson Cancer Center, University of
Kentucky, McGill University (Canada), Eastern Virginia Medical
School, Aaron Diamond AIDS Research Center, The University of
Texas Medical Branch, Göteborg University (Sweden),
University of Kuopio (Finland) and the Netherlands Cancer
Institute (Netherlands).
Manufacturing
Assuming shareholder approval of the asset sale to Bio-Rad,
Bio-Rad will take over Ciphergens manufacturing operations
and pursuant to the manufacture and supply agreement with
Bio-Rad, Bio-Rad has agreed to manufacture and Ciphergen has
agreed to purchase from Bio-Rad the ProteinChip Systems and
ProteinChip Arrays (collectively referred to as the research
tools products) required to support its diagnostics efforts. If
Bio-Rad fails to supply any research tools products to
Ciphergen, including any new research tools products developed
by Bio-Rad for sale to its customers or any new research tools
products Ciphergen has requested Bio-Rad to make and sell to
Ciphergen, under certain conditions Ciphergen has the right to
manufacture or have such research tools products manufactured by
a third party for Ciphergens own use and sale to its
customers and collaborators in the clinical diagnostics market,
subject to payment of a reasonable royalty to Bio-Rad on sales
of such research tools products. In the event that Bio-Rad is
unable to provide the ProteinChip instruments, arrays and
supplies as required, there is no guarantee that we will be able
to find such a third party supplier, or that the cost of
purchasing these items will be commercially reasonable. If we
are not able to obtain the necessary ProteinChip instruments,
arrays, and supplies, our ability to develop diagnostic products
will be adversely affected.
B-12
Ciphergen will be responsible for assuring through its incoming
quality control process that the research tools products it
purchases from Bio-Rad will comply with applicable government
regulations. During 2005, Ciphergen enhanced its quality control
systems in order to comply with U.S. Food and Drug
Administration, or FDA, regulations; that compliance has been
reviewed through an independent audit. Ciphergen believes it is
prepared to fulfill its obligation to assure that such research
tools products are in compliance with the FDAs Quality
System Regulations, or QSRs, in 2006.
Environmental
Matters
Medical
Waste
We are subject to licensing and regulation under federal, state
and local laws relating to the handling and disposal of medical
specimens and hazardous waste as well as to the safety and
health of laboratory employees. Our laboratory facility in
Fremont, California is operated in material compliance with
applicable federal and state laws and regulations relating to
disposal of all laboratory specimens. We utilize outside vendors
for disposal of specimens. We cannot eliminate the risk of
accidental contamination or discharge and any resultant injury
from these materials. Federal, state and local laws and
regulations govern the use, manufacture, storage, handling and
disposal of these materials. We could be subject to damages in
the event of an improper or unauthorized release of, or exposure
of individuals to, hazardous materials. In addition, claimants
may sue us for injury or contamination that results from our
use, or the use by third parties, of these materials, and our
liability may exceed our total assets. Compliance with
environmental laws and regulations is expensive, and current or
future environmental regulations may impair our research,
development or production efforts.
Occupational
Safety
In addition to its comprehensive regulation of safety in the
workplace, the Federal Occupational Safety and Health
Administration has established extensive requirements relating
to workplace safety for healthcare employers, including clinical
laboratories, whose workers may be exposed to blood-borne
pathogens such as HIV and the hepatitis virus. These
regulations, among other things, require work practice controls,
protective clothing and equipment, training, medical follow-up,
vaccinations and other measures designed to minimize exposure to
chemicals and transmission of the blood-borne and airborne
pathogens. Although we believe that we are currently in
compliance in all material respects with such federal, state and
local laws, failure to comply could subject us to denial of the
right to conduct business, fines, criminal penalties and other
enforcement actions.
Specimen
Transportation
Regulations of the Department of Transportation, the
International Air Transportation Agency, the Public Health
Service and the Postal Service apply to the surface and air
transportation of clinical laboratory specimens.
Government
Regulation
General
Our future activities related to diagnostics products are, or
have the potential to be, subject to regulatory oversight by the
FDA under provisions of the Federal Food, Drug and Cosmetic Act
and regulations thereunder, including regulations governing the
development, marketing, labeling, promotion, manufacturing and
export of our products. Failure to comply with applicable
requirements can lead to sanctions, including withdrawal of
products from the market, recalls, refusal to authorize
government contracts, product seizures, civil money penalties,
injunctions and criminal prosecution.
Generally, certain categories of medical devices, a category
that may be deemed to include potential future products based
upon the
ProteinChip®
platform, may require FDA 510(k), or 510(k) de novo
clearance or pre-market approval. Although the FDA believes it
has jurisdiction to regulate in-house laboratory tests, or
home brews, that have been developed and validated
by the laboratory providing the tests, the FDA has not, to date,
actively regulated those tests. Active ingredients
(known as analyte specific reagents or
ASRs) that are sold to laboratories for use in tests
developed in house by clinical laboratories generally do not
require FDA approval or
B-13
clearance. ASRs generally do not require FDA clearance or
pre-market approval if they are (1) sold to clinical
laboratories certified by the government to perform high
complexity testing, (2) manufactured in compliance with the
FDAs QSRs, and (3) labeled in accordance with FDA
requirements, including a statement that their analytical and
performance characteristics have not been established. A similar
statement would also be required on all advertising and
promotional materials relating to ASRs, such as those used in
certain of our proposed future tests. We believe that clinical
laboratory testing based upon our ProteinChip platform, and any
ASRs that we intend to sell to clinical reference laboratories,
currently would not require FDA clearance or approval. The FDA
has publicly stated it is reevaluating its ASR policy, and it is
possible that future revisions to FDA policies may have the
effect of increasing the regulatory burden on manufacturers of
these devices. The commercialization of our products and
services could be impacted by being delayed, halted or
prevented. We cannot be sure that tests based upon the
ProteinChip platform, or a combination of reagents, will not
require FDA 510(k), 510(k) de novo clearance or
pre-market approval.
Regardless of whether a medical device requires FDA approval or
clearance, a number of other FDA requirements apply to the
manufacturer of such a device and to those who distribute it.
Device manufacturers must be registered and their products
listed with the FDA, and certain adverse events, corrections and
removals must be reported to the FDA. The FDA also regulates the
product labeling, promotion and, in some cases, advertising of
medical devices. Manufacturers must comply with the FDAs
QSRs, which establish extensive requirements for design, quality
control, validation and manufacturing. Thus, manufacturers and
distributors must continue to spend time, money and effort to
maintain compliance, and failure to comply can lead to
enforcement action. The FDA periodically inspects facilities to
ascertain compliance with these and other requirements.
Diagnostic
Kits
The Food, Drug and Cosmetic Act requires that medical devices
introduced to the U.S. market, unless exempted by regulation, be
the subject of either a premarket notification clearance, known
as a 510(k) or (510(k) de novo, or a premarket approval,
known as a PMA. Some of our potential future clinical products
may require a 510(k) or (510(k) de novo, others may
require a PMA. Other products, like ASRs, may be exempt from
regulatory clearance or approval.
With respect to devices reviewed through the 510(k) process, we
may not market a device until an order is issued by the FDA
finding our product to be substantially equivalent to a legally
marketed device known as a predicate device. A 510(k) submission
may involve the presentation of a substantial volume of data,
including clinical data. The FDA may agree that the product is
substantially equivalent to a predicate device and allow the
product to be marketed in the U.S. On the other hand, the
FDA may determine that the device is not substantially
equivalent and require a PMA, or require further information,
such as additional test data, including data from clinical
studies, before it is able to make a determination regarding
substantial equivalence. By requesting additional information,
the FDA can further delay market introduction of our products.
If the FDA indicates that a PMA is required for any of our
potential future clinical products, the application will require
extensive clinical studies, manufacturing information and likely
review by a panel of experts outside the FDA. Clinical studies
to support either a 510(k) submission or a PMA application would
need to be conducted in accordance with FDA requirements.
Failure to comply with FDA requirements could result in the
FDAs refusal to accept the data or the imposition of
regulatory sanctions. There can be no assurance that we will be
able to meet the FDAs requirements or receive any
necessary approval or clearance.
Once granted, a 510(k) clearance or PMA approval may place
substantial restrictions on how our device is marketed or to
whom it may be sold. Even in the case of devices like ASRs, many
of which are exempt from 510(k) clearance or PMA approval
requirements, the FDA may impose restrictions on marketing. Our
potential future ASR products may be sold only to clinical
laboratories certified under CLIA to perform high complexity
testing. In addition to requiring approval or clearance for new
products, the FDA may require approval or clearance prior to
marketing products that are modifications of existing products
or the intended uses of these products. We cannot assure that
any necessary 510(k) clearance or PMA approval will be granted
on a timely basis, or at all. Delays in receipt of or failure to
receive any necessary 510(k) clearance or PMA approval, or the
imposition of stringent restrictions on the labeling and sales
of our products, could have a material adverse effect on us.
B-14
As a medical device manufacturer, we are also required to
register and list our products with the FDA. In addition, we are
required to comply with the FDAs QSRs, which require that
our devices be manufactured and records be maintained in a
prescribed manner with respect to manufacturing, testing and
control activities. Further, we are required to comply with FDA
requirements for labeling and promotion. For example, the FDA
prohibits cleared or approved devices from being promoted for
uncleared or unapproved uses. In addition, the medical device
reporting regulation requires that we provide information to the
FDA whenever there is evidence reasonably to suggest that one of
our devices may have caused or contributed to a death or serious
injury, or where a malfunction has occurred that would be likely
to cause or contribute to a death or serious injury if the
malfunction were to recur.
Our manufacturing facilities are subject to periodic and
unannounced inspections by the FDA and state agencies for
compliance with QSRs. Additionally, the FDA will generally
conduct a preapproval inspection for PMA devices. Although we
believe we will be able to operate in compliance with the
FDAs QSRs for ASRs, we have never been inspected by the
FDA and cannot assure that we will be able to maintain
compliance in the future. If the FDA believes that we are not in
compliance with applicable laws or regulations, it can issue a
warning letter, detain or seize our products, issue a recall
notice, enjoin future violations and assess civil and criminal
penalties against us. In addition, approvals or clearances could
be withdrawn under certain circumstances. Failure to comply with
regulatory requirements or any adverse regulatory action could
have a material adverse effect on us.
Any customers using our products for clinical use in the
U.S. may be regulated under CLIA. CLIA is intended to
ensure the quality and reliability of clinical laboratories in
the U.S. by mandating specific standards in the areas of
personnel qualifications, administration, participation in
proficiency testing, patient test management, quality control,
quality assurance and inspections. The regulations promulgated
under CLIA establish three levels of diagnostic
tests namely, waived, moderately complex and highly
complex and the standards applicable to a clinical
laboratory depend on the level of the tests it performs. We
cannot assure you that the CLIA regulations and future
administrative interpretations of CLIA will not have a material
adverse impact on us by limiting the potential market for our
potential future products.
Medical device laws and regulations are also in effect in many
of the countries in which we may do business outside the
U.S. These range from comprehensive device approval
requirements for some or all of our potential future medical
device products, to requests for product data or certifications.
The number and scope of these requirements are increasing.
Medical device laws and regulations are also in effect in some
states in which we do business. There can be no assurance that
we will obtain regulatory approvals in such countries or that we
will not incur significant costs in obtaining or maintaining
foreign regulatory approvals. In addition, export of certain of
our products which have not yet been cleared or approved for
domestic commercial distribution may be subject to FDA export
restrictions.
Employees
As of July 31, 2006, we had 140 full-time employees
worldwide, including 64 in sales and marketing, 26 in research
and development, 30 in manufacturing and 20 in administration.
We also had an additional 17 individuals engaged as independent
contractors. None of our U.S. employees is covered by a
collective bargaining agreement, though many of our European
employees are covered under national labor agreements. We
believe that our relations with our employees are good.
Ciphergens success will depend in large part on our
ability to attract and retain skilled and experienced employees.
Following the closing of the Bio-Rad transaction, we expect
initially to have approximately 40 full-time employees.
Ciphergen has recruited senior management with experience in
diagnostics, laboratory medicine, and clinical medicine. Senior
managers are described here.
|
|
|
|
|
Gail S. Page, President and CEO. From August 2005 to December
2005, Ms. Page was President and Chief Operating Officer,
and prior to August 2005 she was President of Ciphergens
Diagnostics Division and an Executive Vice President of
Ciphergen Biosystems, Inc. From October 2000 to January 2003,
she was the Executive Vice President and Chief Operating Officer
of Luminex Corporation. From 1988 to 2000, she held various
senior level management positions with Laboratory Corporation of
America. In 1993, she was named Senior Vice President, Office of
Science and Technology at LabCorp, responsible for the
management of scientific affairs in addition to the diagnostics
business segment. Additionally, from 1995 to 1997,
|
B-15
|
|
|
|
|
she headed the Cytology and Pathology Services business unit for
LabCorp. From 1988 to 2000, she was a member of the Scientific
Advisory Board and chair from 1993 to 1997.
|
|
|
|
|
|
Michael R. Acosta, Vice President of Quality Assurance and
Regulatory Affairs, joined us in July 2005. Mr. Acosta has
26 years of experience in the pharmaceutical, medical
device and biotech industries. He has spent his entire career in
quality assurance and regulatory affairs. Prior to joining
Ciphergen, Mr. Acosta spent 7 years working for
HemoSense, Inc., a
start-up
medical device company in the Silicon Valley that completed a
successful IPO in 2005. He has also worked for several other
start-up
companies and large companies, such as CR Bard, Baxter, and Alza
Corp. Mr. Acosta brings both domestic and international
regulatory experience to Ciphergen and has a successful track
record with many regulatory agencies.
|
|
|
|
Eric T. Fung, MD, PhD, Chief Scientific Officer, joined us in
2000 as a lead scientist in the newly-formed Biomarker Discovery
Center®
laboratories. He became Chief Scientific Officer in June 2006,
prior to that he was most recently Head of Clinical and Medical
Affairs. Prior to joining Ciphergen, Dr, Fung was a Howard
Hughes sponsored researcher at Stanford University.
Dr. Fung has anatomic pathology training from Stanford
Medical School and obtained his MD and PhD degrees from The
Johns Hopkins University School of Medicine. He graduated with a
BS with honors from the California Institute of Technology.
Dr. Fung also currently holds an Adjunct Assistant
Professor position in the Department of Pathology at The Johns
Hopkins University School of Medicine.
|
|
|
|
James P. Merryweather, PhD, Executive Vice President, Sales and
Marketing, joined us in March 2005. Prior to joining Ciphergen,
Dr. Merryweather spent five years at Incyte Corporation,
most recently as Executive Vice President of Business
Development & Commercial Operations. Prior to joining
Incyte, he was at Millennium Pharmaceuticals as Vice President,
Program Management. Prior to joining Millennium, he spent
15 years at Chiron Corporation in a variety of roles
ranging from Senior Scientist to Director of Project Management.
Dr. Merryweather has spent over 20 years in the
biotechnology industry in senior positions in Research and
Development, Program Management and Business Development.
Dr. Merryweather graduated with a BS degree in Chemistry
from Northern Illinois University and a PhD in Biochemistry from
Washington State University.
|
|
|
|
Simon Shorter, PhD, Vice President of Corporate Business
Development, joined us in September 2004, as Vice President of
Business Development, Diagnostics Division. Prior to joining
Ciphergen, Dr. Shorter held a series of management
positions in R&D, Sales & Marketing and Business
Development at Adeza Biomedical Corporation. Over a
12-year-period,
Dr. Shorter developed an in-depth, practical understanding
of the clinical laboratory and IVD market segments.
Dr. Shorter received his BS degree in Biological Sciences
from The Kings College, University of London, and
subsequently attended University College London, where he
completed a MS degree in Applied Molecular Biology and
Biotechnology. At the University of Oxford, he earned his PhD in
Cellular Biology and Immunology of Human Development followed by
a Post Doctoral Research Fellowship at the University of
California, San Francisco in the immunological basis for
the survival of fetus during human placental development.
|
|
|
|
William C. Sullivan, Vice President of Corporate Operations,
joined us in February 2004, as Vice President, Diagnostics
Operations. Mr. Sullivan has spent over 25 years in
the diagnostics industry, covering all aspects of clinical
laboratory operations and diagnostic manufacturing, including
quality systems, product development, technical transfer,
customer support and operations management. Prior to joining us,
Mr. Sullivan had been serving as a medical device
consultant since 2001. From 1999 to 2001, he was Vice President,
Diagnostic Manufacturing at Visible Genetics, Inc. and from 1998
to 1999, he was Vice President, Operations at Nichols Institute
Diagnostics (a subsidiary of Quest Diagnostics). From 1997 to
1998, Mr. Sullivan was Vice President, Operations at Dianet
Med and from 1989 to 1997, he served at Laboratory Corporation
of America and its predecessor Roche Biomedical in a succession
of positions covering manufacturing operations.
Mr. Sullivan received a BA degree from the College of the
Holy Cross and subsequently attended graduate school at the
University of Pennsylvania. He holds certification as a
Specialist in Immunology from the American Society for Clinical
Pathology.
|
|
|
|
Egisto Boschetti, PhD, Vice President of Research and
Development joined Ciphergen as a result of the BioSepra
acquisition in July 2001. Internationally recognized as an
expert in protein separation by
|
B-16
|
|
|
|
|
chromatography, he served BioSepra and its predecessors as
Research Director since the inception of that business in the
late 1970s. Dr. Boschetti has a degree in
biochemistry from the University of Bologna (Italy) and an MBA
(Paris). He will continue to be engaged with our management team
following the closing of the asset sale.
|
In addition, in 2006, Ciphergen established a Scientific
Advisory Board composed of world-class scientists to assist in
directing the Companys product development strategies.
Members of the Scientific Advisory Board are distinguished
members of academia and industry, with experience in diagnostic
test development and commercialization. These scientists will
meet regularly with our senior management team to help leverage
our intellectual property portfolio, guide our resource
allocation, and evaluate our ongoing diagnostic programs and
prioritize them towards commercialization. Members of the
Scientific Advisory Board are described here.
|
|
|
|
|
Robert C. Bast, Jr., MD, is Vice President for
Translational Research and the Harry Carothers Wiess
Distinguished University Professor for Cancer Research at The
University of Texas M. D. Anderson Cancer Center. Dr. Bast
is best known for developing the Ovarian Cancer (OC) 125
monoclonal antibody that led to the production of the CA125
radioimmunoassay. Serum CA125 levels have provided the first
generally useful marker for monitoring the course of patients
with epithelial ovarian cancer. CA 125 is currently being
evaluated as one component of a screening strategy for ovarian
cancer. Dr. Bast has published more than 500 articles and
chapters, and has edited the textbook Cancer Medicine. He
continues to care for patients with breast and ovarian cancer
and has been listed in the Best Doctors of America and in
Americas Top Physicians. Dr. Bast received his
BA degree cum laude from Wesleyan University and his MD
magna cum laude from Harvard Medical School.
|
|
|
|
Daniel W. Chan, PhD, DABCC, FACB, is Professor of Pathology,
Oncology, Urology and Radiology, Director of Clinical Chemistry
Division, Department of Pathology, and the Director, Center for
Biomarker Discovery at The Johns Hopkins University School of
Medicine. Dr. Chan is an internationally recognized
authority in clinical chemistry, proteomics, immunoassay, and
biochemical tumor markers (particularly breast and prostate
cancer markers). He is particularly well known as a leader in
the concept and methodology of the clinical usefulness of
prostate-specific antigen (PSA) as a marker for prostate cancer.
He has published over 200 scientific articles, five books on
immunoassay automation, endocrinology, and tumor markers. His
research has led to major findings showing the importance of
analytical methodologies of laboratory testing in diagnosing,
managing, and understanding human cancers. He is the
editor-in-chief
of the journal Clinical Proteomics. Dr. Chan received his
PhD from the State University of New York at Buffalo.
|
|
|
|
Ian Jacobs, MD, FRCOG, is Director of the Department of
Gynecological Oncology and of the Institute of Womens
Health at University College London. Professor Jacobs is
recognized as one of Europes leading academic
gynecological oncologists and is President of the European
Society of Gynaecological Oncologists. His research includes
heading the UK Collaborative Trial of Ovarian Cancer Screening
involving 200,000 women in the UK, as well as laboratory studies
of the genetic basis of gynecological cancers. Professor
Jacobs clinical activities and expertise include the
surgical management of gynecological cancer, management of
familial cancer and screening for ovarian and cervical cancer.
Professor Jacobs has authored or co-authored more than 200
articles, reviews and chapters. He qualified at Cambridge
University and London University before training in clinical
medicine and research in Cambridge, at Duke University and at
The Royal London, St Bartholomews and Royal Marsden
Hospitals in London.
|
|
|
|
Joyce G. Schwartz, MD, is Vice President & Chief
Laboratory Officer of Quest Diagnostics Incorporated.
Dr. Schwartz is responsible for medical operations and
medical quality for the companys core laboratory testing
business. Dr. Schwartz is board-certified in anatomic and
clinical pathology, with many years of academic and hospital
experience. Prior to joining Quest Diagnostics,
Dr. Schwartz held a tenured position as Professor at The
University of Texas Health Science Center at San Antonio.
She received her BS and MA degrees from the University of Texas
at Austin and she received her medical degree from The
University of Texas Health Science Center at San Antonio,
where she served as Chief Resident in Anatomic and Clinical
Pathology. Dr. Schwartz has published over 80 articles in
peer reviewed medical and scientific publications.
|
B-17
|
|
|
|
|
William Wallen, PhD, is Senior Vice President and Chief
Scientific Officer of Idexx Laboratories, Inc., a worldwide
leader in innovative products and services for veterinary, food
and water applications. Before joining Idexx, Dr. Wallen
was Senior Vice President and Head, Office of Technology for the
Diagnostics Division of Bayer Healthcare. In his 10 years
with Bayer, Dr. Wallen held various senior scientific and
leadership positions, including as Head of Research and
Development for Bayers laboratory testing and Head of
Research for the nucleic acid diagnostics segment. He has
authored or co-authored more than 50 scientific papers and
articles covering topics in immunology, virology, oncology and
detection methodologies. Dr. Wallen earned his BS degree in
zoology, his MS degree in microbiology from Michigan State
University and his PhD in Molecular Biology from the University
of Arizona College of Medicine.
|
B-18
ANNEX C:
FAIRNESS OPINION
August 14, 2006
Confidential
Board of Directors
Ciphergen Biosystems, Inc.
6611 Dumbarton Circle
Fremont CA, 94555
Members of the Board of Directors:
We have been engaged to evaluate the fairness, from a financial
point of view, to the holders of outstanding shares of the
common stock of Ciphergen Biosystems, Inc., a Delaware
Corporation (Ciphergen or the Company),
of the proposed sale (the Sale) of the assets of
Ciphergens tools business to Bio-Rad Laboratories, Inc
(Bio-Rad) for the consideration (the Sale
Consideration) as per the agreement between Ciphergen and
Bio-Rad (the Asset Purchase Agreement).
In arriving at our opinion (the Opinion), we have
had numerous discussions with management about Ciphergens
operations, financial condition and prospects with respect to
both its tools business and its diagnostics business. We have
reviewed the Asset Purchase Agreement, including the schedules
and exhibits thereto, and analyzed financial and other
information that was publicly available or furnished to us by
the Company, including information provided to us during
discussions with the management of Ciphergen. Included in the
information provided during such discussions were historical
audited financial data of Ciphergen and certain financial
projections of Ciphergen and its tools business prepared by its
management. In addition, we have compared certain financial data
of Ciphergens tools business with various other companies
in generally similar industries with generally similar business
and financial characteristics whose securities are traded in
public markets and conducted such other financial studies and
analyses as we deemed appropriate for purposes of this Opinion.
We did not rely on any one particular financial analysis or
methodology, but formulated our Opinion on the whole of such
analyses.
In rendering our Opinion, we have assumed that the Sale will be
consummated on all material terms described in the Asset
Purchase Agreement. We have relied upon and assumed, without
independent verification, the accuracy and completeness of all
the financial and other information that was reviewed by us,
whether obtained from public sources or provided to us by the
Company. In particular, we have relied upon the estimates and
projections of the management of Ciphergen, which was the basis
of our financial model for the Company. With respect to the
financial projections supplied to us, we have assumed that the
forecasts presented to us by the management team of the Company
were reasonably prepared in good faith and reasonably reflect
the best currently available estimates and judgments of the
management of Ciphergen regarding the future operating and
financial performance of the Company and its tools business. In
addition, we have not assumed any responsibility for making any
independent evaluation or appraisal of the assets or liabilities
of the Company. Oppenheimer has not engaged in any legal
analysis or review of the Agreement itself nor had any such
analysis or review conducted on its behalf and has assumed that
all legal requirements for consummation of the Sale have or will
be complied with. We express no view as to the federal, state or
local tax consequences of the Sale Consideration or to the
accounting treatment of the Sale.
We express no view as to, and our Opinion does not address, the
underlying business decision of Ciphergen to effect the Sale nor
were we requested to consider the relative merits of the Sale as
compared to any other transaction in which Ciphergen might
engage.
C-1
Our Opinion is based on economic, market, financial and other
conditions as they currently exist, and on the information made
available to us as of the date of this letter, and is limited to
the fairness, as of the date hereof, from a financial point of
view, of the Sale Consideration. It should be understood that,
although subsequent developments may affect this Opinion, we do
not have any obligation to update, revise or reaffirm this
Opinion.
Oppenheimer, as part of its investment banking services, is
regularly engaged in the valuation of businesses and securities
in connection with mergers, acquisitions, underwritings, sales
and distributions of listed and unlisted securities, private
placements and valuations for estate, corporate and other
purposes. Oppenheimer will receive a fee for rendering this
Opinion. The Company has agreed to indemnify Oppenheimer under
certain circumstances.
In the ordinary course of our business, Oppenheimer may actively
trade securities of the Company for its own account and for the
accounts of customers and, accordingly, may at any time hold a
long or short position in such securities.
It is understood that this Opinion has been prepared solely for
the use of the Board of Directors of the Company and may not be
disclosed, summarized, excerpted from or otherwise publicly
referred to, or used for any other purposes without
Oppenheimers prior written consent, except that the
Company may provide a copy of this as described below.
Oppenheimer understands that the Company will include this
Opinion in a proxy statement filed with the SEC, which will be
provided to the Companys shareholders. In addition,
Oppenheimer will, if requested by the Company, provide such
additional reasonable and customary disclosure in connection
with such public filings regarding its engagement with the
Company, the basis of its Opinion and compensation.
Based upon the foregoing and such factors as we deemed relevant,
we are of the Opinion that, as of the date hereof, the Sale
Consideration is fair from a financial point of view to the
shareholders of Ciphergen.
Very truly yours,
Oppenheimer & Co. Inc.
C-2
PROXY BALLOT
CIPHERGEN BIOSYSTEMS, INC.
SPECIAL MEETING OF STOCKHOLDERS
THURSDAY, OCTOBER 26, 2006, 2:00 P.M. LOCAL TIME
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
SEPTEMBER 28, 2006
The undersigned stockholder of Ciphergen Biosystems, Inc. (the Company) hereby appoints Gail S. Page with full
power of substitution, the true and lawful attorneys, agents and proxy holders of the undersigned, and hereby
authorizes them to represent and vote, as specified herein, all of the shares of Common Stock of the Company held of
record by the undersigned on September 15, 2006, at the Special
Meeting of Stockholders of the Company to be held on Thursday,
October 26, 2006 (the Special Meeting), at 2:00 p.m., local time, at 6611 Dumbarton Circle, Fremont, California and any adjournments or postponements thereof.
THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO
CONTRARY DIRECTION IS INDICATED, WILL BE VOTED FOR THE PROPOSALS AND AS SAID
PROXYHOLDERS DEEM ADVISABLE ON SUCH OTHER MATTERS AS MAY PROPERLY COME
BEFORE THE MEETING AND ANY ADJOURNMENT(S) OR POSTPONEMENTS THEREOF.
THE UNDERSIGNED ACKNOWLEDGES RECEIPT OF THE NOTICE OF SPECIAL MEETING OF
STOCKHOLDERS RELATING TO THE ANNUAL MEETING.
CONTINUED
AND TO BE SIGNED ON THE REVERSE SIDE
òPlease
detach here
The
Board of Directors Recommends a Vote FOR Items 1 and 2.
1. |
|
To approve the proposed sale of the assets used in our proteomics business,
herein referred to as the research tools business, to Bio-Rad Laboratories, Inc. pursuant
to the asset purchase agreement attached as Annex A to the
accompanying proxy statement. |
|
2. |
|
To approve the proposal to grant discretionary authority to adjourn or postpone the Ciphergen special
meeting to another time or place for the purpose of soliciting additional proxies. |
Address change? If yes, mark box o
and indicate changes below:
|
|
|
|
|
o For
|
|
o Against
|
|
o Abstain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o For
|
|
o Against
|
|
o Abstain |
Date:
Signature(s) in Box
NOTE:
Please sign exactly as name appears hereon. Joint Owners should each sign. Trustees and others
acting in a representative capacity should indicate the capacity in which they sign and give their full
title. If a corporation, please have an authorized officer sign and indicate the full corporate name. If a partnership,
please sign in partnership name by an authorized person.
PLEASE MARK, SIGN AND DATE THIS PROXY AND RETURN IT PROMPTLY WHETHER YOU PLAN TO ATTEND THE MEETING OR NOT. IF YOU
DO ATTEND, YOU MAY VOTE IN PERSON IF YOU DESIRE.